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GRIK2 glutamate receptors ionotropic kainate 2 gene
GTP guanosine-5’-triphosphate
h hour
HAP1 huntingtin associated protein 1
HAT histone acetyltransferase
HBSS Hank’s buffered salt solution
HD Huntington’s disease
HDACs histone deacetylases
hESCs human embryonic stem cells
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HEAT huntingtin, elongation factor 3, the PR65/A
subunit of protein phosphatase 2A and the lipid kinase Tor
HSC haematopoietic stem cells
Htt murine huntingtin gene
HTT huntingtin protein
HTT human huntingtin gene
ID immunodetection
i.e. id est
IFNγ interferon gamma
Ig immunoglobulin
IGF insulin-like growth factor
IgG-H antibody heavy chain
IKK IκB kinase
IκB inhibitor of kappa B
IL interleukin
IP immunoprecipitation
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iPSC inducible pluripotent stem cell
IRAK IL-1R associated kinase
IRFs interferon response factors
JAK janus kinase
JNK c-Jun N-terminal kinases
kb kilo base pair
kDa kilo Dalton
KMO kynurenine 3-monooxygenase
L litre
LPS lipopolysaccharides
M molar
MACS magnetic activated cell sorting
MAPK mitogen-activated protein kinases
M-CFU macrophage colony-forming unit
M-CSF macrophage colony-stimulating factor
MCP-1 monocyte chemoattractant protein 1
MHC major histocompatibility complex
min minutes
miRNA micro RNA
ml millilitre
MPP multipotent progenitor
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
MSNs medium spiny neurons
mTOR mammalian target of rapamycin
MyD88 myeloid differentiation primary response gene (88)
n number
N amino
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NES nuclear export sequence
NFκB nuclear factor kappa-light-chain-enhancer of activated B
cells
NLS nuclear localisation signal
NMDAR N-methyl-D-aspartate receptor
NRSF neuron-restrictive silencer factor
P proline
PAMPs pathogen-associated molecular patterns
PB polybrene
PBMC peripheral blood mononuclear cell
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PET positron emission tomography
PFA paraformaldehyde
PGC-1α peroxisome proliferator activated receptor gamma coactiva-
tor 1 alpha - protein name
PI3K phosphatidylinositide 3-kinases
PIP2 phosphatidylinositol (4,5)-bisphosphate
PKB protein kinase B
PMA phorbol 12-myristate 13-acetate
PMSF phenylmethanesulfonylfluoride or phenylmethylsulfonyl flu-
oride
PPARGC1A Peroxisome proliferator-activated receptor gamma, coacti-
vator 1 alpha - gene name
PPC positive PCR control
PRRs pattern recognition receptors
PVDF polyvinylidene fluoride
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Q glutamine
qPCR quantitative polymerase chain reaction
RANTES regulated and normal T cell expressed and secreted
REST RE1-silencing transcription factor
RISK RNA-induced silencing complex
RNA ribonucleic acid
RNAi RNA interferences
RTC reverse-transcription control
s seconds
SAHA suberoylanilide hydroxamic acid
SDS sodium dodecyl sulfate
SEM standard error of the mean
shRNA small hairpin RNA
siRNA small interfering RNA
SNP single nucleotide polymorphism
Sp-1 specificity protein 1
STAT signal transducers and activators of transcription
T tesla
TAK transforming growth factor βactivated kinase
TBP TATA-binding protein
TBS tris-buffered saline
TCR T cell receptor
TFC total functional capacity
Th T helper cell
TLR Toll like receptors
TNF Tumour necrosis factor
TP53 tumour protein 53
TRAF TNF receptor associated factors
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TRAM TRIF-related adaptor molecule
TRIF TIR-domain-containing adapter-inducing interferon-beta
Treg regulatory T cells
UCL University College London
UHDRS unified Huntington’s disease rating scale
UPS ubiquitin-proteasome system
vs. versus
YAC yeast artificial chromosome
WASP Wiskott-Aldrich syndrome proteins
WT wild type
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Abstract
Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by
a CAG repeat expansion in the huntingtin (HTT ) gene. The peripheral innate im-
mune system contributes to HD pathogenesis and has been targeted successfully
to modulate disease progression, but mechanistic understanding relating this to
mutant (m)HTT expression in immune cells has been lacking.
This thesis demonstrates that human HD myeloid cells produce excessive inflam-
matory cytokines due to cell-intrinsic effects of mHTT expression on the NFκB
pathway, whereby mHTT interacts with IKK, leading to increased degradation
of IκB and subsequent nuclear translocation of RelA. Transcriptional alterations
in intracellular immune signaling pathways were also observed. Using a novel
method of siRNA delivery to lower HTT expression, this thesis shows a reversal
of disease-associated alterations in cellular function - the first time this has been
demonstrated in human cells. Glucan-encapsulated siRNA particles (GeRPs)
were used to lower HTT levels in human HD monocytes/macrophages, result-
ing in reversal of HTT-induced elevated cytokine production and transcriptional
changes. These findings improve our understanding of the role of innate immu-
nity in neurodegeneration, introduce GeRPs as a tool for studying cellular patho-
genesis ex vivo in human cells and raise the prospect of HTT lowering in immune
cells as a therapeutic in HD.
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Abstract
Evaluating immune function in different mouse models of HD, blood and splenic
monocytes replicated the hyper-reactive phenotype seen in HD patients demon-
strating that HD mouse models can be of use to understanding HD immune
pathology and to test immune modulatory therapies.
Furthermore, human HD myeloid cells demonstrated a striking defect in migra-
tion towards different chemokines. Looking at the cell’s ability to form filopodia,
it became apparent that actin-remodelling is reduced and causes decreased mi-
gration.
Work performed in collaboration with Novartis revealed that mHTT levels in im-
mune cell subsets differ significantly between disease stages. Monocyte and T
cell mHTT levels were significantly associated with disease burden scores and
caudate atrophy rates in HD patients. mHTT fragments detected in HD immune
cells may explain the progressive increase in mHTT levels. These findings in-
dicate that quantification of mHTT holds significant promise as a non-invasive
disease biomarker.
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1 Introduction
1.1 Huntington’s disease
Huntington’s disease (HD) is a fatal, autosomal dominant inherited, progressive
neurodegenerative disorder that results from the expansion of a trinucleotide CAG
repeat within the HTT gene that encodes a protein called huntingtin (HTT). The
mean age of onset for the disease is 40 years, with death typically occurring 15-
20 years later (reviewed in (Ross and Tabrizi, 2011)). HD can be found worldwide,
but there are significant geographic differences: in North America and Western
Europe a minimum of 5 in 100,000 people are affected, whereas HD prevalence
in China and Japan is 10-100 fold lower. The Maracaibo region in Venezuela
has the highest prevalence (700 per 100,000) worldwide (Warby et al., 2011). In
the UK the prevalence is thought to be around 6 per 100,000, although it could
be as high as 12.4/100,000 due to unconfirmed, unspecific or mis-diagnosis (as
schizophrenia and Alzheimer’s disease) (Rawlins, 2010; Sackley et al., 2011).
1.1.1 Features of Huntington’s disease
HD is a clinically heterogeneous disease, presenting with various combinations
of cognitive, psychiatric and motor symptoms. The disease was described by and
named after George Huntington in 1872 (Huntington, 1872) and whilst it was not
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the first description of the disease, his paper comprehensively noted the genetic,
movement, cognitive and neuropsychiatric characteristics of HD.
1.1.1.1 Clinical features
Clearly determining the onset of HD is difficult, as many patients have psychiatric
or cognitive symptoms before motor problems present themselves. A definitive
clinical diagnosis is only made when motor abnormalities are noted (Wild and
Tabrizi, 2007).
In the early stages of the disease, minor motor features include restlessness,
hyperreflexia, and fidgety movements of fingers, hands and toes during stress or
when walking. Oculomotor abnormalities are a major feature in HD and are often
one of the earliest features noticed. In later stages of the disease, 90 % of patients
present with involuntary movements such as chorea, differing in the degrees of
dystonia, Parkinsonism and bradykinesia. Moreover, impairments of voluntary
movements leading to clumsiness, reduced motor speed and disturbance in fine
motor control, are key features of HD (Wild and Tabrizi, 2007).
Cognitive changes are an early, near-universal feature in HD and include slowing
of the thought process and executive functions. However, the severity of abnor-
malities varies between patients. Impaired functions include: poor planning and
judgment, impulsive behaviour, disorganisation, lack of insight, distractibility and
loss of initiative (Novak and Tabrizi, 2010).
Psychiatric symptoms, such as depression and anxiety are also common in HD
patients. One study suggests that 40-50 % of HD patients suffer from depression
(Paulsen et al., 2005). Suicide and suicide attempts are up to four times more
common in HD patients compared with in the general population (Farrer, 1986).
Aggressive behaviour or apathy can also be seen in some patients, and on rare
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occasions patients suffer from hypersexuality or psychosis (Novak and Tabrizi,
2010).
1.1.1.2 Brain pathology
Most of the clinical features in HD can be attributed to degeneration within the
central nervous system (CNS). Analysis of post-mortem, end-stage HD reveals
that the total brain volume of HD patient is reduced by 19 % compared with match-
ing controls (Halliday et al., 1998). The highest levels of atrophy are seen in the
striatum, with around 50 % loss in the caudate and putamen, and to a lesser
extent in the cortex (Halliday et al., 1998; Rosas et al., 2001; Vonsattel et al.,
1985). Other regions, such as the cerebral cortex (Halliday et al., 1998), globus
pallidus (Rosas et al., 2003), hypothalamus (Politis et al., 2008), subthalamic nu-
cleus, substantia nigra and the subcortical white matter are also affected, but less
notably so than the striatum (reviewed in (Ross and Tabrizi, 2011)).
The substantial striatal atrophy in HD patient brain is caused by neuronal death,
with a loss of up to 95 % of GABAergic medium spiny neurons (MSNs) (Vonsattel
and DiFiglia, 1998). As a hallmark of HD pathology, intranuclear inclusion bodies,
containing large aggregates of mHTT, are found in neuronal nuclei of end-stage
HD post-mortem brain tissue (Vonsattel, 2008), as well as in the otherwise normal
brains of premanifest HD gene carriers (Go´mez-Tortosa et al., 2001). Aggregates
are not, however, restricted to the cellular nucleus, and can also be found in the
cytoplasm, neuronal dendrites and axon terminals (Vonsattel, 2008). It has been
reported that atrophy occurs before symptom onset, suggesting that the CNS
is able to cope with some degree of neuronal damage before manifesting any
behavioural changes (Rosas et al., 2005; Tabrizi et al., 2009).
Neuronal death may not, however, only be due to cell-autonomous processes
occurring within neurons. Cellular interactions including inter-neuronal as well as
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between glial cells and neurons may also play a role. Interestingly, both increased
numbers of astrocytes (Vonsattel, 2008) and microglia have been detected in HD
brains (Sapp et al., 2001; Tai et al., 2007). Furthermore, transgenic expression
of mHTT in HD mouse astrocytes in vivo causes an age dependent neurological
phenotype similar to HD, underlining the potential importance of non-neuronal
cells in HD pathogenesis (Bradford et al., 2009).
1.1.1.3 Peripheral changes in HD
While primary pathology in HD arises from degeneration in the basal ganglia, HTT
expression has been detected in every tissue tested (Hoogeveen et al., 1993; Li
et al., 1993). Furthermore, HTT is known to interact with cellular processes and
organelles important in both neuronal and non-neuronal cells, including mitochon-
drial function, protein degradation pathways and gene transcription (reviewed in
(Ross and Tabrizi, 2011)). Indeed, widespread pathology can be found in periph-
eral organs, and is associated with weight-loss, skeletal muscle wasting, osteo-
porosis, diabetes, cardiac failure and testicular atrophy (van der Burg et al., 2009)
(Figure 1.1).
Weight loss is a hallmark of HD (Sanberg et al., 1981). The progressive loss
of weight starts in premanifest gene carriers and develops into cachexia in ad-
vanced patients (Djousse´ et al., 2002; Trejo et al., 2004). The constant loss of
weight is due to a high metabolic rate (Goodman et al., 2008; Mochel et al., 2007)
rather than hyperactivity or malnutrition (Djousse´ et al., 2002; Trejo et al., 2004).
Studies in HD mice suggest that dysfunction of the gastrointestinal tract causes
malabsorption of food, which could also contribute to weight loss in HD (van der
Burg et al., 2011).
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Figure 1.1: Peripheral phenotypes in HD patients. Besides neuronal loss, HD pa-
tients suffer from a wide range of peripheral symptoms caused by ubiquitous expression
of mHTT in peripheral tissues. Re-printed from The Lancet, Vol.8, Beyond the brain:
widespread pathology in Huntington’s disease, 765-74, van der Burg et al., ©2009, with
permission from Elsevier.
Skeletal muscle wasting is another feature of HD that is commonly found in pa-
tients (van der Burg et al., 2009). Interestingly, similar to the neuronal phenotype,
myocytes from HD patients form mHTT inclusions, while a range of cellular ab-
normalities such as mitochondrial dysfunction, increased cell death and defective
cell differentiation have been observed (Ciammola et al., 2006). Mutant HTT is
known to repress peroxisome proliferator activated receptor γ co-activator 1 alpha
(PGC-1α) transcription in neurons (Cui et al., 2006) and muscle cells (Chaturvedi
et al., 2009). Inhibition of this transcriptional co-activator known to regulate genes
playing a role in energy metabolism, mitochondrial respiration and number, dis-
rupts mitochondrial function.
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Second to the brain, testis are the organ with the highest HTT expression levels
(Li et al., 1993). Testicular atrophy in HD patients does not affect fertility (Pridmore
and Adams, 1991) but patients demonstrate lower testosterone levels than would
be normally expected (Markianos et al., 2005). Interestingly, testosterone levels
are negatively correlated to disease severity, not only in HD (Markianos et al.,
2005), but also in other neurodegenerative diseases (Okun et al., 2004).
After pneumonia, heart disease is the second leading cause of death in HD and
occurs in about 30 % of patients (Lanska et al., 1988). In HD mouse models, the
myocardium has been found to be atrophic, and as mitochondria demonstrate
altered ultrastructure and increased protein nitration is observed in myocytes,
oxidative stress seems to be a likely reason for cardiac pathology in HD (Mihm
et al., 2007).
Other organs affected in HD patients include bones, decreased density of which
has been reported in premanifest HD gene carriers (Goodman and Barker, 2011),
and the pancreas, where impaired insulin secretion by β -cells leads to diabetes
(Smith et al., 2009). Widespread abnormalities in blood cells have also been
detected; these are discussed separately in Section 1.3.2.
Peripheral changes could be secondary to dysfunction in the CNS. Pathology
in the hypothalamus leads to differences in endocrine signalling such as altered
production and release of growth hormones (Saleh et al., 2009) and cortisol (Aziz
et al., 2009), leading to secondary changes in peripheral tissues. However, there
is evidence that dysfunction is directly due to the expression of mHTT in periph-
eral cells. HTT is ubiquitously expressed in all cells of the body (Li et al., 1993)
and loss of Htt (the mouse homologue to the human HTT ) in mice is embryonic
lethal (Nasir et al., 1995), underlining the importance of HTT expression in pe-
ripheral tissues. It would not, therefore, be surprising if a mutation in HTT leads
to changes in peripheral cells as well. Moreover, peripheral cells demonstrate
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dysfunction when cultured in vitro, indicating the direct effect of mHTT (Bjo¨rkqvist
et al., 2008).
While peripheral, non-neuronal symptoms in themselves greatly affect the quality
of life for patients, they may also contribute to brain pathology. It is known that
patients with higher body weight show slower rates of disease progression, sug-
gesting that defects in peripheral metabolism may lead to insufficient nutritional
support for the CNS contributing to brain dysfunction (van der Burg et al., 2009).
In addition, several recent studies suggest that the peripheral immune system
can be modulated to affect HD progression (see Section 1.3.3).
1.1.1.4 Juvenile HD
Around 7 % of all HD patients carry a HTT allele with more than 60 CAG repeats,
which results in early-onset or juvenile (onset before the age of 20) HD. Five per-
cent of these early onset patients carry CAG repeats of between 80 and 100,
causing disease onset before the age of 10 (Squitieri et al., 2006). Large HTT
CAG repeat expansions not only result in very early disease onset, but also lead
to a fast and devastating rate of progression. While juvenile patients demonstrate
some of the symptoms typical for HD, such as clumsiness, gait disturbance and
depression they do not present with chorea. Furthermore, juvenile patients suffer
from atypical symptoms such as seizures, epilepsy, psychosis, learning difficul-
ties, rigidity and dystonia (Squitieri et al., 2000, 2006). Juvenile subjects suffer
from more widespread brain atrophy, however, like in adult-onset HD the striatum
is the worst affected region within the brain (Nance and Myers, 2001; Vonsattel
et al., 2011). To date, it is unclear why the progression rate and symptoms dif-
fer between adult and juvenile onset HD, but it is likely that longer polyglutamine
(polyQ) expansions in the HTT protein have different effects on its functions.
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1.1.2 HD genetics and age of onset
The HD gene was mapped to human chromosome 4p16.3 in 1983 (Gusella et al.,
1983). Ten years later, the associated HTT gene was isolated and a CAG repeat
expansion was identified as the mutation underlying the disease. The repeat is
located in exon 1, seventeen codons downstream of the ATG start codon (The
Huntington’s Disease Collaborative Research Group, 1993). The whole HTT lo-
cus is 180 kilo base pairs (kb) long and consists of 67 exons. The gene has
a house-keeping like promoter, which allows wide-spread expression in all cell
types (reviewed in (Ross and Tabrizi, 2011)).
In healthy individuals, the number of CAG repeats is fewer or equal to 35. Re-
peats of between 36 and 39 are reduced penetrance range repeats with which
people are at risk of developing the disease in old age. CAG repeats of 40-55
result in an adult onset of HD, whilst longer repeats lead to young adult onset or
juvenile forms of the disease (Bates et al., 2002). The CAG repeat expansion
within the HTT gene is subject to meiotic instability and tends to increase over
multiple generations. This effect is greater in paternal heredity, leading to strong
inheritance via the paternal line (Trottier et al., 1994). There is a strong inverse
correlation between the length of the CAG repeat in the mutant HTT (mHTT ) al-
lele and age of disease onset with longer CAG repeats causing an earlier age of
onset (Figure 1.2).
However, only 50-70 % of variance in age of disease onset depends on the length
of the CAG repeat. The remaining variation is influenced by modifying genes and
the environment. A study on a large Venezuelan HD pedigree found that 59 %
of the age of onset depends on genetic and environmental modifiers (Wexler
et al., 2004), whilst a study looking at siblings found that the CAG repeat length
accounted for 65-71 % of the variance (Rosenblatt et al., 2001).
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Figure 1.2: Correlation between age of onset and CAG repeat length. A clear curvi-
linear relationship can be observed, showing that longer CAG repeats result in earlier age
of onset. Picture re-produced from Wexler et al., 2004. ©with authors of original article.
Several genes such as GRIK2, TP53, HAP1, APOE and PPARG1A have been
suggested as modifiers of disease onset. Several studies have reported the glu-
tamate receptors ionotropic kainate 2 gene (GRIK2) as a modifier of age of onset
in HD (MacDonald et al., 1999; Rubinsztein et al., 1997; Zeng et al., 2006). The
gene encodes for a subunit of the glutamate receptor, which mediates excitatory
neurotransmission in the brain. Interestingly, excitotoxicity has been implicated in
neurodegeneration. However, a recent study genotyping a much larger cohort did
not replicate these findings (Lee et al., 2012). Another possible modifier of age
of onset is Peroxisome proliferator-activated receptor gamma, co-activator 1 al-
pha (PPARGC1A) (Taherzadeh-Fard et al., 2009; Weydt et al., 2009), a transcrip-
tional co-activator facilitating its function via the cyclic adenosine monophosphate
(cAMP) response element-binding protein (CREB), a transcription factor thought
to be affected by the presence of mHTT in a cell (Ross and Poirier, 2004).
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Non-genetic modifiers of HD age of onset include lifestyle and physical activity.
A questionnaire based study demonstrated that a more passive lifestyle (defined
as passive activities lacking physical or intellectual challenges) leads to earlier
disease onset (Trembath et al., 2010). Similarly, studies in a mouse model of HD
showed that environmental enrichment by adding cardboard, paper and plastic
objects into the cages delays disease onset in the R6/1 mouse model of HD
(van Dellen et al., 2000). Furthermore, physical activity has been shown to be
inversely associated with the risk of dementia (Hamer and Chida, 2009).
1.1.3 Huntingtin
1.1.3.1 Huntingtin protein structure
HTT is a 348 kDa protein encoded by the HTT gene, which is ubiquitously ex-
pressed throughout the CNS, peripheral tissues and during embryonic develop-
ment (Li et al., 1993). The CAG repeat located in exon 1 of HTT is translated
into a polyQ stretch located in the amino (N)-terminus of HTT starting at amino
acid 18. The polyQ is followed directly by a poly-proline (P) region, thought to
stabilise the polyQ tract and retain HTT’s solubility (Southwell et al., 2008; Stef-
fan et al., 2004). While the structure of the whole HTT protein has not yet been
resolved, X-ray crystallography has shown that the wild-type protein N17 region
(the first 17 amino acids of the HTT protein) is α-helical and that the proline rich
region takes a polyP helix II formation. The polyQ (17Q) is more flexible forming
an α helix, extended loop and random coil conformation (Kim et al., 2009). While
the N17 headpieces can fold back to bind the polyP region in the wild-type pro-
tein, this interaction gets weaker once the polyQ domain expands, opening the
N-terminus up for possible interactions with other proteins (Dlugosz and Trylska,
2011). Indeed, a yeast-two-hybrid screen found that the HTT polyP region is the
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main domain mediating protein-protein interactions. For example, it binds WW
domain protein, which contain two highly conserved tryptophan residues (Faber
et al., 1998). Changes in HTT protein structure caused by the polyQ expansion,
may change the interaction strength between HTT and its interaction partners,
causing both loss and gain of function.
HTT also has multiple HEAT (huntingtin, elongation factor 3, the PR65/A subunit
of protein phosphatase 2A and the lipid kinase Tor) repeat sequences. These
sequences are around 50 amino acids long and comprise two anti-parallel α-
helices with a helical hairpin in between (Li et al., 2006). Such HEAT sequences
are thought to be involved in protein-protein interactions. The protein also con-
tains a NES (nuclear export sequence) domain near the C-terminus (Xia et al.,
2003), but a nuclear localisation signal has not yet been identified.
1.1.3.2 Post-translational modifications of huntingtin
HTT contains several sites for post-translational modifications, which can regu-
late half-life, localisation, aggregation and toxicity of the protein. Three lysine
residues (K6, K9, K15) found immediately prior to the polyQ expansion at the
N-terminus of the protein appear to compete for SUMOylation and ubiquitination.
SUMOylation of the residues results in nuclear translocation of HTT and pro-
motes its effects on transcription, while ubiquitination induces HTT degradation,
reducing HTT toxicity and abrogating neurodegeneration in a Drosophila model of
HD (Steffan et al., 2004). Furthermore, HTT can be phosphorylated at one thre-
onine (T3) and several serine residues (S13, S16, S421, S434, S536, S1181,
S1201, S2076, S2653 and S2657). The effect of phosphorylation varies depend-
ing on the residue modified. Phosphorylation of S421 and S434 protects HTT
from proteolytic cleavage, while modification of S13 and S16 results in HTT clear-
ance by the ubiquitin-proteasome system (UPS) and via lysosomes (Thompson
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et al., 2009). S421 phosphorylation has been shown to modulate vesicle trans-
port (Zala et al., 2008). Acetylation takes place at residues K9, K178, K236, K345
and K444 (Cong et al., 2011), while the pamitoylation side is cysteine 214 (Yanai
et al., 2006) (all modification sites are shown in Figure 1.3).
Both wild-type and mutant HTT are cleaved by various proteases, including cas-
pase 2, 3, 6 and 8, cathepsins and calpains, generating a range of fragments
(Figure 1.3) (reviewed in (Ross and Tabrizi, 2011)). In addition to proteolysis,
CAG repeat length dependent alternative splicing of HTT exon 1 has been shown
to result in an short poly-adenylated mRNA that is translated into a HTT exon1
protein fragment (Sathasivam et al., 2013). Fragmentation of HTT may therefore
occur on both RNA and protein level. While the physiological role of fragmen-
tation by proteolysis or splicing is unclear, it has been shown that N-terminal
mHTT fragments are necessary for pathology and can be more toxic than the
full-length protein (Graham et al., 2006). Furthermore, expression of N-terminal
mHTT fragments is sufficient to cause HD-like syndromes in animals (Mangiarini
et al., 1996).
1.1.4 Wild-type huntingtin function
The function of wild-type HTT is poorly defined due to the large size of the protein
and a lack of homology to other proteins. Genetic depletion of Htt has shown
that HTT is essential in embryonic development and neurogenesis, as Htt−/−
mice die during embryogenesis (Nasir et al., 1995; Zeitlin et al., 1995). HTT also
plays a crucial role in neuronal function, as conditional knock-out of Htt in adult
mice causes neural loss (Dragatsis et al., 2000). High levels of apoptosis in the
HTT knock-out mice suggest an anti-apoptotic role of the protein (Zeitlin et al.,
1995). Indeed, overexpression of wild-type HTT in an HD mouse model is as
37
Huntington’s disease Introduction
Figure 1.3: HTT protein structure and post-translational modifications. Human
huntingtin structure showing protein domains as well as cleavage sides and other post-
translational modification sides. Re-printed from The Lancet, Vol.10, Huntington’s dis-
ease: from molecular pathogenesis to clinical treatment., 83-98, Ross and Tabrizi,
©2011, with permission from Elsevier.
an anti-apoptotic factor and protects striatal neurons from N-methyl- D-aspartate
receptor (NMDAR) mediated excitotoxicity (Leavitt et al., 2006).
Further evidence for possible functions of HTT is provided by examining its cel-
lular localisation. Within the cell HTT can be found in the cytoplasm; often as-
sociated with microtubules, the Golgi, the endoplasmatic reticulum (ER) and mi-
tochondria (Bhide et al., 1996; Hilditch-Maguire et al., 2000; Panov et al., 2002).
HTT has also been detected on the membranes of synaptic and clathrin-coated
vesicles of the endocytic or secretory pathway, suggesting HTT may be involved
in long- and short-term transport along microtubules, endocytosis, and synap-
tic vesicle exocytosis and recycling (Velier et al., 1998). Indeed, wild-type HTT
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has been shown to be crucial for the transport of brain-derived neurotrophic factor
(BDNF) vesicles along microtubules in neurons by binding dynactin via huntingtin-
associated protein 1 (HAP1) (Gauthier et al., 2004). Interestingly, BDNF transport
is disrupted both in HD and when wild-type HTT levels are reduced, suggesting
reduced BDNF levels as one pathogenic pathway for HD due to loss of wild-type
protein function.
Additionally, HTT is involved in transcriptional regulation. The protein interacts
with transcription factors, and is also proposed to be involved in mRNA and tran-
scription factor shuttling into the nucleus (Imarisio et al., 2008). For example
wild-type HTT stimulates transcription of the gene encoding BDNF by sequester-
ing the repressor element-1 transcription factor/neuron restrictive silencer factor
(REST/NRSF) in the cytoplasm and thereby inhibiting its repressing function at
the BDNF promoter (Zuccato et al., 2003). When HTT is mutated, this interaction
is lost and lower levels of BDNF are seen in the brain.
1.1.5 Mutant huntingtin and HD pathogenesis
While the loss of wild-type HTT function may be important for HD pathology, it is
commonly thought that a toxic gain of function by mHTT, due to abnormal protein
conformation and fragmentation, is the primary cause for HD. This hypothesis is
supported by the fact that mHTT expression can substitute wild-type HTT function
in mice. While knocking out Htt is lethal (Nasir et al., 1995; Zeitlin et al., 1995),
mice homozygote for the mutant Htt allele such as the Hdh150Q/150Q are viable
(Lin et al., 2001). Furthermore, heterozygote and homozygote HD patients show
no difference in symptom severity (Wexler et al., 1987), demonstrating that a loss
of wild-type HTT has a smaller effect than the gain of the mutant allele.
Due to the protein’s size and range of interaction partners, mHTT has been shown
to cause dysfunction in several cellular pathways, cascades and mechanisms.
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The main effects of mHTT are discussed below, and include aggregation, pro-
tein degradation pathways, energy metabolism and transcriptional dysregulation.
In addition, the reasons why neurons are especially vulnerable to the effects of
mHTT expression will be discussed.
1.1.5.1 Aggregate formation
The formation of both intranuclear and cytoplasmic aggregates have been well
described in HD patients (DiFiglia et al., 1997) and mouse models (Davies et al.,
1997). Whilst wild-type HTT is mainly located in the cytosol, mutated protein re-
locates to the nucleus where it forms nuclear inclusions. Interestingly, antibody
staining has shown that these inclusions are mainly made up from N-terminal
fragments, underlining the important role of HTT fragmentation in HD (DiFiglia
et al., 1997). However, in addition to inclusions, mHTT is also present diffusely in
the nucleus and cytoplasm.
Structurally, toxic mHTT fragments as well as the N-terminus of the full-length
mutant protein are composed of a compact hairpin comprised of two β -strands
and a turn (reviewed in (Ross and Tabrizi, 2011)). The abnormally folded protein
can aggregate and build fibrillar structures, a feature typical of disease-associated
misfolded proteins in other neurodegenerative diseases such as Alzheimer’s and
Parkinson’s diseases (Ross and Poirier, 2004; Scherzinger et al., 1999). The
kinetics of and exact mechanisms causing the formation of mHTT aggregates
are still unclear. However, studies of synthetic polyQ repeats have shown that
they can form β -sheets held together by hydrogen bonds, termed polar zippers
(Perutz et al., 1994). These polyQ interactions could function as aggregation
nuclei by precipitating not only mHTT, but also other polyQ proteins. Kinetics of
aggregation are influenced by the surrounding protein domains. Phosphorylation
of mHTT at S13 and S16 for example, reduces the accumulation of aggregates
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found in HD mouse models and decreases disease pathology (Gu et al., 2009).
The role mHTT aggregates play in disease pathology is still debated. Large in-
tranuclear inclusions have been shown to sequester vital proteins such as tran-
scription factors (Steffan et al., 2000), chaperones (Hay et al., 2004) and ubiquitin
(Bennett et al., 2007); thereby interfering with various proteins’ normal function.
In addition, studies have shown that less mHTT aggregation correlates with im-
proved disease progression (Gu et al., 2009; Mielcarek et al., 2011). Conditional
expression of mHTT in MSNs demonstrated, however, that the formation of in-
tranuclear mHTT inclusions alone is not sufficient to cause HD pathology (Gu
et al., 2007, 2005). Moreover, studies have suggested that the formation of ag-
gregates is a cellular coping mechanism in response to mHTT expression. Inter-
estingly, levels of diffuse intracellular GFP-exon 1 HTT rather than the formation
of inclusion bodies predict when neuronal death will occur (Arrasate et al., 2004;
Miller et al., 2011), highlighting the particular role of monomers and oligomers.
1.1.5.2 Protein degradation pathways
Evidence of mHTT aggregates points towards a defect in protein degradation
pathways that normally eliminate damaged or misfolded proteins such as mHTT.
Indeed, another effect of mHTT is the inhibition of cellular protein-recycling and
degradation pathways, such as the UPS (Bennett et al., 2007) and autophagy
(Martinez-Vicente et al., 2010), which add to the accumulation of misfolded pro-
teins.
Ubiquitin, a small regulatory molecule directing proteins to the proteasome to be
recycled, has been found to be strongly associated with mHTT inclusions (Ben-
nett et al., 2007; DiFiglia et al., 1997). Therefore, it may be that mHTT is targeted
for degradation, but the UPS then fails to do so. Indeed, studies have shown
decreased proteasome activity in HD patient’s brain and fibroblast cultures (Seo
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et al., 2004). Furthermore, it has been hypothesised that the proteasome may not
be able to degrade polyQ repeats; and that mHTT could block the proteasome
and hinder protein degradation (Holmberg et al., 2004).
Besides the UPS, the principal mechanism for bulk degradation of cytosolic pro-
teins and organelles, autophagy, is also dysfunctional in HD. Large numbers of
autophagosomes containing mHTT are found in post-mortem HD brain tissue
(Sapp et al., 1997) and HD mouse models (Kegel et al., 2000), suggesting in-
creased levels of autophagy to degrade toxic mHTT. The expansion of the au-
tophagy pathway may however, not result in an increase in proteolysis, as cargo
is not loaded effectively into autophagy vesicles in both HD mouse models and
HD patient lymphoblasts (Martinez-Vicente et al., 2010).
So while cells have mechanisms to degrade both soluble HTT and mHTT aggre-
gates, the processes are not completely effectual. This makes enhancing protein
degradation pathways a promising target for possible therapeutic approaches.
1.1.5.3 Energy metabolism
Mitochondria are another target of mHTT’s toxic function, resulting in compro-
mised energy metabolism, altered calcium handling, apoptosis and oxidative dam-
age (Browne, 2008). Mitochondria isolated from HD patient lymphoblasts and
HD mouse brains demonstrate reduced membrane potential and depolarisation
at lower calcium loads compared with control mitochondria (Milakovic et al., 2006;
Panov et al., 2002). Choo et al. also found impairments in Ca2+ handling, show-
ing that a lower Ca2+ threshold is needed to open mitochondrial permeability tran-
sition pores, this dysfunction is linked to mHTT binding the outer mitochondrial
membrane (Choo et al., 2004). Depolarisation of the mitochondrial membrane
can lead to programmed cell death by release of cytochrome c and increased
caspase activity. Indeed, increased apoptosis, cytochrome c release and cas-
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pase -3, -8 and -9 activity has been demonstrated in myoblast cell cultures from
HD patients (Ciammola et al., 2006). Moreover, neuronal energy metabolism is
hindered by mHTT aggregates which block mitochondria transport along proces-
sors (Chang et al., 2006).
1.1.5.4 Transcriptional dysregulation
Several studies provide substantial evidence for transcriptional dysregulation in
HD. Altered gene expression levels have been observed in both HD patients
(Hodges et al., 2006) and HD mouse models (Luthi-Carter et al., 2002, 2000).
Interestingly, abnormalities are highly comparable between mouse models and
HD patients (Kuhn et al., 2007). Mutant HTT expression in primary striatal neu-
rons has proven the cell-intrinsic effect of mHTT on gene expression (Runne
et al., 2008). Transcriptional changes are already apparent long before symp-
toms onset in the brains of premanifest gene carriers (Dunah et al., 2002), as
well as in embryonic stem cells (Feyeux et al., 2012), indicating transcriptional
dysregulation as a major contributor to HD pathogenesis.
The CREB binding protein (CBP), a transcriptional co-activator, which links CREB
to the basal transcription machinery and plays a role in neuronal survival, is dys-
regulated in HD (Nucifora et al., 2001). CBP is depleted from its normal nuclear
location and interacts with mHTT, both through its histone acetyltransferase (HAT)
domain and polyQ tract, whereby it is recruited into HTT aggregates (Kazantsev
et al., 1999; Nucifora et al., 2001; Steffan et al., 2000). Several other transcription
factors such as Sp1 (specificity protein 1) (Dunah et al., 2002; Li et al., 2002), TBP
(TATA-box binding protein) (Schaffar et al., 2004) and p53 (Steffan et al., 2000),
have also been shown to selectively interact with the expanded polyQ of mHTT,
causing dysregulation of the genes that they control. Interestingly, mHTT also
represses components of the basal transcription apparatus such as transcription
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factor II D and F (Zhai et al., 2005). Thus, mHTT mostly decreases gene ex-
pression by sequestering transcription factors away from the promoters at which
they act (Chen-Plotkin et al., 2006). However, mHTT can also directly bind to
deoxyribonucleic acid (DNA) and alter DNA conformation and transcription factor
binding, also resulting in gene expression changes (Benn et al., 2008).
Besides abnormal transcription factor binding, changes in chromatin remodelling
in the form of abnormal histone modification have been demonstrated in HD.
Histone H3K9 hyper-methylation, which is known to cause gene repression, has
been observed in HD post-mortem brains and mouse models (Ryu et al., 2006).
Furthermore, chromatin silencing hypoacetylation of H3 and H4 has been shown
at promoters of genes down-regulated in HD (Labbadia et al., 2011; Sadri-Vakili
et al., 2007). In keeping with the observation that the majority of dysregulated
genes in HD are down-regulated, this suggests a possible general shift towards
a more repressive chromatin state in HD. Taken together these findings suggest
a central role for transcriptional dysregulation in HD pathogenesis.
1.1.5.5 Specific vulnerability of neurons
While HTT is expressed in all cells of the body, the CNS and specifically MSNs
are the most severely affected areas/cells in the body. The origin of this selective
vulnerability remains unclear, but a number of theories have been postulated and
some are discussed below.
One of the first mechanisms proposed for selective vulnerability is excitotoxic-
ity. In contrast to relatively spared, interneurons, MSNs express high levels of
the NMDAR, which can be activated by glutamate. Overactivation of the recep-
tor causes abnormal Ca2+ influx, resulting in apoptosis (Nicholls, 2009). In vivo
stimulation of NMDAR in rats using its agonist quinolinic acid causes striatal le-
sion and resembles HD closely (Beal et al., 1991; Schwarcz et al., 1983), sup-
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porting the hypothesis of excitotoxicity as a major pathogenic pathway in HD. In-
deed, metabolites of the kynurenine 3-monooxygenase (KMO) pathway such as
3-hydroxykynurenine and quinolinic acid are elevated in HD brain (Guidetti et al.,
2006). Furthermore, glutamate removal from synapses by glial cells is reduced in
HD leaving elevated levels of the neurotransmitter in the HD brain (Lie´vens et al.,
2001). Thus, increased levels of these neurotransmitters may cause excitotoxicity
in MSNs in HD leading to striatal atrophy.
Another possible reason for increased atrophy in the striatum over other regions
is altered BDNF signalling. BNDF is a neurotrophin implicated in neurogenesis,
neuronal differentiation, neuronal survival and synaptic plasticity. As described
in Section 1.1.4, loss of wild-type HTT levels causes reduced BDNF levels in
HD patient brains due to both transcriptional dysregulation and trafficking defects
(Gauthier et al., 2004; Zuccato et al., 2001, 2003). Major sites of BDNF synthesis
are the hippocampus and cortex, while the striatum, even though it contains simi-
lar levels of BDNF, has no means of BNDF production on its own and depends on
delivery of the neurotrophin from the cortex (Altar et al., 1997). This may result in
a greater effect of defective BDNF trafficking on the striatum then other parts of
the brain.
Whether either of the mechanisms described above explain selective cellular vul-
nerabilities is still debated. It is clear however, that while they contribute to HD
pathology, neither of them explains all the defects found in HD patients, such as
wide spread transcriptional dysregulation and defects in metabolism. This sug-
gests multiple pathogenic mechanisms in HD rather than just one cause.
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1.1.6 Models of Huntington’s disease
Representative experimental animal models allow the investigation of human dis-
ease to better understand the underlying biology in ways impossible in human
patients. Moreover, animal models are crucial to test experimental therapeutics.
Since the discovery of the HD gene, a variety of animal models have been es-
tablished to help study the disease. While cell culture, fly (Kazemi-Esfarjani and
Benzer, 2000) and worm (Parker et al., 2001) models are helpful in understand-
ing the basics of HD pathology and high-throughput drug screens (Voisine et al.,
2007), their similarities to the human disease is limited (C. elegans genome is
only 40 % homologous to the human one). Investigating the effects of a CAG
expansion in the HTT gene on the mammalian organism is crucial to understand
complex disease pathology. Transgenic mice are the most commonly used model
organism in the HD field, but rat (von Ho¨rsten et al., 2003), pig (Yang et al., 2010),
sheep (Jacobsen et al., 2010) and monkey (Yang et al., 2008) models are also
used.
HD mouse models can be classified depending on how they were generated.
Transgenic fragment models express an N-terminal part of HTT rather than the
full-length gene, while full-length models express the entire HTT sequence. So
called knock-in models also express the whole gene, but are generated by ex-
panding the CAG repeat in the original mouse Htt gene allowing expression of
the mHTT at normal allelic levels.
1.1.6.1 Fragment mouse models of HD
The R6/2 model was the first transgenic HD model to be developed and is cur-
rently the most commonly used in research. The mice ubiquitously express a
transgene for the 5’ end of the human HTT gene carrying only exon 1, including
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150 CAG repeats (Mangiarini et al., 1996). As the mouse model does not express
the full-length HTT gene, it is referred to as a fragment model. The age of disease
onset in the R6/2 mice is around 8 weeks and death occurs between weeks 12
and 15 (Li et al., 2005). The mice display a progressive neurological phenotype
including motor features such as resting tremor, movements resembling chorea
and stereotypic involuntary movements. The underlying brain pathology shows
a 20% reduction in brain volume in R6/2 mice when compared with wild-type
(WT) mice, although no significant neuronal loss is detected (Mangiarini et al.,
1996). Widespread HTT inclusions are found in the brains of R6/2 mice (Meade
et al., 2002) and intranuclear inclusions, present before symptom onset are strik-
ingly similar to the human phenotype (Davies et al., 1997). Detailed behavioural
testing reveals motor deficits in form of reduced rotarod and balance beam per-
formance, as well as learning difficulties in the T-maze and Morris water maze
(Carter et al., 1999; Lione et al., 1999). R6/2 mice also demonstrate peripheral
changes such as weight loss and muscle wasting (van der Burg et al., 2008), key
features of the human disease. At the weaning age of 3 weeks, the R6/2 mice are
no different to WT mice, but with the development of motor features, the weight of
the mice starts to decrease. In addition, R6/2 females are sterile while males are
not (Mangiarini et al., 1996). Further mimicking the peripheral phenotypes of HD
patients, R6/2 mice develop diabetes (Bjo¨rkqvist et al., 2005) and show changes
in their hypothalamic-endocrine system (Bjo¨rkqvist et al., 2006).
The mice display an aggressive and fast-progressing form of HD, although they
only express the first of the 67 exons of HTT. This highlights the importance of
the N-terminus and polyQ domain of the HTT protein. However, the potentially
important process of HTT proteolytic cleavage cannot be modelled in a fragment
model.
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The HD-N171 mouse is another transgenic mouse model used less widely. The
mice express the first 171 amino acids of HTT carrying 82Q under the control
of the PRNP promoter. They display a similar phenotype to the R6/2 model, but
with a less aggressive progression. Motor deficits start at 4 months of age and
end-stage disease is reached after around 6 months (Schilling et al., 1999).
1.1.6.2 Full-length HD mouse models
The most commonly used full-length HD models are the bacterial artificial chro-
mosome (BAC) and yeast artificial chromosome (YAC) HD mice, expressing the
full-length human HTT gene under its own promoter.
While the YAC mice are available with 46 or 72 polyQ repeats (Hodgson et al.,
1999), the most commonly used mice carries 128Q (Slow et al., 2003). A control
line carrying a normal polyQ of 18Q is also available (Hodgson et al., 1999). The
YAC128 mice initially exhibit hyperactivity and develop progressive motor deficits
from the age of 6 months. At 12 months of age, the disease progresses to hypoki-
nesis (Slow et al., 2003). Cognitive impairments, manifest as poor performance
in a swimming T-maze test, are also apparent in YAC128 mice (Van Raamsdonk
et al., 2005a). Within the brain YAC128 mice demonstrate selective degenera-
tion similar to the pattern seen in HD patients. Significant atrophy is seen in the
striatum, globus pallidus and cortex while the hippocampus and cerebellum are
spared (Van Raamsdonk et al., 2005b). Appearance of nuclear mHTT inclusions
coincides with onset of behavioural abnormalities and occur with greater preva-
lence in atrophy-prone brain regions (Van Raamsdonk et al., 2005b).
BACHD mice carry 97Q and, similar to the YAC128 mice, demonstrate slow dis-
ease progression with a normal life span. Motor deficits are first detected at 2
months and manifest robustly around 6 months of age, although no brain atro-
phy is detected at this age. After 12 months of age, selective neurodegeneration,
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primarily in the striatum and cortex, is seen in BACHD mice (Gray et al., 2008).
Interestingly, both the YAC128 and BACHD mice are 20-30 % heavier than WT
mice at all ages (Gray et al., 2008; Slow et al., 2003). Weight loss is a major
feature of HD and is observed in other mouse models (see Section 1.1.6.1 and
1.1.6.3).
1.1.6.3 Knock-in HD mouse models
The most commonly used knock-in models for HD are the HdhQ111 (Wheeler et al.,
1999), CAG140 (Menalled et al., 2003) and Hdh150Q/150Q (Lin et al., 2001) mice,
in which 111, 140 or 150 CAG repeats, respectively, were inserted via gene tar-
geting into the endogenously expressed Htt gene. Overall the knock-in models
have milder phenotypes and a later onset than other models. The CAG140 mice
for example do not show motor symptoms before 1 year of age (Menalled et al.,
2003). For Hdh150Q/150Q , disease onset can be observed from 12 months when
weight starts to drop, to 18 months of age when the motor task deficits are first
noted (Woodman et al., 2007). A recent report found cognitive impairments as
early as 6 months of age, showing deficits in a water maze test (Brooks et al.,
2012). At 22 months, Hdh150Q/150Q mice demonstrate a phenotype similar to 12
week old R6/2 mice, including features such as transcriptional dysregulation in
the striatum and cerebellum, and 20% weight loss (Woodman et al., 2007). Fur-
thermore behavioural and motor deficits, including gait abnormalities, loss of grip
strength and reduced performance at motor tasks, are also observed (Lin et al.,
2001). Widespread Htt aggregates are also detected in the brain and peripheral
organs of Hdh150Q/150Q mice (Moffitt et al., 2009).
In this study, one model of each of the three categories was used to evaluate
immune function and an overview of all three can be found in Table 1.1.
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Table 1.1: Overview of HD mouse models used in this thesis.
R6/2 mice Hdh150Q/150Q YAC128
gene human HTT carry-
ing only exon 1
expansion inserted
in the endogenous
gene - both alleles
entire human gene
CAG
repeat
length
150 150 128 (control line ex-
pressing 18)
age of on-
set
8 weeks 12-18 months 6-9 months
late stage 12-15 weeks 22 months 12 months
motor
pheno-
type
resting tremor,
movements re-
sembling chorea
and involuntary
movements
gait abnormalities,
loss of grip strength
Motor deficits as the
other models, with
hypokinesis late on
brain
pathology
20 % reduction in
brain volume, but
no significant neu-
ronal loss
Similar to R6/2,
transcriptional
dysregulation found
specific cortical and
striatal atrophy, with
striatal neuron loss
peripheral
pheno-
types
weight loss, muscle
wasting, diabetes
20 % weight loss no weight loss-
mice are fat
usage widely used less widely used widely used
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1.1.7 Therapeutic intervention in HD
1.1.7.1 Treatment of symptoms
While no treatment to slow disease progression is available, a wide range of
symptomatic drug treatments are available for HD (reviewed in (Novak and Tabrizi,
2010; Ross and Tabrizi, 2011)). Chorea, one of the most prominent motor phe-
notypes in HD, is commonly treated with neuroleptics such as olanzapine, risperi-
done and haloperidol. Tetrabenazine, the first HD specific symptomatic drug ap-
proved by the FDA (food and drug administration, USA), is a dopamine-depleting
agent used to treat chorea. Selective serotonin reuptake inhibitors such as citalo-
pram and fluoxetine are given to HD patients to treat depression, anxiety or ag-
gression. In addition, non-pharmacological treatments such as physiotherapy to
strengthen gait and balance, and nutritional advice to counteract weight loss are
important to improve the quality of life for HD patients.
1.1.7.2 Strategies to slow disease progression
To date, no cure or treatments to slow the progression of the disease are avail-
able. However, a large amount of research is focused on finding an effective
disease-modifying therapy and several putative approaches are discussed below.
Targeting transcriptional dysregulation
One possible therapeutic target is the transcriptional dysregulation caused by
mHTT. The use of histone deacetylases (HDACs) inhibitors could prevent the
chromatin silencing, hypoacetylation of H3 and H4 found in HD (Labbadia et al.,
2011; Sadri-Vakili et al., 2007) and open chromatin up again. HDACs inhibitors
are already used in cancer and several compounds are available for potential
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clinical trials. In HD, the HDAC inhibitors sodium butyrate (Ferrante et al., 2003)
and SAHA (suberoylanilide hydroxamic acid) (Hockly et al., 2003) have been
shown to improve motor deficits in the R6/2 mouse model of HD by increasing
histone acetylation both in the brain and periphery. Further studies revealed that
SAHA decreases HDAC4 and HDAC2 protein levels in the cortex (Mielcarek et al.,
2011). As SAHA treatment demonstrates toxic side effect (weight loss) in mice
(Hockly et al., 2003), other HDAC4 inhibitors are now being investigated.
Improvement of neuronal function
One way to improve neuronal function and stop neuronal loss is to block exci-
totoxicity caused by overactivation of the NMDAR by glutamate or kynurenine
metabolites. Glutamate receptor antagonists such as rituzole and memantine
have shown promise in HD mouse models, but have shown little effect in clinical
settings (Mestre et al., 2009; Milnerwood et al., 2010). Modulation of the KMO
pathway to reduce the levels of the NMDAR agonists 3-hydroxykynurenine and
quinolinic acid, while increasing the levels of the neuroprotective NMDAR antag-
onist kynurenic acid, has shown beneficial effects in yeast, fly and mouse models
of HD (Campesan et al., 2011; Giorgini et al., 2005; Zwilling et al., 2011).
Another possible way to improve neuronal function in HD is to increase the lev-
els of the neurotrophin BDNF, which is depleted in the HD brain (Gauthier et al.,
2004; Zuccato et al., 2003). Indeed, overexpression of the BDNF gene in YAC128
prevented neuronal loss and motor abnormalities (Xie et al., 2010). Adenoviral
administration of BDNF into the striatum of R6/2 mice delayed motor impairments
and prolonged survival (Cho et al., 2007), demonstrating the promise of this strat-
egy.
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Cellular replacement therapy
Given the striking loss of striatal MSNs early on in the disease, cell replacement
therapies may have great therapeutic potential in later stages of the disease. Sev-
eral studies using allogenic striatal cell grafts in rodent (Hurelbrink et al., 2002;
Pundt et al., 1996) and non-human primates (Palfi et al., 1998) demonstrate graft
integration and recovery of motor and cognitive function. These findings pro-
moted several clinical studies with mixed outcome (reviewed in (Benraiss and
Goldman, 2011)). While some studies saw no clear clinical improvements (Fur-
tado et al., 2005; Kopyov et al., 1998), other groups reported temporary func-
tional integration of the graft and clinical stabilisation (Bachoud-Le´vi et al., 2000).
One major drawback for this approach is the limited access and ethical concerns
surrounding fetal donor cells. Readily renewable sources for transplants have
therefore been investigated. Human embryonic stem cells (hESCs) can be differ-
entiated into MSNs in vitro and integrate in vivo following xenotransplantation in
rats (Aubry et al., 2008). However, ESC-derived grafts have been reported to in-
duce formation of teratomas (Roy et al., 2006). Another problem, using allogenic
graft, is the immune response the host may mount towards the graft.
In a new approach, inducible pluripotent stem cells (iPSCs) isolated and engi-
neered from the patient themselves, are being considered for use, avoiding acti-
vation of the immune system. This strategy involves genetically reprogramming
fibroblasts to iPSCs (Park et al., 2008; Takahashi et al., 2007), before correct-
ing the CAG repeat expansion via homologous recombination, differentiating the
cells into MSNs and transplanting the cells into the brain of the patient. So far,
several human HD iPSC lines have been established (The HD IPSC Consortium,
2012) and it has been shown that correction of the CAG repeat in iPSCs can re-
verse mHTT-driven transcription changes (An et al., 2012). Furthermore, iPSCs
differentiate into DARPP-32 positive striatal neurons in vitro and in vivo (in mice)
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after correction of the CAG repeat, demonstrating the potential of this approach
for therapy (An et al., 2012).
HTT lowering therapies
A conditional mHTT exon 1 expressing mouse model, in which mHTT expressing
can be turned off using doxocycline, showed that lowering the mHTT load in
mice improves brain pathology and behavioural phenotypes (Yamamoto et al.,
2000). For therapy, HTT load can be reduced by either lowering mHTT transcript
expression levels using RNA interference (RNAi) or antisense oligonucleotides
(ASOs), or by increasing the clearance of mHTT protein.
In order to enhance mHTT clearance, the autophagy pathway can be stimulated
(Renna et al., 2010). The use of the autophagy activator rapamycin demonstrates
a decrease in toxic effects in fly and mouse HD models (Ravikumar et al., 2004).
However, the stimulation of cellular protein degradation processes is not specific
to one protein and therefore leads to increased degradation of all proteins, in-
creasing the likelihood of unwanted side-effects.
Small interfering RNAs (siRNA), short hairpin RNA (shRNA) or ASOs, on the
other hand, can be designed to be highly selective for the HTT mRNA transcript.
Both siRNA and shRNA use the cell’s internal micro RNA (miRNA) pathway (Sah
and Aronin, 2011). While miRNAs are naturally encoded in the genome, shRNAs
are delivered and inserted into the genome via viral transduction. The sequences
of both RNAs are then transcribed and cleaved by drosha into hairpin RNAs.
Once exported into the cytoplasm via exportin-5, the hairpins are cut by dicer into
double stranded RNA (dsRNA). siRNA is already a dsRNA molecule and is deliv-
ered into the cytoplasm, joining the miRNA pathway at this stage. All three types
of short RNA can now be incorporated into the RNAi silencing complex (RISC),
where the active guide strand can bind the corresponding target mRNA, activating
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argonaut-2 mediated cleavage and RNA degradation (Rand et al., 2005). ASOs
are single stranded 15-25 bp long oligonucleotides, which also bind their target
mRNA and either cause RNase-H-mediated degradation of the target mRNA or
physically hinder protein translation (Bennett and Swayze, 2010).
When discussing gene silencing approaches for HD, one main question is whether
to lower gene expression of both the wild-type and mutant HTT alleles, or to take
a mHTT specific approach. Since wild-type HTT has a range of functions (dis-
cussed in Section 1.1.4), lowering wild-type HTT levels in cells may have delete-
rious effects on the cells. Indeed, HTT knock-out mice die during embryogenesis
at day E8.5 (Nasir et al., 1995; Zeitlin et al., 1995) and deletion of wild-type HTT
in adult mice causes neuronal loss (especially in the striatum and cortex), motor
deficits and behavioural changes (Dragatsis et al., 2000), underlining the crucial
role wild-type HTT plays in brain development and function.
Initial proof-of-principle studies have knocked-down mHTT by targeting regions
specific to the human mHTT transgene used to generate the mouse (Harper
et al., 2005; Rodriguez-Lebron et al., 2005). These studies showed that partial
lowering of mHTT load (around 70 %) can reduce neuropathology, improve mo-
tor behaviour and extend life in HD-N171(Harper et al., 2005) and R6/1 mouse
models (Rodriguez-Lebron et al., 2005). Interestingly, suppressing wild-type HTT
expression by 60 % in the striatum of mice was found to be tolerated for at least
four months (McBride et al., 2008). Furthermore, non-allele-specific silencing,
by injection of shRNA containing adeno-associated virus (AAV) into the striatum,
has been shown to improve HD phenotypes, while being tolerated in the HD-N171
mice (Boudreau et al., 2009). These data suggest that non-allele-specific silenc-
ing may also be usable as therapy for HD, although more research is needed to
determine the effects of lowering wild-type HTT levels in the cells. Nonetheless,
the prospect of total HTT lowering as therapy is positive, seen that allele-specific
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silencing is likely not to be available for all HD patients. While RNAi is not able
to distinguish between HTT alleles carrying different length CAG repeats, several
single nucleotide polymorphisms (SNPs) have been identified in the HTT gene,
three of which are associated with 75 % of HD patients and can be targeted with
five siRNAs (Lombardi et al., 2009; Pfister et al., 2009). This leaves 25 % of HD
patient without targetable differences between their wild-type and mutant allele at
this point in time. Additionally, all different SNP targeting siRNA are likely to need
separate safety and toxicity evaluations and trials, demonstrating the practical
advantages of one siRNA targeting total HTT (Sah and Aronin, 2011).
Consistent in vivo delivery of the siRNA or ASOs is crucial in CNS disorders.
While peripheral administration is less invasive and capable of targeting periph-
eral tissues affected in the disease, crossing of the blood brain barrier (BBB)
is challenging. Direct delivery into the brain via intraparenchymal or intracerre-
broventricular routes are a way around this and have been used successfully
in different HD mouse models using both RNAi (Boudreau et al., 2009; DiFiglia
et al., 2007) and ASOs (Carroll et al., 2011). Using rhesus macaques, it has
been shown that RNAi delivery into the brain is also safe in larger mammals,
although distribution within the brain and away from the injection site has been
limited (McBride et al., 2011). Implantable infusion systems are used in trials for
Parkinson’s disease to deliver glia-cell derived neurotrophic factor (Lang et al.,
2006; Patel et al., 2005) and could be used in HD. However, peripheral admin-
istration using subtypes of AAV (e.g. AAV9) known to pass the BBB should be
investigated for the use in HD, as they are less invasive and also target peripheral
organs, which are known to also be affected in HD (van der Burg et al., 2009).
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Treatment in the premanifest phase of disease
In the search for a treatment, it is important to note that a significant amount
of neuronal loss occurs before clinical onset of the disease. Treatment of pre-
manifest gene carriers would be optimal to rescue this neuronal function. As
HD is caused by a single, fully penetrant mutation in the HTT gene, HD gene
carriers can be identified before onset of clinical symptoms. This allows the
study of pathogenic events preceding clinical onset by many years and makes
pre-symptomatic treatment a feasible possibility (reviewed in (Ross and Tabrizi,
2011)).
However, in order to treat HD gene carriers without symptoms, robust biomarkers
are needed to track the success of any treatment. These biomarkers should track
with disease progression and already be changed in premanifest gene carrier,
while not being present in the control population. So far a range of clinical as-
sessments in the form of motor and cognitive tasks, and neuroimaging measures
have been validated as endpoints for clinical trials. A set of nineteen cognitive
tasks assessing psychomotor, memory and facial recognition has proven sen-
sitive to distinguish individuals according to the time to predicted onset (Stout
et al., 2011). The TRACK-HD study further identified emotion recognition and
speed tapping tasks as clinical endpoints for trials (Tabrizi et al., 2012). Using 3
tesla magnetic resonance imaging (3T MRI), striatum and white matter atrophy
were found to be significantly increased in premanifest gene carriers compared
with controls over 24 months (Tabrizi et al., 2012). Given the need to measure at-
rophy rates over 24 months to acquire robust data usable as biomarker, the need
for new instantly measurable biomarkers remains high.
Biochemical biomarkers are molecules that can be measured in body fluids. The
use of cerebrospinal fluid (CFS) is particularly appealing as it carries high con-
centrations of brain proteins, but due to the invasive nature of lumbar puncture
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the method is less usable in a clinical setting for HD. Blood samples on the other
hand, are easy to acquire and contain molecules from the periphery and CNS. In
addition dysfunction of blood cells (Bjo¨rkqvist et al., 2008) may also be quantifi-
able as biomarker. Discrepant and highly variable findings from many biochemi-
cal compounds tested so far limit their potential as biomarkers and no robust wet
biomarker has been identified for HD yet. However, increased levels of 8-hydroxy-
2-deoxyguanosine and pro-inflammatory cytokines interleukin (IL)-6 and tumour
necrosis factor (TNF)α, and decreased levels of (insulin-like growth factor) IGF-
1, BDNF, glutathione peroxidase and copperzinc superoxide dismutase all show
promise as possible biomarkers (reviewed in (Weir et al., 2011)), but further work
to validate each of these molecules is needed.
1.2 The immune system
The immune system is a collection of various haematopoietic cells and molecules,
which work together to protect the body from infectious organisms and the dam-
age these may cause. In order to protect individuals effectively against diseases,
the immune system has to recognise and detect the infection to then eliminate
it. The immune system is subdivided in two arms: the innate and the adaptive
immune system (Walport et al., 2008).
1.2.1 The innate immune system
The innate immune system provides immediate defence against pathogens by a
process called inflammation. Specialised chemical mediators, such as cytokines
and chemokines, are produced at the site of infection, and innate immune cells
such as monocytes, macrophages, dendritic cells (DCs) and granulocytes are
thereby recruited. These cells have the ability to identify simple, regularly oc-
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curring molecules on microbes, called pathogen-associated molecular patterns
(PAMPs) with their germ line-encoded pattern recognition receptors (PRRs). De-
pending on the cell type, they can either kill the microbe by releasing toxic sub-
stances (granulocytes) or phagocytose them (macrophages and DCs). Engulfing
the microorganism not only aids the clearance of the infection locally, but is also
the first step to activate the adaptive immune system as it results in antigen pre-
sentation (Walport et al., 2008).
1.2.1.1 Haematopoiesis of myeloid cells
Haematopoietic stem cells (HSC) are located within the bone marrow and give
rise to all blood cell types, including lymphocytes, myeloid cell, erythrocytes and
megakaryocytes, the cells producing platelets. HSCs differentiate into multi-
potent progenitor (MPP) cells before committing to common lymphoid progeni-
tors (CLPs) or common myeloid progenitors (CMPs). CMPs can then either be-
come megakaryocyte/erythrocyte progenitors or granulocyte/monocyte progeni-
tors (GM-CFUs) (Gereige and Mikkola, 2009).
During development, the first wave of haematopoietic progenitors appear in the
extra-embryonic yolk sack leading to the production of primitive macrophages
(Gordon and Taylor, 2005). Later during fetal development, progenitor cells start
colonising in the fetal liver and produces large numbers of macrophages, which
in turn migrate to all organs to establish tissue macrophages populations (Gor-
don and Taylor, 2005). In adults, monocytes differentiate within the bone marrow.
GM-CFUs differentiate via different developmental stages such as macrophages
colony-forming unit (M-CFU), monoblasts and pro-monocytes, into inflammatory
monocytes and enter the blood stream (Figure 1.4). These circulating monocytes
patrol the blood stream for danger signals and can migrate into tissues to give
rise to different antigen presenting cells: tissue resident macrophages and DCs.
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Recruitment into tissues is increased by pro-inflammatory and metabolic stimuli,
contributing to host defense and tissue repair (Gordon and Taylor, 2005). Re-
search into the origin of the brain macrophage population has shown that these
cells, called microglia, originate from a erythromyeloid precursor during the initial
wave of haematopoisis in the yolk sack and not from blood monocytes like the
other tissue macrophage types (Chan et al., 2007; Ginhoux et al., 2010; Kierdorf
et al., 2013).
It is to note that, while monocytes can differentiate into DCs, classical DCs and
plasmacytoid DC differentiate directly from CMPs. Furthermore, the lymphoid DC
subtype originated directly from CLPs (Geissmann et al., 2010).
1.2.1.2 Monocytes
Monocytes are a heterogenous population compromising 10 % of peripheral blood
leukocytes in humans and 4% in mouse. The cells vary in size as well as nuclear
morphology and degree of granularity (Auffray et al., 2009). In humans, mono-
cytes are characterised by their high surface expression of Cluster of differen-
tiation (CD)14. Depending on CD16 expression levels on the cell surface, two
monocyte subtypes are functionally distinguishable: CD14high CD16− monocytes
and CD14+ CD16+ monocytes (Passlick et al., 1989).
All monocytes circulating in the blood stream will migrate into different tissues
sooner or later. Therefore, monocytes express different chemokine receptors.
Chemokines are small molecules that establish a chemotactic gradient from their
release point, which attracts cells carrying the corresponding receptor. The mono-
cyte chemoattractant protein 1 (MCP-1, also called CCL2) is one of the key regu-
lators of monocyte and macrophage migration during inflammation, and acts via
its cell surface receptor (CCR2). Interestingly, monocytes and macrophages are
also the main producer of MCP-1 (Deshmane et al., 2009). Classical CD14high
60
The immune system Introduction
Figure 1.4: Development of monocytes, macrophages and DCs. Fetal and adult
monocyte development shown from its origin in the bone marrow over blood to
their final destination in different tissue. HSC: haematopoietic stem cell, GM-CFS:
granulocyte/macrophage colony-forming units, M-CFU: macrophage colony-forming
units, G-CFU: granulocyte colony-forming units. Reprinted by permission from Macmillan
Publishers Ltd: Nature Reviews Immunology, Gordon and Taylor, 2005. ©2005.
CD16− monocytes express high levels of the CCR2 chemokine receptor, whilst
CD14+CD16+ monocytes express CCR5 and not CCR2. It is therefore thought
that CD14high CD16− monocytes circulate in the blood and respond to inflamma-
tory activators such as MCP-1, while CD14+ CD16+ monocytes represent a more
mature phenotype found in one place in the tissue producing high levels of pro-
inflammatory cytokines (Ziegler-Heitbrock, 2007). In mouse, monocytes express
CD11b and two subsets similar to humans are distinguishable: CCR2+CXCR1−
Ly6C+ migratory monocytes and CCR2− CXCR1+ Ly6C− resident, inflammatory
monocytes (Gordon and Taylor, 2005).
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1.2.1.3 Macrophages
Tissue-specific macrophages are the resident phagocytic cells and play an im-
portant role in homeostasis as well as inflammation. They are highly specialised
after differentiation and demonstrate different phenotypes depending on their lo-
cation (Gordon and Taylor, 2005). For example, osteoclasts are macrophages
specialised in bone remodelling and Kupffer cells can be found in the liver clear-
ing debris from the blood and regenerating liver tissue after damage (Mosser and
Edwards, 2008; Pollard, 2009).
The CNS is populated by more than one type of macrophage. Microglia are dis-
tributed equally throughout the brain, while perivascular macrophages and men-
ingeal macrophages can only be found in regions where they are exposed to
circulating blood. Interestingly, while all three cell types are from mesenchy-
mal/ myeloid origin, microglia demonstrate distinct differences from the other
central and peripheral macrophage types. Firstly, while macrophages are typ-
ically round, microglia have numerous process extensions with which the cells
constantly and actively survey the whole brain (Nimmerjahn et al., 2005). Sec-
ondly, microglia demonstrate an actively repressed phenotype compared with
other tissue macrophage populations. Interactions between neurons and mi-
croglia, e.g. the interaction between surface molecule CD200 and its receptor
CD200R, keeps microglia in their inactive state. Disturbance of this interac-
tion, for example by neuronal loss leads to activation of microglia (Hoek et al.,
2000). Thirdly, macrophages and microglia differ in the way they can be acti-
vated (Ransohoff and Perry, 2009). Peripheral macrophages respond to both
stranger signals (e.g. lipopolysaccharide (LPS) or dsRNA) and danger signals
(cytokines such as TNFα). Macrophages can be activated either classically with
LPS and type-1 cytokines such as interferon (IFN)-γ or alternatively with IL-4
and IL-10. Classically activated macrophages usually produce pro-inflammatory
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response triggering cytokines such as IL-6, IL-1, IL-12 and TNF-α as well as
reactive nitrogen and oxygen species (NO, superoxide). Alternatively activated
macrophages are more anti-inflammatory, producing low levels of IL-6 and IL-1,
but high levels of IL-10 and transformation growth factor (TGF)-β (Martinez et al.,
2006; Van Ginderachter et al., 2006). Triggers for microglia activation are dis-
tinctively different. Microglia are located behind the BBB and therefore normally
protected from serum proteins. The presence of serum protein such as fibrinogen
indicates a breach of BBB integrity and activates microglia (Adams et al., 2007).
Given their close interaction with neurons in steady state, microglia are also ac-
tivated by changes in neurotransmitter levels such as glutamate and adenosine
triphosphate (ATP) (Haynes et al., 2006; Taylor et al., 2003), and by the loss of
neuronal input (Hoek et al., 2000). But microglia also respond to chemokine and
cytokine similar to peripheral macrophages (reviewed in (Ransohoff and Perry,
2009)). Thus, while microglia are from the same myeloid progenitor as other
peripheral macrophages they differ distinctively, while sharing some signalling
cascades such as NFκB.
Tissues are populated by macrophages and DCs during development, raising the
question as to whether these populations are self-renewing or constantly replen-
ished by infiltrating blood monocytes. Most tissue-specific macrophage popula-
tions are thought to be self-renewing under steady state conditions but can be re-
plenished from blood monocytes under stress/inflammation (Merad et al., 2002).
Microglia, however, seem to originate from erythromyeloid precursors during the
first wave of haematopoiesis in the embryo (Kierdorf et al., 2013) and be sus-
tained by self-renewal life long (Ajami et al., 2007). During inflammation microglia
expand rapidly locally, causing microgliosis solely by expansion of the endoge-
nous microglia population with little contribution and infiltration of peripheral cells
(Ajami et al., 2007). While microglia are self-renewing, stem cells are capable of
replenishing the microglia pool in the brain. This has been shown using trans-
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plantation studies in which lethally irradiated mice were injected with green fluo-
rescent stem cells (Simard and Rivest, 2004). The cells migrated into the CNS
and differentiated into fully functional microglia. However, while this proves the
haematopoetic origin of microglia, it does not model steady state conditions as
γ-whole body irradiation induces temporary holes in the BBB allowing infiltration
of peripheral cells (Diserbo et al., 2002).
1.2.1.4 Innate immune cell function
In response to inflammatory stimuli, peripheral as well as central innate immune
cells migrate to the site of infection or injury. They produce increased levels of
cytokines, chemokines and other inflammation markers in order to recruit and ac-
tivate other immune cells. Furthermore, presentation of antigens to the adaptive
immune system is a key function of macrophages and DCs. The cells acquire
these antigens via phagocytosis. Protein fragments of the particles taking up can
then be processed and presented to T cells via major histocompatibility complex
(MHC) class II (Walport et al., 2008).
Migration
Blood monocytes and tissue macrophages can, once activated by a danger sig-
nal, migrate into tissues or secondary lymphoid tissues, respectively. Migration
is driven by chemoattractants forming a gradient towards the site of infection, re-
quires adhesive interactions between the leukocytes and endothelial cells, and
remodeling of the actin cytoskeleton.
Actin is a 42 kDa protein, which in monomeric form is called globular (G)-actin.
G-actin can be transformed into a polymeric filament (F-actin) by binding of ATP
which stimulates the formation of G-actin dimers, which function as nucleation
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sites for the formation of long filaments. F-actin fibres are polarised with a barbed-
end which is elongated. Capping of the barbed-end stops filament growth (Stos-
sel et al., 2006). This process is regulated and modulated by different intracellular
molecules and signalling pathways.
On immune cells, chemokine receptors, which are typically guanosine-5’-diphos-
phate (GDP) heterotrimeric G-protein binding serpentine receptors, induce a sig-
nalling cascade modulating the actin cytoskeleton. Activation of the phosphatidyli-
nositide 3-kinases (PI3K) leads to the phosphorylation of phosphatidylinositol
(4,5)-bisphosphate (PIP2) to PIP3, which can in turn activate guanine nucleotide
exchange factors (GEFs). GEFs switch Rho GTPases, the critical signal trans-
ducer between membrane receptors and the cytoskeleton, from an inactivated
state binding GDP to an activated guanosine-5’-triphosphate (GTP)-bound state
(Jones, 2000). Members of the Rho family include RhoA (formation of stress
fibres), Rac1 (formation of lammelipodia) and CDC42 (formation of filopodia)
(Nobes and Hall, 1995). Upon activation, Rho GTPases interact with various
proteins to initiate actin polymerisation. One protein complex they interact with
is the actin-related protein 2/3 (ARP2/3) complex. ARP2/3 binds, mediated by
Wiskott-Aldrich syndrome proteins (WASP), pre-existing actin filaments and func-
tions as a nucleation seed, mimicking dimeric G-actin, for polymerisation of new
actin branches (Prehoda et al., 2000). Linear elongation of actin without branch-
ing is mediated by formins, which remain bound to the growing end of the actin
fibre and mediate linear polymerisation (Chesarone et al., 2010). Profilin aids
polymerisation, by binding G-actin, catalysing the exchange of adenosine diphos-
phate (ADP) to ATP on the actin monomers and recruiting the actin-ATP monomer
to a barbed end of a actin filament (Kang et al., 1999). Other proteins such as
cofilin severs existing actin filaments and contribute to actin dissociation. Cofilin
is inhibited by phosphorylation, allowing F-actin growth. In the leading edge actin
severing generates new actin filaments to which ARP2/3 can bind and stimulate
65
The immune system Introduction
branching (Ridley, 2011).
Reorganisation of the actin network and polymerisation of actin filaments against
cell membranes provides the force necessary for cellular movement, which oc-
curs in three steps (Figure 1.5) (Mattila and Lappalainen, 2008). At first, protru-
sive structures, called lamellipodia and filopodia, form at the leading edge. Lamel-
lipodia are thin (0.1-0.2 µm) sheet like structures containing a branched network
of actin. Filopodia are 0.1-0.2 µm in diameter and up to 20 µm long finger-like
structures developing on the edge of the lammelipodia. They are supported by a
core of tightly bundled F-actin filaments. In both structures, the barbed-ends of
the actin fibres are located towards the cell membrane, with elongation of the fil-
aments leading to cell extension (Jones, 2000). The leading edge then connects
to the surface, while the cell nucleus and plasma moves towards the new centre
of the cell due to the actinmyosin contraction forces on the cells. Lastly, the actin
myosin fibres retract at the tail of the cell, the cell detaches from the substrate
and the whole cell retracts (Mattila and Lappalainen, 2008).
Cytokine production during inflammation
Innate immune cells are activated by PAMPs, these are molecules that different
bacteria and virus have in common and present a danger signal. To recognise
these molecules innate immune cells express PPRs such as Toll like receptors
(TLRs) (Walport et al., 2008). The eleven TLRs described in humans so far com-
prise a major group of PPRs and play a key role in inflammation (reviewed in
(Kumar et al., 2009; Takeda et al., 2003)). TLRs dimerise to achieve highly spe-
cific molecule recognition (reviewed in (Kumar et al., 2009; Okun et al., 2009)).
While most TLRs build homodimers, TLR2 forms heterodimers with TLR6 (to
recognise peptidoglycan, the main component of the gram-positive bacterial cell
wall, and fungal zymosan) and TLR1 (to recognise lipopeptides). TLR4 is the
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Figure 1.5: Cell migration occurs in three steps. (a) The actin driven protrusion of
lammelipodia and filopodia at the leading edge, is followed by (b) adhesion of the leading
edge to the substrate, initiated by filopodia. Finally, (c+d) contraction of the cytoplasmic
actin fibre and disassembly of the cell adhesion points lead to retraction of the tail end.
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Molecular cell
biology, Mattila and Lappalainen, 2008. ©2008.
67
The immune system Introduction
main receptor for LPS, an endotoxin from gram-negative bacteria known to elicit
strong immune responses in mammals and frequently used as an experimental
stimulus in vitro (Kumar et al., 2009). Following TLR stimuli, several signalling
cascades are activated (Figure 1.6).
Figure 1.6: Signalling downstream of TLR4. Activation of TLR4 leads to activation
of different signalling pathways including activation of the NFκB, MAPK and PI3K/AKT
pathway via MyD88, IRAK1/4 and TRAF6. Independent from MyD88, interferon response
factors (IRFs) are activated.
One of the signalling cascades activated downstream of TLR4 is the nuclear fac-
tor kappa-light-chain-enhancer of activated B cells (NFκB) pathway. Toll-inter-
leukin 1 receptor domains of ligand-bound TLRs interact with adapter molecules
such as myeloid differentiation primary response gene 88 (MyD88), TIR-domain-
containing adapter-inducing interferon-β (TRIF) and TRIF- related adaptor mol-
ecule (TRAM) (Yamamoto et al., 2003). MyD88 carries a death domain with
which it activates IL-IR-associated kinases (IRAK), leading to the phosphoryla-
tion and activation of IKK (IκB kinase). This kinase in turn phosphorylates IκB
(inhibitor of kappa B), which is then ubiquitinated and degraded by the protea-
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some, thereby dissociating from NFκB transcription factors it sequestered in the
cytoplasm. The free NFκB molecules can then translocate to the nucleus and
activate gene transcription (Figure 1.6) (Beinke and Ley, 2004). The NFκB family
has five members- NFκB1 (or p50), NFκB2 (or p52), RelA (or p65), RelB and
c-Rel. These molecules build homo- or heterodimers to activate transcription of
over 150 target genes including pro-inflammatory cytokines (IL-6, TNF-α, IL-1β ),
cell adhesion molecules (ICAM-1, P-selectin), and acute phase proteins as well
as growth factors (GM-CSF) (Pahl, 1999).
Other pathways activated downstream of TLR4 are the PI3K/ AKT/ mTOR (Phos-
phatidylinositide 3-kinases/ Protein Kinase B (PKB)/ mammalian target of ra-
pamycin) and MAPK (mitogen-activated protein kinases) pathways. PI3K is ac-
tivated downstream of TLR by the adapter proteins MyD88, which binds PI3K’s
catalytic p85 subunit and thereby activates the kinase (Laird et al., 2009). PI3K
then produces phosphatidylinositol-3,4-bisphosphate, which AKT can bind via its
pleckstrin homology domain (Franke et al., 1997). Once membrane bound, AKT
phosphorylates itself and interacts with downstream effectors such as the NFκB
pathway by inducing the activation of IKK via mTOR (Dan et al., 2008). The MAPK
pathway is activated via the adapter protein TNF receptor associated factors 6
(TRAF6) downstream of MyD88, which activates the MAPK kinase kinase called
transforming growth factor β activated kinase (TAK-1). TAK-1, in turn, phospho-
rylates the MAPK kinases, MKK3 and MKK6, upstream of p38 MAPK and c-Jun
N-terminal kinases (JNK), and thereby leads to the activation of the transcription
factors AP-1 (activator protein 1) and ELK (E twenty-six (ETS)-like transcription
factor 1) (Barton and Medzhitov, 2003).
In addition to signalling downstream of TLR receptors, the JAK/STAT (janus ki-
nase/ signal transducer and activator of transcription) signalling pathway is a key
element in the communication between immune cells and is mainly activated
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through cytokine receptors. Cytokines binding their receptors lead to the acti-
vation and cross-phosphorylation of JAK molecules. In turn the tyrosine kinases
phosphorylate the intracellular domain of the receptor. STAT molecules then bind
these phosphotyrosine residues with their SH2 domain and get phosphorylated
by JAK allowing the STATs to dimerise via a phosphotyrosine-SH2 interaction
and STAT dimers translocate into the nucleus to act as transcription factors and
induce transcription of cytokine genes (Figure 1.7) (Shuai and Liu, 2003).
Figure 1.7: JAK/STAT signalling pathway. Cytokine receptor dimerisation leads first
to phosphorylation of janus kinases (JAK) followed by STAT phosphorylation. Phospho-
STATs dimerise and affect transcription in the nucleus. Reprinted by permission from
Macmillan Publishers Ltd: Nature Reviews Immunology, Shuai and Lui, 2003. ©2003.
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Transcription of the genes encoding for cytokines is followed by the translation
into proteins and cytokine release from the cell. In the classical cytokine release
pathway, cytokines are translated in the ER and Golgi before they are secreted
via secretory granules or vesicles. This release can be constitutive or regulated
by receptor binding of the vesicle before release (Lacy and Stow, 2011). Non-
classical ways of cytokine release include membrane transporters, exosome re-
lease, microvesicle shedding and cell lysis (Lacy and Stow, 2011). TNFα and IL-6
are both secreted via the classical ER/ Golgi pathway. TNFα is membrane bound
and cleaved extracellularly by metalloproteases (Shurety et al., 2000), while IL-
6 is released in a soluble form (Manderson et al., 2007). IL-1β is released in
a non-classical way; first a pro-form is produced and accumulates in the cyto-
plasm, before upon cell activation the proform is cleaved by caspase-1 and IL-1β
is secreted. The exact way of IL-β secretion depends on the cell type, but mecha-
nisms include cell lysis, exocytosis via the secretory lysosomes and microvesicle
shedding (Eder, 2009).
Phagocytosis
Both macrophages and immature DCs can ingest particles in a process called
phagocytosis. Special receptors on the phagocytic cells can bind either PAMPs
on the intruder, complement factor C3b or antibodies bound to the intruder, trig-
gering the cytoskeleton to change and the cell membrane to close around the
particle forming a phagosome. The phagosome then fuses with the lysosome
and internalised particles or microbes are degraded by proteases. The resulting
peptides are loaded onto MHC II molecules and presented on the cell surface to
activate the adaptive immune system (Walport et al., 2008).
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1.2.2 The adaptive immune system
The adaptive immune response is mediated by two types of lymphocytes: T cells,
which develop in the thymus and B cells, that develop in the bone marrow.
The T cell receptor (TCR) on the surface of T cells recognises peptide fragments
presented on MHC molecules on the surface of other cells. In addition, T cells
express a co-receptor, either CD4 or CD8. These molecules determine whether
the TCR can bind MHC class II (only expressed on specialised antigen presenting
cells like DCs, macrophages and B cells) or MHC class I molecules (expressed on
all cells). There are different types of CD4+ effector T cells, which differ in their
cytokine production profile: Thelper1 (Th1), which mainly activate macrophages;
Th2, which activate B cells; Th17, which enhance the neutrophil response and
regulatory T cells (Treg), which dampen the immune response. CD8+ effector T
cells specific for the displayed peptide kill the presenting cell by releasing toxic
substances (degranulation).
Naive B cells express a receptor called surface immunoglobulin (Ig). Immunoglob-
ulins can bind soluble and membrane bound chemical structures. When B cells
bind their antigen, they internalise it and present it on MHC class II to antigen-
specific CD4+ Th2 cells. These in turn stimulate the B cells by providing co-
stimulatory signals like CD40-CD40 ligand interaction and cytokine production.
Effector B cells are called plasma cells as the cells enlarge their cytoplasm and
ER to produce antibodies, soluble forms of the B cell receptor. Both T and B cells
have the ability of establishing a long-lasting memory immune response (Walport
et al., 2008).
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1.3 Immune dysfunction in Huntington’s disease
1.3.1 Central immune dysfunction
Neuroinflammation is becoming increasingly associated with neurodegenerative
disorder such as Parkinson’s, Alzheimer’s and Huntington’s disease. In all three
diseases, microglia are found to be activated. It remains, however, unclear as to
whether the cells act in an immunoprotective manner, or if they contribute to the
disease pathology (reviewed in (Bjo¨rkqvist et al., 2009)).
Increased complement production by microglia (e.g. C3 and C4), and comple-
ment activation of neurones, myelin and astrocytes, has been demonstrated in
the striatum of HD patients (Singhrao et al., 1999). Furthermore, post-mortem
studies of HD brains found an accumulation of activated microglia and reactive
gliosis in regions affected by HD such as the striatum and cortex (Sapp et al.,
2001; Vonsattel et al., 1985). Positron-emission tomography (PET) studies, us-
ing 11C-(R)-PK11195 binding peripheral benzodiazepine receptors as a surro-
gate marker of microglial activation, supported these finding by demonstrating
early microglial activation in premanifest gene carriers in the striatum and cor-
tex (Tai et al., 2007). Microglial activation further correlates to striatal neuronal
dysfunction measured by 11C-raclopride PET (Tai et al., 2007). The same group
showed that the level of microglial activation correlates with the neuronal loss,
again measured by 11C-raclopride PET and disease severity, measured by the
Unified Huntington’s Disease Rating Scale (UHDRS) score (Pavese et al., 2006).
1.3.2 Peripheral immune dysfunction
Alongside dysfunction of CNS immune cells, peripheral immune cells such as
monocytes are found to behave abnormally. Proteomic profiling of HD plasma
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samples identified several abnormal proteins that correlate with disease progres-
sion and that are involved in the regulation of the innate immune system. Those
include immune molecules IL-6 and complement proteins C7 and C9, as well as
clusterin and β -actin, each of which were identified as significantly up-regulated
in HD patient plasma compared with controls (Dalrymple et al., 2007).
Widespread activation of the innate immune system is detectable in HD plasma
throughout the course of disease. Abnormal IL-6 levels in plasma are detectable
on average sixteen years before the predicted onset of clinical signs. Additionally,
serum levels of other pro-inflammatory cytokines such as IL-8 and TNFα are in-
creased significantly in HD versus control samples (Bjo¨rkqvist et al., 2008). Simi-
larly chemokine levels are elevated in HD patients plasma compared with control
(Wild et al., 2011). Furthermore, cytokines levels are also up-regulated in post-
mortem striatal tissue and IL-6 and IL-8 levels in human CSF correlate strongly
with peripheral cytokine levels (Bjo¨rkqvist et al., 2008). It has been shown that
peripheral human monocytes express mHTT and are hyper-reactive in terms of
IL-6 production upon LPS stimulation in vitro. The same was found after stimula-
tion of macrophages and microglia from different HD mouse models, suggesting
that mHTT triggers cell-autonomous innate immune activation in the CNS and
periphery in parallel (Bjo¨rkqvist et al., 2008) (Figure 1.8).
The NFκB pathway has previously been implicated in HD. Khoshnan et al. have
shown that overexpression of mHTT exon 1 can activate the NFκB pathway by
directly interacting with IKK in inducible rat PC12 cells and striatal extracts from
R6/2 mice (Khoshnan et al., 2004). This pathway is therefore a possible mecha-
nistic candidate for the increased production of IL-6 in peripheral and central im-
mune cells in HD. However it remains to be seen that this interaction also occurs
in a human system with expression of full-length HTT at normal allelic expression
levels. Another candidate pathway for alteration in HD is JAK/STAT signalling
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Figure 1.8: Immune activation, induced by mutant HTT, in both peripheral and cen-
tral immune cells in HD. Innate immune cell dysfunction is caused by mHTT indepen-
dently in microglia and blood monocytes leading to increased cytokine production and
thereby interaction with surrounding cells. On a cellular bases these changes might be
caused by altered cellular signalling. ©Bjo¨rkqvist et al., 2008. Originally published in J
Exp Med 205: 1869-1877. DOI jem.20080178.
pathway, which takes part in the regulation of cellular responses to cytokines.
1.3.3 The immune system as modifier of disease progression
Alongside immune cell dysfunction, several recent studies have suggested that
the peripheral immune system can act as a modifier of HD neuropathology. Bone
marrow transplantation of wild-type cells into two lethally irradiated HD mouse
models normalises abnormal peripheral levels of cytokines and chemokines, and
partially suppresses motor and neuropathological defects (Kwan et al., 2012a).
In HD, excitotoxicity has been linked to metabolites of the KMO pathway. While
quinolinic acid is an agonist for NMDA causing excitotoxicity, kynurenic acid is
a neuroprotective antagonist. Oral administration of a small-molecule prodrug
inhibitor of KMO increases kynurenic acid levels, while extending the life span,
preventing synaptic loss, and decreasing microglial activation in a mouse model
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of HD. As the drug cannot cross the blood brain barrier, the neuroprotective ef-
fect via increased brain kynurenic acid levels is secondary to inhibition of KMO in
peripheral immune cells (Zwilling et al., 2011). Studies in an HD fly model have
shown similar results, as inhibition of KMO leads to the accumulation of neuro-
protective metabolites and ameliorates neurodegeneration in the fly (Campesan
et al., 2011).
Furthermore, modulation of the cannabinoid receptor 2 (CB2) has proven to
modulate HD progression (Bouchard et al., 2012). CB2 is expressed on cen-
tral and peripheral immune cells and is critical in decreasing the production of
pro-inflammatory cytokines during inflammation by dampening the NFκB sig-
nalling cascade. Genetically deleting CB2 accelerated the disease onset and
behavioural deficits (Bouchard et al., 2012; Palazuelos et al., 2009), while treat-
ment with a CB2 agonist suppresses motor deficits and CNS inflammation while
extending life span in an HD mouse model. Strikingly, this positive effect can
be blocked with an antagonist that is restricted to the periphery, demonstrating
the importance of peripheral immune cells in modulating the pathogenesis of HD
(Bouchard et al., 2012).
Together, these studies provide strong evidence that the immune system plays
a disease-modifying role in HD neuropathogenesis, but the mechanism by which
mHTT expression in human immune cells causes this effect has not yet been
established.
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1.4 Aims of my thesis
1. Characterisation of monocytes and macrophage cell functions such as cy-
tokine production, phagocytosis and migration in HD patients versus control
samples.
2. Identification of the mechanism(s) by which mHTT expression causes hu-
man immune cell dysfunction.
3. Modulation of HTT levels by overexpression and siRNA-mediated knock-
down techniques to investigate the role cell-intrinsic HTT plays in human
HD monocyte and macrophage function and test the feasibility of reversing
peripheral immune dysregulation by cell-targeted HTT-lowering.
4. Measurement of total and mHTT levels in primary human immune cell sub-
sets, as a potential biomarker for HD progression.
5. Evaluation of HD mouse models as to the models’ ability to mimic the im-
munological changes found in HD patients.
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2.1 Materials
Standard tissue culture plates and flasks were bought from Corning. Primary hu-
man and murine monocytes were grown in BD Primaria plates (BD Biosciences).
Other tissue culture materials such as phosphate buffered saline (PBS), Hank’s
buffered salt solution (HBSS), RPMI1640 media, OptiMEM media, trypsin, fetal
calf serum (FCS), L-glutamine and penicillin/streptomycin were bought from Invit-
rogen. If not stated otherwise lab chemicals were bought from Sigma Aldrich. Re-
combinant cytokines and chemokines such as human and murine MCP-1, human
RANTES, human granulocyte-macrophage colony-stimulating factor (GM-CSF),
human IL-6, human and murine IFNγ and murine macrophage colony-stimulating
factor (M-CSF) were bought from R&D Systems. ATP and LPS were bought from
Sigma Aldrich and C5a from Calbiochem. Magnets, magnetic beads and columns
for magnetic cells sorting (MACS) were bought from Miltenyi.
2.2 Human subjects
All human experiments were performed in accordance with the Declaration of
Helsinki and approved by the University College London (UCL)/UCL Hospitals
Joint Research Ethics Committee (LREC 03/N008). All subjects provided in-
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formed written consent. Blood samples were obtained from control subjects and
genetically-diagnosed HD patients, recruited from the Huntington’s disease clinic
at the National Hospital for Neurology and Neurosurgery, London. Premanifest
HD mutation carriers were identified according to the absence of diagnostic mo-
tor abnormalities on the UHSRS (Huntington Study Group, 1996), whilst patients
with motor abnormalities were classed as having early or moderate-stage dis-
ease using the total functional capacity (TFC) scale (13-7, early; 6-3, moderate)
(Shoulson, 1981). Subjects with inflammatory or infective conditions were ex-
cluded.
2.3 Animals
R6/2 (Mangiarini et al., 1996) and Hdh150Q/150Q (Lin et al., 2001) mice were kindly
provided by Prof Gillian Bates and bred in facilities at King’s College London.
The R6/2 mice were bred by backcrossing R6/2 males to (CBA×C57BL/6)-F1
females. Hdh150Q/150Q mice were on a mixed C57BL/6/CBA background, crossing
CBA Hdh150Q/150Q males with C57BL/6 Hdh150Q/150Q females. All animals had
unlimited access to water and breeding chow (Special Diet Services) in open-top
cages. R6/2 mice were also given mashed food consisting of powdered chow
mixed with water from 12 weeks of age. Mice were housed with WT mice and
were subject to a 12 h light dark cycle.
2.4 Magnetic resonance imaging (MRI)
Volumetric 3T MRI sequences were obtained as part of the TRACK-HD study
London cohort. Details of the imaging protocols and rigorous quality control pro-
cedures used in the study are published (Tabrizi et al., 2009, 2012, 2011). Follow-
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up scans were positionally matched to the baseline images and change over 36
months was calculated using the robust boundary shift integral technique (Le-
ung et al., 2010). Rates of atrophy were expressed as a percentage of baseline
volume and annualised. All image analysis was carried out blinded to subject
identity and group.
2.5 Tissue culture
Work with cell lines and primary cells was carried out in a designated tissue cul-
ture facility using strict aseptic technique. All media and solutions were bought
pre-sterilised and sterile plastic-ware was used. All procedures, including prepa-
ration of media, were performed in a tissue culture hood with a laminar flow unit.
All solutions and media were pre-warmed to 37 ◦C prior to use. All cells were
cultured in an incubator at 37 ◦C with 5% CO2.
2.5.1 Maintenance of cell lines
Vials containing frozen cells were removed from liquid nitrogen and were thawed
rapidly in a 37 ◦C water bath. The cell suspension was added to 10 ml of appro-
priate pre-warmed media and centrifuged at 300×g for 5 min. The supernatant
was then decanted, the cells resuspended in 5 ml fresh standard growth medium
and seeded into 25 mm2 filter-capped tissue culture flasks.
For freezing, cells were counted using a Neubauer counting chamber and 2×106
cells were centrifuged for 5 min at 300×g. Pellets were resuspended in 1.5 ml
freezing media (90 % FCS and 10 % DMSO), dispensed into sterile cryovials and
put in an isopropanol-regulated cryopreservation box at -80 ◦C overnight before
long term storage in liquid nitrogen.
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U937 cells
U937 cells are a human histiocytic lymphoma cell line, established in 1974 (Sund-
stro¨m and Nilsson, 1976) and were obtained from the American Type Culture
Collection (ATCC). They were cultured in suspension in RPMI1640 media (In-
vitrogen #31870074, formulation in Appendix A.1) containing 10 % FCS, 2 mM
L-glutamine, 50 Units/ml penicillin and 50 µg/ml streptomycin using 175 mm2 fil-
ter topped tissue culture (T175) flasks. Cells were maintained at a density be-
tween 1×105 and 2×106 cells per ml by replacing or adding fresh media every
3-4 days. In order to differentiate the cells into mature monocytes 10 nM 12-
O-tetradecanoylphorbol-13-acetate (PMA) was added to the culture media for 3
days (Alciato et al., 2010). U937 cells were lentivirally transduced to express
(m)HTT exon 1 as described in Section 2.5.2.
HEK293T cells
HEK293T is a human embryonic kidney cell line, purchased from ATCC. These
adherent cells were cultured in T175 flasks using complete OptiMEM media (In-
vitrogen #31985047, formulation is confidential as it contains components to al-
low the use serum-free media during transfections without loss of cell viability,
see protocol in Section 2.5.2) containing 10 % FCS, 50 Units/ml penicillin and
50 µg/ml streptomycin. They were split every 2-4 days at a 1:3 to 1:10 ratio.
Culture media was removed, cells were washed with PBS before 3 ml of 0.25 %
trypsin solution were added to the flask. After 5-10 min incubation at 37 ◦C, when
the cell layer was dispersed, 10 ml of complete OptiMEM media were added and
cells were aspirated by pipetting. Cell suspensions was divided into new culture
flasks.
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2.5.2 Establishing a mHTT-expressing myeloid cell line
Lentiviral vectors
The A2UCOE HD exon 1 vectors used in this study were (see Appendix A.2 for
plasmid maps):
• p’HRsincpptUCOEeGFP+linker+WPRE (vector backbone without HTT )
• p’HRsincpptUCOE+htt exon1 IRES eGFP 29CAG
• p’HRsincpptUCOE+htt exon1 IRES eGFP 71CAG
• p’HRsincpptUCOE+htt exon1 IRES eGFP 129CAG
All four vectors were generous gifts from Prof Gillian Bates, King’s College Lon-
don. The A2UCOE vector backbone was modified from (Zhang et al., 2007) as
follows: a polylinker containing PmeI-SnaBI-BstBI sites was ligated into the NdeI
site, at the same time destroying the NdeI site at the 3 end of the polylinker; a
woodchuck post-translational regulatory element was ligated into the BstBI site;
exon 1 human HTT-IRES-eGFP was ligated into the SalI-NdeI sites.
Plasmid DNA preparation
Plasmid DNA was multiplied by transformation of chemically competent OneShot
TOP10 E. coli (Invitrogen). Chilled E.coli cells were mixed with 100 ng A2UCOE
plasmid DNA and incubated for 30 min on ice. Cells were heat shocked for 30 s in
a 42 ◦C water bath before being placed back onto ice for 2 min. Next, 250 µ l S.O.C
media (Invitrogen) were added and the vials were incubated in a 37 ◦C shaker for
one hour. The bacteria was then streaked out onto sterile agar plates, containing
100 µg/ml ampicillin (Sigma Aldrich) to select for clones containing the plasmid
DNA, which encodes for an ampicillin resistance gene. Single colonies were
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picked and grown in LB broth containing 50 µg/ml ampicillin overnight. Standard
QIAGEN Maxiprep kits were used to isolate plasmid DNA from 400 ml bacterial
culture the next day. Bacteria was centrifuged for 15 min at 6000×g and pellets
were resuspended in 10 ml lysis buffer (P1- provided with the kit). After adding
10 ml of buffer P2 (provided with the kit) and an incubation for 5 min at room tem-
perature, 10 ml of ice-cold buffer P3 (provided with the kit) was added. Suspen-
sions were mixed by inversion and incubated for 20 min on ice. Following a 60 min
spin at 8000×g, supernatants were filtered through a QIAfilter (provided with the
kit) and loaded onto Qiagen-tip 500 columns (provided with the kit), previously
equilibrated with 10 ml QBT buffer (provided with the kit). After the supernatant
had dripped through by gravity, columns were washed twice with 30 ml QC buffer
(provided with the kit) and DNA was eluted with 15 ml QF buffer (provided with
the kit). Plasmid DNA was then precipitated with 10.5 ml 100 % isopropanol, fol-
lowed by a 60 min spin at 6000×g. After washing the DNA pellet with 5 ml 70 %
ethanol (diluted in ddH2O) and a 30 min 6000×g centrifugation step, pellets were
air-dried, resuspended in water and concentration was measured using a Nano
Drop Spectrophotometer.
DNA sequencing
To ensure stability of the CAG repeat length and integrity of the inserted HTT
exon 1, all constructs were sequenced. Sequencing reactions were carried out
in non-skirted 96-well plates (Thermo Scientific), mixing 1 µ l BigDye (Applied
Biosystems), 5 µ l BetterBuffer (Microzone), 0.75 µ l 5 µM primer (CCG TGC GGA
GGT GCT CCT CG), 7.25 µ l ddH2O and 1 µ l (=150ng) cleaned DNA. After a short
spin down, plates were run on a Tetrad thermal cycler (Bio-rad) (program: 96 ◦C
for 1 min followed by 25 cycles of 96 ◦C for 10 secs and 65 ◦C for 2 mins). PCR
products were extracted, adding 3.75 µ l 0.125 M ethylenediaminetetraacetic acid
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(EDTA) and 45 µ l 100 % ethanol to each well before leaving the plate at room
temperature for 15 min. After spinning the plate at 3000×g for 30 min at 4 ◦C,
the plates was inverted onto tissue and centrifuged again at 185×g. Next, 60 µ l
70 % ethanol was added to each well and the plate was centrifuged at 1650×g
for 15 min at 4 ◦C, followed by an inverted spin at 185×g for 1 min. Plates were
then placed uncovered on a PCR block and held at 37 ◦C for 5 min to remove
final traces of ethanol. Finally samples were analysed via electrophoresis using
a 3730XL DNA Analyzer (Applied Biosystems) and data was viewed using the
Applied Biosystems Sequence Analysis Software V5.2.
All vectors showed no mutations from the reference HTT sequence from national
center for biotechnology information (alignments in Appendix A.3). However, the
CAG length in the A2UCOE HD 29Q vector had expanded to 31 repeats, but as
this is still within the non-pathological CAG repeat range the vector was used as
control.
Virus production and titration
For virus production, 50 µg A2UCOE HD vector DNA, 17.5 µg pMD.G2 envelope
and 32.5 µg pCMVdR8.74 packaging plasmids (both produced by PlasmidFac-
tory, patent with Michael Antoniou) were added to 6 ml serum free OptiMEM me-
dia and sterilised by filtration through a 0.22 µm filter. This DNA solution was
mixed with 6 ml sterile filtered serum-free OptiMEM media containing 1.6 µM
polyethylenimine (PEI) (Sigma Aldrich) and incubated for 20 min at room tem-
perature. Twelve ml of the PEI/DNA mix were then added to one 70 % confluent
T175 flask of HEK293T cells and incubated for 4 h before fresh complete Opti-
MEM media was added. Viral supernatants were collected and concentrated by
filtration through a 0.22 µm syringe filter and centrifugation (4000×g for 24 h at
4 ◦C) after 48 h.
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For virus titration, U937 cells were seeded at 1×105 into 24-well plates before
adding either 1, 0.1 or 0.01 µ l of concentrated virus and 8 µg/ml polybrene (PB)
per well. After two days the percentage of virally transduced cells was assessed
according to green fluorescent protein (GFP) expression, which is co-transduced
with all A2UCOE plasmids, using flow cytometry (Section 2.9). The number of
infectious units was then calculated from the percentage of transduced cells (Fig-
ure 2.1), assuming 108 virus particles per ml and dividing the percentage of trans-
duced cells by the percentage virus used (1µ l virus is 100 %, 0.1µ l virus is 10 %,
0.01µ l virus is 1 %). For the example in Figure 2.1, a concentration of 2×106 virus
particles per ml was calculated. To achieve 15 % final transduction rate for 1× 106
cells, 1.5× 105 viral particles were needed, equating to 50 µ l viral supernatant.
Lentiviral transduction
In order to limit the number of viral DNA integration events in the transduced cell
to a minimum, a transduction rate of 10-20 % was choosen for these experiments.
This level of efficiency is though to result in a single DNA insertion per cell reduc-
ing the likelyhood of unwanted gene disruptions during the transduction protocol.
One×106 U937 cells were incubated with an appropriate amount of titrated virus
and 8 µg/ml PB in serum free OptiMEM media. After 4 h of incubation, media was
changed into complete OptiMEM media. Three days later transduced cells were
sorted using fluorescence-activated cell sorting (FACS) with a MoFlo cell sorter
(Beckman Coulter). Using the 488 laser, successfully transduced GFP express-
ing cells were sorted from non-transduced cells in order to isolate a 100 % pure
population of U937 cells expressing the A2UCOE vectors. GFP expression in
the cells did not change over a period of 4 weeks in culture. For a mature mono-
cyte phenotype, transduced and sorted cells were differentiated using 10 nM PMA
added to the media for 3 days.
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Figure 2.1: Titration of lentivirus expressing HTT exon 1. U937 cells were incubated
with different amounts of lentivirus containing HTT exon 1 and GFP; and the percentage
of transduced cells was measured by assessing GFP expression by flow cytometry. After
(A) gating on living, single cells, gates for positive GFP expression were drawn using
(B) untransduced U937 cells. Using virus at (C) 1:100, (D) 1:1 000 or (E) 1:10 000 fold
dilution resulted in a titration curve from which virus concentration was calculated.
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2.5.3 Collection of buccal epithelial cells
Buccal swabs were collected in Catch-ALL sample collection swabs (Epicenter
Biotechnologies). Each subject rinsed their mouth twice before rolling the swab
firmly on the inside of their cheek, approximately twenty times on each side.
Swabs were then snap frozen and stored at -80 ◦C before shipping to Novar-
tis, where cells on the swab were lysed and used for HTT quantifications (Section
2.8.6).
2.5.4 Preparation of primary human immune cells
Isolation of primary human blood monocytes
Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples
using density centrifugation, by layering the samples on top of sterile, 100 %
Histopaque-1077 solution (Sigma Aldrich). After spinning for 30 min at 400×g
the layer of PBMCs was carefully transferred into a fresh, sterile 50 ml centrifuge
tube and washed with PBS (centrifuged for 5 min at 300×g). Cells were then re-
suspended and counted using a Neubauer counting chamber. Following centrifu-
gation (300×g for 5 min), the supernatant was carefully decanted and the cells
were resuspended in 10 µ l anti-human CD14 beads (Miltenyi Biotec) and 90 µ l
MACS buffer (PBS including 1 % bovine serum albumin (BSA) and 2 mM EDTA)
per 107 cells. After incubating for 15 min in the fridge, the samples were washed
with 2 ml MACS buffer (300×g for 5 min) and resuspended in 500 µ l MACS buffer.
Magnetic cell sorting was prepared by rinsing MACS columns placed in the mag-
net with 500 µ l MACS buffer before loading the samples onto the columns. Af-
ter allowing the cell suspension to drop through by gravity, the columns were
washed three times with 1 ml MACS buffer. Labelled CD14+ monocytes were
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eluted by taking the columns out of the magnetic field and pushing 2 ml MACS
buffer through the column using a plunger. Isolated monocytes were counted
and used for experiments. Following each cell sorting a proportion of cells was
used to check sorting efficiency by flow cytometry. On average, the sorted cell
population contained 85-95% CD14+ cells (Figure 2.2).
Isolation of primary human blood T and B cells
Isolation of T cells and B cells was carried out by dividing the flow-through of
the monocyte isolation, described above, in two equal parts. After spinning
the sample for 5 min at 300×g at 4 ◦C, cell pellets were resuspended in 540 µ l
MACS buffer and 60 µ l anti-CD3 (for T cells) or anti-CD19 (for B cells) MACS
microbeads were added. Following a 15 min incubation in the fridge and centrifu-
gation (300×g for 5 min), cells were purified using a MACS column as described
above for monocytes. After eluting the purified cells, they were counted using a
Neubauer counting chamber, centrifuged (300×g for 5 min), snap-frozen in 20 µ l
protease inhibitor solution (PBS with complete protease inhibitor cocktail (Roche))
and shipped to Novartis for TR-FRET measurements (Section 2.8.6). Sorting of
T cells resulted in around 90 % purity, while B cells were around 80-85 % pure
(Figure 2.2).
Differentiation of human macrophages
Monocytes were isolated as described above and cells were seeded in R10 me-
dia (RPMI1640 media containing 10 % FCS, 2 mM L-glutamine, 50 Units/ml peni-
cillin and 50 µg/ml streptomycin) supplemented with 20 ng/ml recombinant human
GM-CSF to induce macrophage differentiation. The medium was changed three
days after seeding, providing the cells with fresh media and growth factors. Cells
demonstrated a macrophage phenotype after 6 days in culture.
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Figure 2.2: Purity of CD14+ monocytes, CD3+ T cells and CD19+ B cell post mag-
netic cell sorting. Mononuclear blood cells were isolated from whole blood by density
centrifugation. (A) CD14+ monocytes were further purified using magnetic activated cell
sorting, providing a 85-95 % pure monocyte suspension. Flow-through from the magnetic
sorting of monocytes was used to isolate (B) CD3+ T and (C) CD19+ B cells. T cells were
around 90 % pure following the sort, B cells around 80-85 % .
2.5.5 Knock-down of HTT in primary human monocytes and
macrophages
Production of glucan encapsulated siRNA containing particles (GeRPs)
Glucan particles were prepared as described previously (Soto et al., 2012). Sacch-
aromyces cerevisiae (100 g of SAF-Mannan; SAF Agri) was suspended in 1 L
0.5 M NaOH and heated to 80 ◦C for 1 h. The insoluble material containing the
yeast cell walls was collected by centrifugation at 5000×g for 20 min. This insol-
uble material was then resuspended in 1 L 0.5 M NaOH, and incubated at 80 ◦C
for 1 h. The insoluble residue was again collected by centrifugation (5000×g for
20 min) and washed three times with 1 L of water, three times with 200 ml propan-
2-ol and three times with 200 ml acetone. The resulting slurry was placed in
a glass tray and dried at room temperature (20 ◦C) to produce 12.7 g of a fine,
slightly off-white powder.
Fluorescent glucan particles were prepared as described previously (Aouadi et al.,
2009). Briefly, glucan particles (1 g) were washed with sodium carbonate buffer
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(0.1 M sodium carbonate, pH 9.2) and resuspended in 100 ml sodium carbonate
buffer. 5-(4,6-Dichlorotriazinyl) aminofluorescein (Invitrogen; 1 mg/ml in ethanol)
was added to the buffered glucan particle suspension (10 % v/v) and mixed at
room temperature in the dark overnight. Tris buffer (2 mM Tris/HCl, pH 6.8) was
added, incubated for 15 min and glucan particles were washed with 100 ml ster-
ile pyrogen-free water until the supernatant was clear (repeat centrifugation at
3,000×g for 10 min). The glucan particles were then flash-frozen, freeze-dried in
the dark and stored at room temperature in the dark.
To load siRNA into 107 glucan particles, siRNA (10 µ l 7 mM siRNA, from Dhar-
macon, Table 2.1 ) was mixed with sterile, pyrogen-free saline (Sigma Aldrich,
40 µ l), HEPES buffer (Invitrogen, 30 µ l 0.1 M, pH 7.5 in saline) and glucan parti-
cles (10 µ l 109 particles/ml in saline), and incubated for 2 h at room temperature
in the dark. The siRNA was trapped by complex formation inside the glucan
particles by adding 10 µ l EndoPorter (GeneTools, diluted 1:1 with saline) and in-
cubated for 15 minutes at room temperature as previously described (Tesz et al.,
2011). Loaded GeRPs were snap-frozen on dry ice in single use aliquots and
stored at -80 ◦C. Loading reactions were scaled up or down proportionately to
produce the desired number of GeRPs.
Table 2.1: siRNA sequences used in HTT knock-down experiments
Primer Sequence
anti-HTT siRNA Guide strand 5’- pUUCAUCAGCUUUUCCAGGGUC-3’
Passenger
strand
5’ -CCCUGGAAAAGCUGAUGACGG -3’
scrambled siRNA Guide strand 5’-pUUUCGAAGUACUCAGCGUGAG-3’
Passenger
strand
5’-CACGCUGAGUACUUCGAACUU-3’
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Transduction of primary cell cultures
Monocytes were isolated from whole blood (Section 2.5.4), seeded onto poly-L-
lysine coated coverslips and treated with fluorescent GeRPs, which contained no
siRNA for 12 h to assess GeRP uptake using microscopy (Section 2.11.2).
Macrophages, which were transfected on day three of the differentiation protocol,
were transfected with green fluorescent GeRPs containing no siRNA at various
ratios (1:1; 1:3; 1:10) for 4 h, after which fresh culture medium was added to the
cultures. Uptake rates were measured 24 h later by flow cytometry (Section 2.9).
Macrophages were treated with either scrambled or anti-HTT siRNA containing
GeRPs at a 1:10 cell to particle ratio on day 3 of the differentiation protocol. Four
hours after adding GeRPs, fresh media was added to the cells. Analysis of HTT
RNA and protein levels via qPCR (Section 2.10) and TR-FRET (Section 2.8.6),
respectively and cytokine profiling (Section 2.6.1) took place three days later.
Monocytes were rested for 16 h post isolation before treatment with either scram-
bled or anti-HTT siRNA containing GeRPs at a 1:10 cell to particle ratio for 4 h.
Three days later, transcriptional changes were analysed using qPCR (Section
2.10).
2.5.6 Preparation of primary murine cells
Blood
Blood was obtained by cardiac puncture in mice culled by a rising concentra-
tion of CO2. In order to prevent clotting, blood was collected into EDTA coated
tubes (BD Vacutainer collection tubes). To analyse white blood cells, 1 ml red
blood cell lysis buffer (ammonium chloride buffer from eBioscience) was added
per 1 ml of blood and the samples were incubated for 5 min at room temperature.
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After spinning at 300×g for 5 min, the lysis step was repeated twice. Cells were
then resuspended in 270 µ l MACS buffer and 30 µ l anti-mouse CD11b magnetic
beads. After 15 min incubation in the fridge, the samples were isolated using
MACS columns as described in Section 2.5.4.
Spleen
Spleens were dissected from the mice and stored in RPMI1640 media until the
preparation started. To obtain a single cell suspension, spleens were cut into
pieces and digested using 2 ml digest buffer (RPMI media including 10 % FCS,
15 mM HEPES, 0.5 % Collagenase type 4 (Sigma Aldrich C1889)). After 30 min
incubation at room temperature the remaining spleen pieces were filtered through
a 70 µm nylon cell strainer (BD Falcon). Afterwards the splenocytes were cen-
trifuged (300×g for 5 min) and the pellet was incubated with 1 ml red blood cell ly-
sis buffer (ammonium chloride buffer from eBioscience) for 5 min at room temper-
ature. After another spin, the cells were resuspended in 20 ml PBS and counted
using a Neubauer counting chamber. An appropriate number of cells was used ei-
ther for flow cytometry (see Section 2.9) or MACS using 10 µ l anti-mouse CD11b
magnetic beads and 90 µ l MACS buffer per 107 cells as described in Section
2.5.4.
Bone marrow
Mice were sacrificed by neck dislocation or by rising concentration of CO2. Femur
and tibia were dissected out at the hip joint and any remaining muscle tissue
was carefully removed. The bones were placed in a petri dish filled with cold
RPMI1640 media and cut at the joints. Bone marrow was flushed out into a sterile
50 ml tube by rinsing the shaft with media using a 5 ml syringe and 26 gauge
needle, while holding the bone shaft with forceps. Cell lumps were disaggregated
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by pipetting up and down several times before the cells were passed through a
70 µm nylon cell strainer. After washing with RPMI1640 media (centrifuge for
5 min at 300×g) cells were counted using a Neubauer counting chamber. The
cell suspension was labelled with 10 µ l anti-mouse CD11b magnetic beads and
and 90 µ l MACS buffer per 107 cells and sorted as described in Section 2.5.4.
The isolated CD11b positive cell population resembled an early monocyte popu-
lation, but was also used as a source for bone marrow-derived macrophages. For
the differentiation sorted bone marrow cells were seeded at 3×106 million cells
in 2 ml R10 media supplemented with 20 ng/ml recombinant murine M-CSF onto
6-well plates. After 3 days cells were provided with fresh media and growth factor.
The cells resembled a macrophage phenotype from day 6.
Peritoneal macrophages
In order to prevent bleeding into the abdominal cavity mice were killed using ris-
ing concentration of CO2, not neck dislocation. Fur covering the peritoneum was
carefully removed and 5 ml of ice-cold, serum free RPMI1640 media were in-
jected into the abdominal cavity using a 26 gauge needle. After massaging the
mouse abdomen for 1-2 min, cells were recovered through a small incision using
sterile plastic pasteur pipettes and put on ice as quick as possible. To remove
contamination with red blood cells, the centrifuged (5 min at 300×g) cell sus-
pension was incubated with 1 ml red blood cell lysis buffer (ammonium chloride
buffer from eBioscience) for 5 min at room temperature. Afterwards, cells were
washed with 5 ml PBS (centrifuged at 300×g for 5 min). The obtained cell sus-
pension contained macrophages as well as neutrophils. Cultures were enriched
for macrophages by removing non-adherent neutrophils by media changing and
washing the cells after 2 h in culture.
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2.6 Functional analysis of myeloid cells
2.6.1 Cytokine profiling
Primary human monocytes and macrophages, (m)HTT expressing U937 cells
and GeRP treated macrophages were isolated and differentiated as described
in Sections 2.5.4, 2.5.2 and 2.5.5, respectively. Five hundred thousand cells,
seeded in 24-well plates, were primed with 10 ng/ml human IFNγ and stimulated
with 2 µg/ml LPS. After 24 h, supernatants were collected for analysis of cytokine
levels (Section 2.7.2) and cells were lysed for protein measurement (Section 2.8).
For experiments using primary human cells, n numbers represent samples from
different individuals (biological repeats). For the cytokine profiling of mHTT ex-
pressing U937 cells, several wells of the same cell line were stimulated and anal-
ysed separately (technical repeats).
To evaluate the cytokine profiles of murine cell cultures, blood monocytes iso-
lated from individual Hdh150Q/150Q mice were seeded at 100,000 cells into 96-well
plates in 100 µ l R10 media. Due to the low cell numbers of blood monocytes
recovered from R6/2 mice, cells were pooled according to genotype and multi-
ple wells were seeded at 100,000 cells into 96-well plates in 100 µ l R10 media.
Splenic and bone marrow monocytes, and peritoneal macrophages were seeded
in 24-well plates at a density of 500,000 cells per well. Bone marrow derived
macrophages were used for stimulation experiments after differentiation in 6-well
plates at 3×106 million cells per well (see Section 2.5.6). All murine culture were
primed with 10 ng/ml murine IFNγ and stimulated with 2 µg/ml LPS. After 24 h,
supernatants were collected for analysis of cytokine levels (Section 2.7.2) and
cells were lysed for protein measurement (Section 2.8).
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2.6.2 Migration assay
To assay migration abilities of the myeloid cells a Boyden chamber/ transwell
system (Corning) was used.
Migration assay for blood monocytes
The lower chamber of the 5µm transwell was filled with RPMI media contain-
ing 1 % FCS, 2 mM L-glutamine, 50 Units/ml penicillin and 50 µg/ml streptomycin
supplemented with either 50 ng/ml CCL2 (MCP-1), 100 µM ATP, 10 nM C5a or
100 ng/ml RANTES (concentrations established in dose-response curve shown
in Figure 2.3). Half a million monocytes were added on top of the 5 µm transwell
inserts and incubated at 37 ◦C for 1.5 h to allow migration. Afterwards the tran-
swells were removed and the contents of the lower chamber was centrifuged at
300×g for 5 min. Cell pellets were resuspended in 50 µ l PBS and counted using
a Neubauer counting chamber.
Migration assay for macrophages
One hundred thousand macrophages were seeded into 8 µm transwell inserts,
which were placed into wells filled with RPMI media containing 1 % FCS, 2 mM L-
glutamine, 50 Units/ml penicillin and 50 µg/ml streptomycin supplemented with ei-
ther 50 ng/ml CCL2 (MCP-1), 100 µM ATP, 10 nM C5a or 100 ng RANTES (same
stimuli as used for monocytes above). The cells were incubated for 16 h, after
which the inserts were removed from the wells. Cells on the upper side of the
insert membrane were gently removed using cotton buds, while the cells on the
lower side were fixed in ethanol and stained with 1 mg/ml crystal violet. The fixed,
stained cells were counted in multiple fields of view using ImageJ software. Pic-
tures were taken on a light microscope (Nikon Eclipse TS100, Objective 20×) with
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Figure 2.3: Dose-response for different chemokines used in migration assay. (A+B)
Monocyte migration towards 1, 10, 20, 50 and 100 ng/ml MCP-1 and RANTES was tested
in one control sample establishing a peak for migration towards (A) MCP-1 at 50 ng/ml,
while migration towards (B) RANTES increased further using 100 ng/ml. Validating find-
ing in murine HD microglia (Kwan et al., 2012b), monocyte migration towards (C) ATP
and (D) C5a was tested and found to peak at 100 µM and 50 nM, respectively. In order
to replicate the findings in murine microglia, 100 µM ATP and 10 nM C5a were used in all
experiments.
attached digital camera (Nikon DS-Fi1) with the NIS-Elements F 3.00 software.
2.6.3 Phagocytosis assay
Murine peritoneal (Section 2.5.6) and human (Section 2.5.4) macrophages were
stimulated with 2 µg/ml LPS in R10 media overnight. One hour before the assay,
macrophages were washed three times with PBS and serum-free RPMI1640 was
added to the cells. Carboxylate-modified fluorescent yellow-green latex beads
(Sigma Aldrich) were added to the cells at a 10:1 ratio and were incubated at
37 ◦C for 1 h. Cells were then washed with cold PBS twice and incubated with
PBS containing 10 nM EDTA for 10 min on ice before the cells were detached from
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the culture wells by trituration. The cells were then fixed using 3.7 % paraformalde-
hyde (PFA). After 20 min at room temperature, the PFA was washed off the cells
and they were stained with surface markers specific for the macrophage lineage
for analysis by flow cytometry (as described in Section 2.9).
2.6.4 Adhesion assay
In order to assess cell adhesion, murine peritoneal macrophages were harvested
as described in Section 2.5.6. Macrophages were seeded in 24-well plates and
left to adhere to the plastic for 2 h. Afterwards adhered cells were removed and
counted using a Neubauer counting chamber.
2.7 Immunoassays
2.7.1 Enzyme-linked immunosorbent assay - ELISA
To analyse the IL-6 production by stimulated myeloid cells isolated from mice, the
R&D Systems mouse IL-6 Quantikine immunoassay kit was used. Culture super-
natants were diluted 1:50 and loaded onto the pre-coated IL-6 ELISA plate. After
adding 50 µ l assay diluent RD1-14 to the 50 µ l cell culture supernatant the plate
was mixed by tapping for 1 min and incubated at room temperature for 2 h. Next,
the plate was washed with wash buffer five times using a squirt bottle. In order to
remove the liquid the plate was inverted and blotted against a clean paper towel.
Then 100 µ l IL-6 conjugate were added into each well and incubated for 2 h at
room temperature. Following another five washes 100 µ l substrate solution were
added to each well and incubated in the dark for 30 min at room temperature.
Finally 100 µ l of stop solution were added to each well and the optical density of
each well was measured using a microplate reader (Tecan Sunrise) set to 450
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nm (wavelength correction set to 540 nm) using the Xfluor software. Each sam-
ple was run in duplicate and IL-6 concentrations were calculated using a standard
curve.
The human CCL2/MCP-1 Quantikine ELISA kit (R&D) was used to assess in vitro
MCP-1 production by primary human macrophages treated with IFNγ and LPS
(Section 2.6.1). Culture supernatants were diluted 1:20 before 200 µ l sample or
standard were added to each well. After incubation for 2 h, plates were washed
three times with wash buffer (included in kit). After inverting the plate to dry out
the wells, 200 µ l MCP-1 conjugate were added to each well and incubated for
1 h at room temperature. Following another three wash steps, 200 µ l substrate
solution were added and incubated for 30 min at room temperature. Finally, 50 µ l
stop solution were added into each well and optical density was determined using
a microplate reader (Tecan Sunrise) set to 450 nm (wavelength correction set to
540 nm) using the Xfluor software. Each sample was run in duplicate and MCP-1
concentrations were calculated using a standard curve.
2.7.2 Mesoscale assay
The MSD 96-well 4-spot assay for IL-1β , IL-6, IL-8 and TNFα was used to anal-
yse cytokine production by primary human macrophages, (m)HTT expressing
U937 cells and GeRP-treated macrophages. For primary human monocytes a
MSD 96-well 7-spot plate analysing IL-1β , IL-12p70, IFNγ, IL-6, IL-8, IL-10, TNFα
was used. Cytokine production from murine cells was measured using the MSD
mouse pro-inflammatory 7-Plex tissue culture kit analysing IL-1β , IL-12p70, IFNγ,
IL-6, KC, IL-10, TNFα levels.
Depending on the type of stimulation, 25 µ l of undiluted, 1:10 or 1:20 diluted
culture supernatants were added onto the MSD plate and incubated with vigorous
shaking for 2 h at room temperature. Then, the plate was washed three times
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with PBS containing 0.05 % Tween before 25 µ l detection antibody were added
and incubated with vigorous shaking for 1.5 h at room temperature. Following a
second wash step, 150 µ l read buffer were added and the plate was analysed
using the SECTOR machine and analysis software. An eight point calibration
curve was run on every plate to calculate the concentrations of cytokine in each
sample. Unless stated otherwise cytokine levels were normalised to the amount
of protein measured in the corresponding well.
2.8 Protein chemistry
2.8.1 Protein isolation
Protein was isolated by lysing cells in RIPA buffer (25 mM Tris HCl pH7.6, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS))
containing one complete protease inhibitor cocktail (mini) tablets (Roche) per
10 ml buffer. The appropriate amount of RIPA buffer was added directly into the
culture well and the plates shaken in the fridge for 5 min. Protein solutions were
frozen at -80 ◦C before analysis.
2.8.2 Bicinchoninic acid (BCA) protein assay
Cell lysates were diluted appropriately (between 2-10 fold depending on the cell
type analysed) and 20 µ l of the protein solution were analysed by adding 200 µ l
working solution (1:50 ratio of BCA reagent A to B)(Thermo Scientific) in a 96-well
format. The plate was incubated for 2 h at 37 ◦C before reading at 562 nm in a
microplate absorbance reader (Tecan Sunrise) using the XFluor software. Each
assay was performed in duplicate and the BSA standards provided by the kit were
run on each plate.
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2.8.3 Immunoprecipitation
HTT immunoprecipitations were performed as described (Landles et al., 2010),
with the following adaptations. PBMCs, collected by density centrifugation of
50 ml whole blood, were lysed in 500 µ l ice-cold lysis buffer (50 mM HEPES
(pH 7.0), 150 mM NaCl, 10 mM EDTA, 1 % NP-40, 0.5 % sodium deoxycholate,
0.1 % SDS, 0.1 % BSA, 10 mM dithiothreitol (DTT), 1 mM phenylmethanesulfonyl-
fluoride (PMSF), one complete protease inhibitor cocktail (Roche)). Lysates were
pre-cleared prior to immunoprecipitation by incubation with 50 µ l (1:1 slurry) pre-
washed G-Sepharose-agarose beads (Invitrogen) for 6 h at 4 ◦C. Immunoprecipi-
tations were carried out overnight, mixing 1.5 mg pre-cleared protein supernatant,
30 µ l protein G-Sepharose-agarose beads (1:1 slurry) and 2 µg antibody (Table
2.2) in a 1 ml final volume. Beads were pelleted by centrifugation at 13,000×g
for 30 s, washed four times with lysis buffer, resuspended in 16 µ l 2× Laemmli
buffer and denaturated at 75 ◦C for 5 min. Immunoprecipitates were then used for
immunodetection of HTT, and in some case immunodetection of co-precipitated
IKK via western blot (Section 2.8.5).
Table 2.2: Antibodies used for immunoprecipitation of HTT.
Antibody Epitop Company
anti-human IgG - Alpha Diagnostic (#20008-250)
2166 HTT aa443-457 Millipore (MAB2166)
2B7 HTT aa7-13 obtained from Novartis (Weiss
et al., 2011)
3B5H10 N171 (65Q) Sigma Aldrich
4C9 HTT aa51-71 obtained from Novartis
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2.8.4 Immunoblot analysis of IκB degradation
Monocytes were isolated from whole blood (Section 2.5.4) and seeded at a den-
sity of 1x106 cells/well into 24-well plates and rested for 16 h. Cells were stim-
ulated with 2 µg/ml LPS over a 2 h time-course before western blotting (Section
2.8.5).
2.8.5 Western blotting
Cell pellets were lysed in RIPA buffer (Section 2.8.1) and protein content was
measured using a BCA protein assay (Section 2.8.2). Ten µg of protein were
mixed with 5x Laemmli buffer, before denaturation at 95 ◦C for 10 min. Lysates
were run on Novex(R) Tris-Glycine gels (depth 1.5 mm) (Invitrogen), using 8 %
gels to dissolve large proteins such as HTT and 4-20 % gradient gels for smaller
proteins (≤100kDa). The kaleidoscope precision plus protein standard (Bio-rad)
was loaded on every gel to mark protein size. Gels were run for 2-4 h at 130 V in
the XCell II Blot Module CE Mark tank (Invitrogen) filled with 1× Tris-Glycine SDS
page buffer (SLS). Gels were transferred onto polyvinylidene fluoride (PVDF)
membranes (pre-wetted in 100 % methanol for 1 min) using the same XCell II Blot
Module at 30 V for 2 h for smaller proteins and 14 V for 20 h for HTT. Membranes
were then blocked with 5 % skimmed milk in Tris-buffered saline (TBS), pH 7.0,
containing 0.1 % Tween20 (TBS-T) for 2 h. Blocked membranes were incubated
with primary antibody (Table 2.3) in 5 % milk in TBS-T overnight. After washing
several times with TBS-T, membranes were incubated for 1 h with the matching
anti-mouse or anti-rabbit secondary alkaline phosphatase (AP) antibody (Sigma
Aldrich; both used 1:10,000 diluted). Signals were visualised using CDP-Star
substrate (Applied Biosystems) on Kodak BioMax MR-1 film, after washing vig-
orously with TBS-T. Membranes were stripped using ReBlot Plus strong solution
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(Millipore) for 10min, before reprobing with anti-GAPDH antibody and secondary
anti-rabbit-AP antibody as a loading control. Developed films were scanned using
an Epson scanner and densitometry of digital images was achieved by using the
TotalLab TL100 software.
Table 2.3: Primary antibodies used for western blot
Antibody Dilution Company
anti-human HTT, 1H6 1:1000 Abnova (Lunkes et al., 2002)
anti-human HTT, 2166 1:1000 Millipore
anti-human HTT, 4C9 1:500 obtained from Novartis
anti-human HTT, MW1 1:500 obtained from the Developmental Studies
Hybridoma Bank developed under the aus-
pices of the NICHD and maintained by The
University of Iowa (Ko et al., 2001)
anti-human GAPDH 1:2000 Sigma Aldrich
anti-human IκB 1:500 Santa Cruz
anti-human IKKγ 1:2000 Santa Cruz
anti-human phospho-
Cofilin
1:500 Cell Signaling
2.8.6 Time-resolved Fo¨rster resonance energy
transfer - TR-FRET
Cells were lysed in 100 µ l PBS containing 1 % TritonX-100 and a protease in-
hibitor cocktail (Roche) per 1x106 cells and 5 µ l cell lysate were transferred into
low-volume wells of white 384-microtiter plates (Greiner). A total of 1 µ l detection
buffer (50 mM NaH2PO4, 400 mM NaF, 0.1 % BSA, and 0.05 % Tween, plus anti-
body mix) was added, with the final antibody amount per well for soluble mHTT
and total HTT detection being 0.25 ng 2B7-Tb plus 20 ng MW1-D2, or 1 ng 2B7-
Tb plus 10 ng 2166- Alexa Fluor 488, respectively. Plates were rotated at 1000×g
for 30 s and incubated for 1 h. TR-FRET readout was performed with an EnVision
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Reader (PerkinElmer). After the excitation of the donor fluorophore Tb (CisBio)
at 320 nm and a time delay of 100 ms, the resulting Tb and acceptor D2 (CisBio)
or Alexa Fluor 488 (Invitrogen) emission signals were read at 620 nm and 665
or 520 nm, respectively (Figure 2.4A/B). Ratios of 665/620 nm and 520/620 nm
signals corresponded to mutant and total HTT levels, respectively. TR-FRET de-
tection of insoluble, aggregated mHTT was performed by using MW8 antibodies
labelled with either Tb (donor) or D2 (acceptor) fluorophores (Figure 2.4C). The
TR-FRET protocol was the same as the one used for soluble mutant HTT. Total
protein levels of cell lysates were quantified using a BCA protein assay (Section
2.8.2). HTT protein levels are shown as a percentage of the signal intensity over
lysis buffer background signal after normalisation to total protein levels (4F). All
assays were carried out blinded to subject group.
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Figure 2.4: Antibody combinations used in the TR-FRET immunoassay. (A) Mea-
suring total HTT, cell lysates were incubated with the 2B7-Tb and the 2166-AlexaFluor
488(A488) antibodies detecting both wild-type and mutant HTT. (B) For mHTT-specific
detection, cell lysates were stained with N-terminal 2B7-Tb and the polyglutamine spe-
cific MW1 antibody. (C) MW8-Tb and MW8-D2 antibodies were used to detect insoluble
mHTT aggregates.
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2.9 Flow cytometry
2.9.1 Cell surface marker staining
A maximum of 1x106 cells were transferred into a round bottom 96-well plate.
The plate was centrifuged at 300×g for 5 min and supernatants were removed by
flicking the plate. Fifty µ l of the relevant, diluted antibody (Table 2.4), prepared
in FACS buffer (PBS with 1 % FCS and 0.02 % sodium azide) were added to
each well and mixed by trituration. Cells were stained, in the dark, for at least
20 min on a shaker at 4 ◦C. Afterwards the cells were washed once in 200 µ l
FACS buffer (centrifuged at 300×g, 5 min) and either resuspended in 200 µ l FACS
buffer, transferred to FACS tubes and analysed directly or fixed in 200 µ l FACS
buffer containing 0.5 % PFA and kept at 4 ◦C, in the dark until analysis.
Table 2.4: Directly conjugated antibodies used for FACS.
Antibody Used concen-
tration
Company
anti-human CCR2 PE 0.25 µg/ml R&D Systems
anti-human CD14 APC 0.25 µg/ml eBioscience
anti-human CD206 PE 0.5 µg/ml BioLegend
anti-human CD64 FITC 5 µ l per test BD Pharmingen
anti-mouse CD3e PE 2 µg/ml eBioscience
anti-mouse CD3e APC 2 µg/ml eBioscience
anti-mouse CD4 APC 2 µg/ml eBioscience
anti-mouse CD8a FITC 5 µg/ml eBioscience
anti-mouse CD11b PE 2 µg/ml eBioscience
anti-mouse CD11c FITC 2 µg/ml eBioscience
anti-mouse CD19 FITC 5 µg/ml eBioscience
anti-mouse CD45R(B220) APC 2 µg/ml eBioscience
anti-mouse F4/80 APC Cy7 2 µg/ml BioLegend
anti-mouse MHC II APC 2 µg/ml eBioscience
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Non-stained and single-colour stained cell controls were always performed. Sam-
ples were run on a FACScalibur (BD Bioscience) with CellQuest software Pro (BD
Bioscience). Data analysis was performed using FlowJo7.2.5 (Tree Star).
2.9.2 Phosphoflow analysis of STAT phosphorylation
PBMCs were isolated from blood using density centrifugation. In order to remove
platelets, cells were washed with 25 ml HBSS (centrifuged at 200×g for 10 min).
Cell pellets were resuspended in 5 ml HBSS and counted using a Neubauer
counting chamber. 1×106 cells were distributed in six FACS tube (BD Biosciences)
each per subject and each tube was filled up to 1 ml with HBSS before resting the
cells for 30 min at 37 ◦C; followed by trituation and resting for additional 10 min
at 37 ◦C. After centrifugation at 300×g for 5 min, the pellet were vortexed before
5 µ l of CD64 antibody (Table 2.4), diluted 1 in 3 in HBSS, were added and in-
cubated for 15 min in the dark at room temperature. Samples were washed with
1 ml HBSS (centrifuged 300×g for 5 min) before stimulation. For each subject,
three tubes remained unstimulated with the addition of 1 ml fresh HBSS and one
tube was stimulated with either 20 ng/ml IFNγ, IL-6 or GM-CSF in 1 ml HBSS.
Samples were incubated for 20 min at 37 ◦C before adding 1 ml 37 ◦C pre-heated
BD Phosflow Cytofix buffer and incubating at 37 ◦C for an additional 10 min. Af-
ter centrifugation at 300×g for 5 min, the supernatants were poured off and 1 ml
-20 ◦C cold BD Phosflow Perm Buffer III was added and the samples were incu-
bated for 30 min in the dark on ice. Afterwards, the samples were washed twice
with 1 ml BD Phosphoflow stain buffer (centrifuged at 300×g for 5 min). Finally,
samples were stained intracellularly with pSTAT antibodies (Table 2.5) for 30 min
in the dark at room temperature. After washing with 2 ml BD Phosphoflow stain
buffer (centrifuged at 300×g for 5 min) samples were analysed on a FACScalibur
with CellQuest software Pro. Data analysis was performed using FlowJo7.2.5.
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Table 2.5: Intracellular antibodies used for FACS
Antibody Used concen-
tration
Company
Alexa Flour 647 anti-human pSTAT1 10 µ l per test BD Biosciences
Alexa Flour 647 anti-human pSTAT3 5 µ l per test BD Biosciences
Alexa Flour 647 anti-human pSTAT5 5 µ l per test BD Biosciences
2.9.3 Imaging flow cytometry
Primary human CD14+ monocytes were seeded at 2×106 into 6-well plates and
left to rest for 16 h. The cells were stimulated with 2 µg/ml LPS over a 90 min
period before being scraped off the plates. Pelleted cells (300×g for 5 min) were
fixed for 15 min and permeabilised for 10 min using the eBioscience Fix/Perm
solutions, before NFκB p65 XP antibody (1:200; Cell Signaling) diluted in perme-
abilisation buffer was added. After 30 min incubation shaking at 4 ◦C, cells were
washed twice with FACS buffer and centrifuged for 5 min at 400×g. Secondary
anti-rabbit IgG PE antibody (eBioscience) was added at 1:100 in FACS buffer
and incubated for 30 min before washing the cells twice with FACS buffer. Cells
were resuspended in 80 µ l FACS buffer and stained with 1 µg/ml 4’,6-diamidino-2-
phenylindole (DAPI) just before analysis. Samples were run on the ImageStreamX
analyser (Amnis) and analysed using the IDEAS software. Gating on in focus, sin-
gle cells, the similarity feature (Similarity Erode(Object(M04,BF,Tight)2) Dapi p65)
was used to establish the rate of p65 translocation by measuring the overlap of
DAPI and p65 staining. Translocation rate was normalised to baseline levels.
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2.10 Transcriptome analysis
2.10.1 RNA isolation
RNA was isolated using the QIAGEN RNAeasy Mini kit. Cells were lysed in 600 µ l
lysis buffer, before RNA was precipitated by adding an equal amount of 70 %
ethanol (diluted in ddH2O). Samples were then transferred onto spin columns
(provided with the kit) and washed once with 350 µ l RW1 buffer(provided with the
kit) (centrifuged 15 s at 8,000×g), before adding 80 µ l DNase solution (QIAGEN).
After 15 min incubation at room temperature, columns were washed again with
350 µ l RW1 buffer (centrifuged 15 s at 8000×g), followed by two washes with
500 µ l RPE buffer (provided with the kit) (15 s and 2 min spins at 8,000×g). The
columns were then dried at 8000×g for 1 min and RNA was eluted using 20-40 µ l
RNase-free water (provided with the kit). Finally, the RNA concentration was
measured using a Nano Drop Spectrophotometer. RNA was stored at -80 ◦C.
2.10.2 Reverse transcription of RNA to cDNA
For the reverse transcription reaction, SuperScript II reverse transcriptase (In-
vitrogen) was used, mixing 500 ng RNA diluted in 10 µ l RNase-free water with
1 µ l random primers (500 µ l/ml) and 1 µ l dNTPs (10 mM each) (both Invitrogen).
The mix was heated to 65 ◦C for 5 min, then quickly chilled on ice before 4 µ l 5×
First-Strand buffer, 1 µ l 0.1M DTT and 1 µ l RNaseOUT (40 units/ µ l) (all Invitro-
gen) were added. After incubating for 2 min at room temperature, 1 µ l (200 Units)
SuperScript II reverse transcriptase was added. To start transcription the mix is
incubated at 25 ◦C for 10 min followed by 42 ◦C for 50 min. To stop the enzyme,
the mix was incubated for 5 min at 95 ◦C and put on ice immediately afterwards.
cDNA was then stored at -20 ◦C.
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2.10.3 Quantitative PCR
For quantitative PCR (qPCR) analysis, SYBR Green master mix from Applied
Biosystems was used. For the reaction 12.5 µ l SYBR Green, 10.75 µ l H2O, 1 µ l
cDNA (equating to 5 ng cDNA per reaction) and 0.75 µ l of primer (300 pM, Table
2.6) were mixed. The PCR reactions were prepared in MicroAmp fast optical 96-
well reaction plates and subsequently covered with MicroAmp optical adhesive
film (Applied Biosystems). After centrifuging the plates for 10 s at 300×g, they
were run on a 7500 fast real-time PCR system (Applied Biosystems) using 7500
software. The PCR cycling conditions were as followed: 95 ◦C for 10min followed
by 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1min. All reactions were run in trip-
licate. In addition to the genes of interest, endogenous control genes (GAPDH,
B2M and BACTIN) were always run as well for each sample. In order to anal-
yse the data, the Ct value of each sample was determined by the 7500 software
(example shown in Figure 2.5).
Figure 2.5: Example of Ct values for qPCR. Example graph showing Ct value deter-
mination for three genes, run in duplicate from the same sample (green- B2M, red and
yellow - GAPDH, blue- HTT). X-axis shows number of PCR cycles run and y-axis shows
the corresponding level of SYBR Green fluorescences (Rn) over the background. The
green horizontal line shows the threshold determining the Ct value (point where thresh-
old cuts amplification curve) for each gene.
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Table 2.6: Primers used for qPCR
Primer Sequence
human BACTIN forward AAG GCC AAC CGT GAA AAG AT
reverse GTG GTA CGA CCA GAG GCA TAC
human AKT1 forward CAT CAC ACC ACC TGA CCA AG
reverse CTC AAA TGC ACC CGA GAA AT
human B2M forward GAA TTC ACC CCC ACT GAA AA
reverse CCT CCA TGA TGC TGC TTA CA
human CD40 forward CAC CTC GCT ATG GTT CGT CT
reverse CTG GTG GTG GCA GTG TGT CTC TC
human CCR1 forward CCC TTG GAA CCA GAF AGA AG
reverse CCA GGC CAA TGA CAA ATA CC
human CCR2 forward GAC AAG CCA CAA GCT GAA CA
reverse CAC CGC TCT CGT TGG TAT TT
human CCR5 forward CTG AGA CAT CCG TTC CCC TA
reverse GCT CTT CAG CCT TTT GCA GT
human GAPDH forward AAC AGC GAC ACC CAT CCT C
reverse CAT ACC AGG AAA TGA GCT TGA CAA
human HTT forward AGT GAT TGT TGC TAT GGA GCG G
reverse GCT GCT GGT TGG ACA GAA ACT C
human IL6 forward TAC CCC CAG GAG AAG ATT CC
reverse AGT GCC TCT TTG CTG CTT TC
human IL10 forward TGC CTT CAG CAG AG GAA GA
reverse GGT CTT GGT TCT CAG CTT GG
human IRAK1 forward CTA CCT GCC CGA GGA GTA CA
reverse GTG CTT CTC AAA GCC ACT CC
human JUN forward TTT CGG GAG TGT CCA GAG AG
reverse GAG AAG CCT AAG ACG CAG GA
human TLR4 forward CTC CTG CGT GAG ACC AGA AA
reverse GGT TGA GAA GGG GAG GTT GT
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In order to normalise the samples, the Ct value for each gene was subtracted by
the mean Ct value of the three house-keeping genes for the same condition. The
relative gene expression was then calculated, setting one condition as standard,
using the following formula :
relative gene expression = 2−(Ct from gene of interest/Ct from standard gene)
2.10.4 SABioscience Human NFκB Signaling Pathway RT
Profiler PCR Arrays
RNA quality control
For the PCR arrays, RNA was isolated from 2x106 unstimulated monocytes using
the QIAGEN RNeasy Mini Kit (Section 2.10.1). RNA integrity was evaluated using
2100 RNA bioanalyser chips (Agilent). The eukaryote total RNA 6000 nano chip
is a miniature electrophoresis system analysing the integrity of the S18 and S28
ribosomal RNA molecules. High quality RNA samples demonstrate clear 18S
and 28S RNA bands (Figure 2.6) and only samples demonstrating non-degraded
RNA were used.
To run the chip, 550µ l Agilent RNA 6000 nano gel matrix was transferred into a
spin filter tubes and centrifuged for 10 min at 1500×g. Then, 65 µ l of the filtered
gel was mixed with 1µ l RNA 6000 nano dye, vortexed thoroughly and centrifuged
for 10 min at 13,000×g. With the chip in the loading station, 9 µ l gel-dye mix
was pipetted into the bottom of the well marker G before pressurising the system
using the syringe in the loading station. After 30 s the pressure was released
and 9 µ l gel-dye mix was transferred in the two wells above the well labelled G.
Next, 5 µ l of the RNA 6000 nano DNA marker were dispensed into all sample
and the ladder well. This twenty five nucleotide marker allows aligning of all
electrophoresis reactions, as each well was read separately. Following this, 1 µ l
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Figure 2.6: Example of high quality RNA sample analysed on the bioanalyser. RNA
samples were run on RNA 6000 chips in miniature electrophoresis reactions. Non-
degraded RNA demonstrates two clear bands on the gel and two clear peaks for 18S
and 28S ribosomal RNA.
ladder and 1 µ l of each sample were added into the corresponding wells and the
chip was vortexed for 60 s. Chips were run on a Agilent 2100 bioanalyser using
the Agilent 2100 expert software.
Reverse transcription
RNA was reverse transcribed using the RT2 First Strand kit for cDNA transcrip-
tion, adding 1 µg RNA resuspended in 8 µ l water to 2 µ l GE buffer before incu-
bating the mix for 5 min at 42 ◦C. After chilling the mix on ice, 10 µ l of RT cocktail
(4 µ l 5×RT buffer 3, 1 µ l P2 (primer control mix), 2 µ l RT enzyme and 3 µ l wa-
ter) were added to each RNA sample and incubated at 42 ◦C for 15 min before
the reaction was stopped by heating to 95 ◦C for 5 min. Ninety one µ l non-DEPC
treated nuclease-free water were added to each 20 µ l reaction and the cDNA was
stored at -20 ◦C until use.
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PCR reactions
For the PCR reaction, 1350 µ l 2×RT2 SYBR Green qPCR Mastermix and 1248 µ l
water were added to the cDNA synthesis reactions, before adding 25 µ l of this ex-
perimental cocktail into each well of the primer coated array plates using a mul-
tichannel pipette. Plates were centrifuged for 10 s at 300×g and run on a 7500
fast real-time PCR system (Applied Biosystems) using the 7500 software. PCR
cycling conditions were as followed: 95 ◦C for 10 min followed by 40 cycles of
95 ◦C for 15 s and 60 ◦C for 1 min. A melting curve, ranging from 60-95 ◦C was
run on each plate to exclude the occurrence of primer dimers.
Each PCR array plate included primers for 84 genes of interest, five house-
keeping genes (B2M, BACTIN, GAPDH, RPL13A and HPRT1) and seven wells
for quality controls. One control well was the genomic DNA control, which in-
cludes primers specific for genomic DNA. If the Ct value for this well was below
35, the results for the whole plate were discarded. Three wells for the reverse-
transcription control (RTC) tested the efficiency of the reverse-transcription re-
action performed with the RT2 First strand kit by detecting template synthesised
from the kits built-in external RNA control. The three wells for the positive PCR
control (PPC) consists of a predispensed artificial DNA sequence, testing the ef-
ficiency of the PCR itself. Plates with an average (CtRTC-average CtPPC) ≥ 5 were
discarded, as values higher than 5 indicate an inhibitor of reverse transcription in
the sample. To guarantee the same PCR efficiency between plates, the average
Ct of the PPC controls had to range within two cycles for all plates analysed.
Analysing the data, the Ct value of each sample was determined by the 7500
software (Figure 2.5). In order to normalise the samples, the Ct value for each of
the 84 genes of interest was subtracted by the mean Ct value of the five house-
keeping genes for the same sample. The relative gene expression was then
calculated, setting one condition as standard, using the following formula :
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relative gene expression = 2−(Ct from gene of interest/Ct from standard gene)
Fold changes were calculated by dividing the relative gene expression of one
condition by the relative gene expression of the control.
Network analysis
A gene network was constructed using STRING, a database and web resource
composed of known and predicted protein-protein interactions of both physical,
functional and bibliometrical nature collected from a large number of biological re-
sources (Jensen et al., 2009). Cytoscape, an open source software for integrating
interaction networks with high-throughput expression data (Shannon et al., 2003)
was utilised to highlight and analyse differential gene expression in monocytes
isolated from HD and control subjects. This produced a network with 9366 inter-
actions (edges) between the 84 genes (nodes), with only five genes connected
solely by ’textmining interactions’.
Promoter analysis
Genomatix Gene2Promoter software was used to compare the transcription fac-
tor binding sites in the promoters of different genes. After entering the gene
names, the program lists all known transcription factor binding sites in the gene’s
promoter (set to look at 1000 bp upstream the first transcription start site and
500 bp downstream of the last transcription start site). Grouping the genes into
changed and unchanged allowed comparisons between transcription factor bind-
ing site prevalence in the genes changed in HD samples. Multiple binding sites
of a certain transcription factor in one gene promoter were not valued higher than
a single binding site.
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2.11 Microscopy
2.11.1 Imaging differentiated macrophages
Monocytes were seeded at a density of 2×106 cells per well in 6-well plates and
differentiated into macrophages. After six days macrophage morphology was
assessed under the microscope (Nikon Eclipse TS100, Objective 40×) and rep-
resentative pictures were taken using the attached camera (Nikon DS-Fi1) and
NIS-Elements F 3.00 software. The number of macrophages was counted in
three or four fields of view, including 20-30 cells each, using the ImageJ software.
2.11.2 Analysis of GeRP uptake
For immunofluorescence experiments on primary monocytes, autoclaved 13 mm
glass coverslips (VWR) were coated with 1 mg/ml poly-L-lysine for 10 minutes at
room temperature. Coverslips were subsequently washed three times with sterile
double-distilled water and air dried. Monocytes were seeded onto the coverslips
at a density of 1×105 per coverslip and left to attach overnight. Monocytes were
then incubated with empty green fluorescent GeRPs (1:10 ratio) for 12 h, washed
three times with PBS and fixed with 4 % PFA, for 20 min at room temperature.
After fixation, coverslips were washed three times with PBS and mounted in anti-
fade medium (DAKO) with 1 µg/ml DAPI. Images were acquired using a Zeiss
510 meta microscope (Objective 63x/1.4 Oil DIC, 1024x1024, zoom 4) with Zeiss
LSM software, overlaying the bright-field image of the cells with the 405 nm and
488 nm fluorescence channels for DAPI and green fluorescence, respectively.
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2.11.3 Phalloidin staining to assess actin remodeling
To analyse actin remodeling in primary monocyte-derived macrophages, 1× 105
monocytes were seeded on non-coated autoclaved 13 mm glass coverslips and
differentiated into macrophages as described in Section 2.5.4. Macrophages
were stimulated with 100 µM ATP or 50 ng/ml MCP-1 for either 5 or 10 min be-
fore being fixed with 4 % PFA, for 20 min at room temperature. After fixation,
coverslips were washed three times with PBS and treated with 0.1 % Triton X-100
in PBS for 5 min. After washing the coverslips three times again with PBS, cells
were stained with one Unit of Alexa Fluor 568 phalloidin (Invitrogen) for 20 min
at room temperature. After washing again with PBS, cells were mounting in anti-
fade medium (DAKO) with 1 µg/ml DAPI. Images were acquired using a Zeiss 510
meta microscope (Objective 63×/1.4 Oil DIC, 512×512) with Zeiss LSM Image
browser software. The number of filopodia forming cells as well as the number of
total cells were counted in at least 10 fields of view, including 20-30 cells each,
using the ImageJ software.
2.12 Statistical analysis
Chapter 3
To allow for repeated measures for some subject and potential heteroskedastic-
ity, generalised estimating equations with robust standard errors were used to
estimate the associations between HTT protein levels and disease stage, and
with disease burden. For models relating atrophy to mHTT levels, ordinary least
squares regression was used with mean mHTT levels used for multiple measures.
Statistical analyses were adjusted for age and gender. Analysis was performed
in STATAv12.
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Chapter 4
For cytokine profiling data, inter-group differences were identified by one-way AN-
OVA with post-hoc Tukey HSD testing to allow for multiple comparisons. Data
were corrected for age and gender before analysis. Cytokine profiling data from
U937 cells and HTT knock-down cells were analysed by two-way ANOVA with
Bonferroni post-tests. Changes in phagocytosis ability and gene expression chan-
ges measured by qPCR were analysed using unpaired two-tailed student t tests.
Paired two-tailed student t tests were used to analyse the effects of anti-HTT
siRNA compare to scrambled siRNA in cells from the same individual.
Chapter 5
Inter-group differences in migration ability were identified by two-way ANOVA with
Bonferroni post tests. Chemokine receptor expression differences were analysed
using one-way ANOVAs with Dunnett’s multiple comparison for multiple groups,
while unpaired two-tailed student t tests were used for comparisons between
two groups only. MCP-1 production by macrophages as well as p-cofilin levels
in monocytes were statistically evaluated using an unpaired two-tailed student t
tests. Lastly filopodia formation after different treatment conditions was analysed
using two-way ANOVAs with Bonferroni post-tests.
Chapter 6
Cytokine production by transgenic HD mice was compared with WT mice using
unpaired two-tailed student t tests. The abundance of different immune cell sub-
types in the spleen of HD mice as well as all functional comparisons between HD
and wild-type mice were analysed using unpaired two-tailed student t tests.
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3.1 Background
Mutant HTT expression in the CNS is the primary pathogenic factor for the de-
velopment of HD and increasing expression levels are associated with disease
severity and toxicity in various models (de Almeida et al., 2002). However, HTT is
expressed ubiquitously (Li et al., 1993) and HD patients exhibit multiple systemic
changes (van der Burg et al., 2009). One of the peripheral tissues affected is
the immune system, where increases in innate immune proteins found in patient
plasma track with disease progression (Dalrymple et al., 2007). Inflammatory
cytokines and chemokines are elevated in the plasma of HD patients, the origin
of which appears to be hyper-reactive monocytes (Bjo¨rkqvist et al., 2008; Wild
et al., 2011). Work presented in Chapter 4, demonstrates that this phenotype
is caused by cell-intrinsic effects of mHTT expression, likely by interaction with
the NFκB pathway. Furthermore, recent studies using peripherally-administered
KMO inhibitors (Zwilling et al., 2011) and bone marrow transplantation (Kwan
et al., 2012a) show that both can improve the HD phenotype in mice, suggesting
the immune system as a modifier of HD. Hyper-reactivity, as observed in mono-
cytes, is also found in murine HD microglia (Bjo¨rkqvist et al., 2008), and microglial
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activation is seen before symptom onset in HD mutation carriers (Tai et al., 2007).
Peripheral immune dysfunction, therefore, may be pathogenically important in it-
self, but may also offer a window onto relevant CNS dysfunction.
While many putative therapeutic approaches for HD attempt to lower mHTT levels
in the CNS or systemically (Sah and Aronin, 2011), non-invasive means of quan-
tifying mHTT in the CNS and thereby measuring the success of any HTT lowering
attempts, do not exist. Peripheral readouts using easily available tissues such as
blood, may be of value in assessing the effects of systemically-delivered HTT-
lowering therapies and detecting peripheral effects of centrally-delivered thera-
pies. Furthermore, given the cell-intrinsic nature of the immune defects in HD
patient immune cells (see Chapter 4), mHTT levels may track with disease pro-
gression and be of value as biomarker. The HD field has the unique opportunity
of predictive genetic testing, which allows identification of individuals who carry
the gene defect before the onset of symptoms. This provides the opportunity for
early intervention, ideally preventing or delaying disease onset. However, in order
to track the success of any therapeutic approach in premanifest HD gene carri-
ers, robust and practical measures of disease progression (i.e. biomarkers) are
needed. While TRACK-HD has provided evidence that imaging measures such
as brain atrophy and cognitive tests such as an emotion recognition task could
be useful biomarkers for HD (Tabrizi et al., 2012), robust wet biomarkers are still
to be found.
The aim of this project was to utilise a recently described TR-FRET immunoassay
(Weiss et al., 2011) to quantify total HTT and mHTT levels in different peripheral
cells obtained from HD patients, including different immune cells subsets and ep-
ithelial cells. To evaluate whether total HTT and/or mHTT levels may be useful as
biomarker, measures were correlated with known markers of disease progression
such as brain atrophy and disease burden score.
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3.2 Contributions
The study was a collaboration between UCL, London and Novartis, Basel. Ulrike
Tra¨ger collected all samples, sorted the immune cell types, performed quality
control, and shipped them to Dr Andreas Weiss and Stephan Grueninger for HTT
quantification. Dr Weiss also performed all assay quality control experiments.
Data was then unblinded by the statisticians Ruth Farmer and Prof Chris Frost for
analysis. Brain scan data was provided from the TRACK-HD study. Dr Christian
Landles has quantified HTT fragmentation in the human PBMC samples collected
by Dr Ralph Andre and Ulrike Tra¨ger. Findings presented in this chapter were
published in the Journal of Clinical Investigation:
Weiss A, Tra¨ger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri
N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi
SJ (2012) Mutant huntingtin fragmentation in immune cells tracks Huntington’s
disease progression. J Clin Invest 122: 3731-3736
3.3 Methods
Different immune cell subsets were isolated from whole blood using magnetic
cell sorting (Section 2.5.4), while epithelial cells were harvested using buccal
smears (Section 2.5.3). TR-FRET immunoassays were used to quantify total
and mutant HTT levels (Section 2.8.6). Brain atrophy measures were obtained
as part of the TRACK-HD study (Section 2.4) and disease burden scores were
calculated as [CAG repeat length - 35.5] × age. HTT fragments were visualised
by immunoprecipitation and western blot (Section 2.8.3 and 2.8.5). Statistical
methods used are detailed in Section 2.12.
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3.4 Results
3.4.1 Mutant but not total HTT accumulates in immune cells
from HD patients
In order to measure mutant and total HTT protein levels in different immune cell
subsets, monocytes, T cells and B cells were isolated from blood samples col-
lected from eight premanifest HD mutation carriers, ten early-stage and eight
moderate-stage HD patients, and twelve control subjects. Cheek swabs to har-
vest buccal epithelial cells were collected from 84 subjects including all blood
donors. For some participants multiple swabs and/or blood samples were taken
over a period of one year.
Most HD patients carry 40-50 CAG repeats in their mHTT allele (Myers, 2004).
The patient cohort used in this study was broadly within this range with the ex-
ception of one early HD patient expressing mHTT with 59 polyQ repeats (Table
A.2). In order to validate that the 2B7-MW1 antibody pair used in the TR-FRET
immunoassay selectively detects mutant (≥40Q) over wild-type HTT (≤40Q, but
with an average of 18 repeats), an allelic series of purified HTT with increasing
polyQ repeat lengths was analysed by TR-FRET. This showed a ten fold higher
sensitivity for mHTT containing 40Q compared with the wild-type protein with 18Q
(Figure 3.1). Furthermore, while there is a steep increase in TR-FRET signal be-
tween 20-40 polyQ repeats, the signal reaches a plateau at 40 repeats being the
same between 40 and 60 polyQ repeats. This shows that an increase in mHTT
signal in this range correlates with an increase in mHTT concentration, unrelated
to polyQ repeat length.
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Figure 3.1: TR-FRET detects mHTT protein with a ten fold higher sensitivity than
wild-type HTT protein. (A) Coomassie-stained gel verified lengths and purity of N-
terminal HTT protein fragments (548aa) with increasing polyglutamine repeat lengths.
GST-tagged HTT proteins were expressed in E. coli and isolated via PreScission col-
umn purification followed by GST-cleavage. (B) 2B7-MW1 TR-FRET signal intensities for
detection of 11 fmol purified HTT protein with increasing polyglutamine repeat lengths.
Figure by Dr Andreas Weiss.
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Measuring total HTT levels by TR-FRET using the 2B7-2166 antibody pair, showed
no significant difference (p>0.05) between HD patients and controls in any of the
cell types analysed (Figure 3.2).
Figure 3.2: Relationship between total HTT levels and disease stage. Total HTT
protein levels in monocytes, T cells, B cells and buccal cells were quantified by TR-
FRET using 2B7 and 2166 anti-HTT antibodies. Total HTT levels in all four cell types
showed no significant differences between HD patients and control subjects, or between
HD gene carriers at different disease stages. Coloured circles indicate multiple samples
from a single subject. Experiment performed in collaboration with Dr Andreas Weiss and
Stephan Grueninger.
Mutant HTT levels, analysed using the 2B7-MW1 antibody pair in an TR-FRET
immunoassay, were statistically significantly higher (p≤0.001) in all cell types iso-
lated from HD patients compared with controls. Furthermore, mean mHTT levels
increased with successive disease stage in each leukocyte cell type, with dif-
ferences (p≤0.01) between premanifest and manifest HD patients, and between
premanifest and early HD (0.021≤p≤0.051), but not between early and moder-
ate HD (Figure 3.3, Table 3.1). Mutant HTT levels in buccal epithelial cells were
significantly elevated in HD compared with control cells, but not different between
disease stages (Figure 3.3).
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Figure 3.3: Relationship between mHTT levels and disease stage. Mutant HTT pro-
tein levels in monocytes, T cells, B cells and buccal cells were quantified by TR-FRET
using the 2B7 antibody and a polyQ-specific antibody, MW1. Mutant HTT protein was
detected in all samples from HD patients and premanifest HD mutation carriers, as com-
pared with controls. Differences in mean mHTT levels in leukocytes were observed be-
tween premanifest and manifest HD patients (p≤0.01), and between premanifest and
early-stage HD subjects (p=0.051 and p≤0.05 for monocytes and T cells/B cells, re-
spectively). No differences were detected between HD disease stages in buccal cells.
Coloured circles indicate multiple samples from a single subject. Experiment performed
in collaboration with Dr Andreas Weiss and Stephan Grueninger.
Table 3.1: P-values for associations between cellular mHTT levels and disease
stage adjusted for age and gender.
A estimated using linear contrasts
Number of
observations/
subjects
p-value
HD vs.
controlA
pre-
HD vs.
manifestA
early HD
vs. pre-
HD
moderate
vs. early
HD
Monocytes 40/38 <0.001 0.007 0.051 0.404
T cells 38/36 <0.001 0.001 0.021 0.217
B cells 38/36 <0.001 <0.001 0.024 0.260
Buccal cells 98/84 <0.001 0.406 0.439 0.923
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3.4.2 Levels of mHTT in HD immune cells correlate to disease
burden score
Disease burden scores (Penney et al., 1997) are based on an individual’s age and
HTT CAG repeat length. The score correlates with clinically relevant endpoints
(Tabrizi et al., 2012), and is therefore an important and easily accessible marker
for disease progression in HD. To correlate the HTT levels measured in primary
human cells with this marker, disease burden scores were calculated for each
HD patient. After adjustment for age and gender, there was a strong (p<0.001)
positive association between disease burden and mHTT levels in monocytes and
T cells (Figure 3.4). A significant (p<0.05) association was also observed for B
cells, but no evidence of an association was found in buccal epithelial cells (Figure
3.4).
Figure 3.4: Associations between mHTT levels and disease burden score. Mutant
HTT protein levels in leukocytes showed a statistically significant positive association
with HD disease burden score, while levels in buccal epithelial cells do not show an
association with HD disease burden score. Repeated measurements for a single subject
are joined by a line.
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Given that disease burden score is a function of CAG repeat length, and to investi-
gate whether mHTT accumulates more in immune cells with longer CAG repeats,
mHTT levels were correlated with the CAG expansion length of the patient. A sig-
nificant association between the two factors was observed in monocytes and T
cells (Figure 3.5). Interestingly, however, B cells did not show a significant asso-
ciation between CAG and mHTT, while the association between disease burden
score and mHTT levels was significant in these cells. Buccal epithelial cells also
did not demonstrate any association between CAG repeat and mHTT levels.
Figure 3.5: Associations between mHTT levels and CAG repeat length. Mutant HTT
protein levels in monocytes and T cells, but not B cells and buccal epithelial cells, show a
statistically significant association with CAG repeat length. Repeated measurements for
a single subject are joined by a line.
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3.4.3 Levels of mHTT in HD immune cells correlate to brain
atrophy
Brain changes, in particular caudate atrophy, provide a quantifiable measure of
disease-associated changes in brain volume and have proven to be valuable
markers of disease progression that could be used as biomarker for future clinical
trials, tracking disease progression even in premanifest HD carriers (Tabrizi et al.,
2012). Investigating whether mHTT levels, which were shown to associate with
disease burden score, may be useful as a biomarker, the relationship between
mHTT levels in peripheral cells and rates of caudate atrophy, whole brain atro-
phy and ventricular expansion was examined, in a subset of HD subjects. These
subjects had undergone 3T MRI as part of the TRACK-HD study (Tabrizi et al.,
2009, 2012, 2011). Mutant HTT levels in monocytes were significantly (p<0.05)
associated with rates of caudate atrophy, while the association between caudate
atrophy and mHTT levels in T cells was borderline significant (p=0.086) (Figure
3.6).
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Figure 3.6: Relationship between mutant HTT levels and caudate atrophy. Mutant
HTT levels in monocytes are significantly associated with caudate atrophy rates mea-
sured by serial volumetric MRI. Hollow points indicate an average of two mHTT readings
for a single subject.
Furthermore, mHTT levels in monocytes also significantly associated with whole
brain atrophy and ventricular expansion. The association with whole brain atrophy
was also significant in T cells (Figure 3.7). No association between mHTT levels
and caudate, whole brain atrophy or ventricular expansion was detected in B cells
and buccal epithelial cells (Figure 3.6 and 3.7)
Figure 3.7 (following page): Relationship between mutant HTT levels and whole
brain atrophy and ventricular expansion. Mutant HTT levels in monocytes are signifi-
cantly associated with whole brain atrophy rates as well as ventricular volume gain mea-
sured by serial volumetric MRI. A weak association was also observed between mHTT
levels in T cells and whole brain atrophy, while B cells and buccal cells are not associated
with brain changes. Hollow points indicate an average of two mHTT readings for a single
subject.
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To investigate whether the association between brain atrophy and mHTT levels
merely reflects their mutual associations with disease burden, this factor was ad-
justed for in a secondary analysis by adjusting the formula used in the statistical
regression model. The association between mHTT and brain atrophy remained
significant or close to significance for caudate atrophy and ventricular expansion
in monocytes (p=0.007, p=0.093, respectively), and for caudate atrophy in T cells
(p=0.099) (Table 3.2). However, these results must be interpreted cautiously due
to the small sample size. Nonetheless, this is the first report of a biochemical
measure known to cause pathology in peripheral cells, that is significantly asso-
ciated with measures of structural brain changes in a neurodegenerative disease.
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3.4.4 HTT proteolysis occurs in human peripheral tissues
Mutant HTT fragments accumulate in HD rodent brain (Landles et al., 2010) and
have been detected in HD patient brain post-mortem (DiFiglia et al., 1997; Vonsat-
tel et al., 2011). One possible explanation for the progressive increase in mHTT
levels in leukocytes, while total HTT levels are unchanged, is a progressive ac-
cumulation of mHTT N-terminal fragments that are not detected in the TR-FRET
total HTT signal. While HTT fragments can be detected directly by western blot,
cross-reactivity of some anti-HTT antibodies targeting the polyQ region of other
polyQ domain proteins makes interpretation of the blots difficult. To avoid this
problem, an unbiased strategy combining immunoprecipitation and immunode-
tection was employed to identify HTT fragments (Landles et al., 2010). HTT was
immunoprecipitated from PBMCs from early-stage HD and control subjects, using
three different anti-HTT antibodies (the N-terminal aa7-13 binding 2B7 antibody,
the aa443-457 binding 2166 antibody and the polyproline domain binding aa51-
71 binding 4C9). Immunodetection by western blot was done using the 4C9 and
2166 antibodies. Several sizes of HTT fragments were immunoprecipitated and
detected by each of the anti-HTT antibodies in both the control and HD sam-
ples (Figure 3.8). Genuine HTT fragments are seen in precipitates from all three
anti-HTT antibodies but not in the IgG control.
There are no antibodies specific for either wild-type or mutant HTT available. De-
tection of mHTT relies on the use of a HTT-specific antibody (such as 2B7, 2166,
4C9, 1H6), in combination with antibody recognising the polyQ domain such as
MW1 and 3B5H10. PolyQ-specific antibodies, however, work better the longer
the repeat in the protein is, making it difficult to specifically detect N-terminal
mHTT fragments using samples with the typical adult onset CAG repeat length
between 40-50 CAG repeats. Neither the MW1 or 3B5H10 antibodies will detect
mHTT by western blot analysis of such samples. Therefore, samples were taken
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Figure 3.8: HTT protein fragments are present in PBMCs. HTT in PBMCs from two
HD subjects and an age-matched control was immunoprecipitated with 2B7, 2166 or 4C9
anti-HTT antibodies, as compared with an IgG control. Immunoprecipitates were blotted
with 4C9 (top panel) and 2166 (bottom panel) anti-HTT antibodies. Several HTT-specific
bands were found in HD patient and control subject PBMC samples. IP = immunoprecip-
itation; ID = immunodetection; IgG-H = antibody heavy chain. Experiment performed in
collaboration with Dr Christian Landles.
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from two young onset HD patients with 73 and 59 repeats and an age-matched
control. HTT was immunoprecipitated using the HTT-specific 2B7 and 2166 an-
tibodies as well as the polyQ domain-specific 3B5H10 antibody, which does not
immunoprecipitate any wild-type HTT. HTT fragments were immunodetected with
the 2166 (Figure 3.9, top panel) and 1H6 (Figure 3.9, middle panel) anti-HTT an-
tibodies. Furthermore, mHTT fragments were detected with the MW1 antibody
(Figure 3.9, bottom panel), which only specifically recognises expanded polyQ
tracts. Using this approach, mHTT-specific fragments were readily identified in
young onset HD patient PBMCs, as compared with those from a control subject.
As expected 3B5H10 does not precipitate any proteins detectable with anti-HTT
antibodies in controls, while both 2B7 and 2166 precipitates from control sam-
ples demonstrated HTT fragments when immunodetected with 2166 or 1H6. In
addition to HTT fragments, young onset HD patients also demonstrate specific
mHTT fragments. Mutant HTT fragments were not present in controls cells and
precipitated by all three antibodies (see red boxes in Figure 3.9 ). Moreover,
some small mHTT fragments (see yellow boxes in Figure 3.9) were only precip-
itated using the N-terminal 2B7 anti-HTT antibody and the polyQ MW1, and not
the more C-terminal 2166 antibody. These findings indicate that some of the
fragments were derived from the N-terminus of the mHTT protein and suggest
that full-length mHTT is continuously cleaved to produce N-terminal fragments in
patients’ peripheral immune cells.
Figure 3.9 (following page): Mutant HTT protein fragments are present in HD
PBMCs. HTT protein in PBMCs from two young-onset HD patients (HTT CAG re-
peat lengths of 76 and 59) and an age-matched control was immunoprecipitated with
2B7, 3B5H10 or 2166 anti-HTT antibodies as compared with an IgG control. Immuno-
precipitates were blotted with either the 2166 anti-HTT (top panel); the 1H6 anti-HTT
antibody (middle panel) or the polyQ-specific MW1 antibody (bottom panel). Several
mHTT-specific bands were found in the lysates from the young-onset HD patient PBMCs
(coloured boxes), including N-terminal HTT fragments (yellow boxes) immunoprecipitated
with the 2B7 and 3B5H10 antibodies, but not with the more C-terminal epitope-binding
2166. IP = immunoprecipitation; ID = immunodetection; IgG-H = antibody heavy chain.
Experiment performed in collaboration with Dr Christian Landles.
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3.5 Discussion
The search for robust biomarkers is vital in order to commence therapeutic in-
tervention before disease onset in HD gene carriers. The TRACK-HD study has
proven that brain imaging measures and selected cognitive tests can be used as
endpoints in such studies (Tabrizi et al., 2009, 2012, 2011). Changes in the im-
mune system have been identified long before the appearance of the first symp-
toms, with plasma cytokine being present on average sixteen years before dis-
ease onset (Bjo¨rkqvist et al., 2008). In this study, a significant increase of mHTT
over disease progression has been detected in peripheral immune cells, but not
other peripheral cells. These findings suggest that mHTT levels but not total HTT
levels, measured in peripheral immune cells could be a possible biomarker for
HD. Furthermore, mHTT levels in monocytes and T cells were significantly asso-
ciated with disease burden and brain atrophy indicating the potential relevance of
these cell types to pathogenic and clinical events in HD, given that other periph-
eral cells tested in this study did not demonstrate any association with markers of
disease progression.
mHTT levels were also found to be associated with CAG repeat length in mono-
cytes and T cells. As disease burden score is, at least in part, a function of CAG
and also correlates with mHTT levels in these cells, this result is unsurprising.
Interestingly, however, mHTT levels correlated with disease burden score but not
CAG repeat length in B cells, indicating that CAG is not the only factor contributing
to the accumulation of mHTT in these cells.
In order for mHTT measures to be used as a part of a biomarker battery for
trials, the assay needs to be validated using a larger cohort. Given the overlap
between the different disease stages and the fact that no significant difference
between early and moderate patients could be detected (Figure 3.3), longitudinal
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data will help understand how mHTT levels change over disease progression and
how robust changes will relate to other disease progression measures such as
brain atrophy. In addition to this, the protocol used in this study would not be
suitable for a clinical trial with several endpoint measures. Here, three immune
cell subtypes were isolated in a time consuming protocol before mHTT levels
were assayed. However, given that all three cell types show an increase in mHTT
that correlates with disease burden score, the use of unsorted PBMC pellets for
mHTT measurements should be considered in taking this strategy forward.
There are several possible explanations for the progressive increase in mHTT
levels in leukocytes, while no differences were apparent in total HTT levels. Ac-
cumulation of mHTT over the lifespan of the cells is unlikely as, although some
leukocytes are long-lived, monocytes typically persist for only 2-8 days in the
bloodstream (Whitelaw, 1966). Another possible explanation is the accumulation
of extended CAG repeat expansions in the HTT gene due to somatic DNA in-
stability. However, this is not seen in peripheral immune cells (MacDonald et al.,
1993). A selective increase in mHTT expression as the disease develops and
progresses cannot be excluded, but seems improbable as total HTT levels did
not change. The most likely explanation is a progressive accumulation of mHTT
N-terminal fragments that are not detected in the TR-FRET total HTT signal. In-
deed, using a immunoprecipitation and immunodetection strategy both HTT and
mHTT fragments could be detected in primary human immune cells. Compar-
ing the fragment profile in PBMCs from young onset HD patients precipitated
with an N-terminal (2B7) antibody and with a more C-terminal (2166) antibody,
small mHTT fragments were only detected with 2B7 suggesting proteolysis at the
N-terminus. Given a recent publication demonstrating that CAG repeat depen-
dent aberrant splicing of HTT causes translation of HTT exon 1 protein fragments
(Sathasivam et al., 2013), one of the small HTT fragments detected in this study
may be due to splicing events. However, testing splicing events in primary human
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PBMCs, Sathasivam et al. only detected a splicing product in one out of eight
PBMC samples suggesting alternative splicing events may be rare in this cell
type (Sathasivam et al., 2013). While, mHTT fragments are known to accumu-
late in HD rodent brain (Landles et al., 2010) and HD patient brain (DiFiglia et al.,
1997; Vonsattel et al., 2011), and HTT protein proteolysis has been demonstrated
in lymphoblast cell lines from HD patients (Toneff et al., 2002), this is the first time
fragmentation has been shown in primary human peripheral cells.
Lastly, the findings in this study may be of use in future HTT lowering studies
(Sah and Aronin, 2011), as non-invasive quantification of mHTT in CNS tissue or
CSF in human subjects is not currently possible. The success of any forthcoming
trials to lower mHTT levels will rely on indirect pharmacodynamic outcome mea-
sures. While it is not know how lowering of HTT levels specifically in the brain,
for example by injection of a viral vector containing siRNA or ASOs would effect
peripheral cells, it would be of interest to investigate the effect on blood cells in
upcoming animal studies. Furthermore, studies looking into lowering HTT sys-
temically, for example using small molecules aimed at enhancing HTT clearance,
may be enhanced by the application of such quantification to investigate levels of
HTT lowering. Ex vivo testing of peripheral immune cells before the trial may also
prove to be useful in identifying subjects in whom such therapies are most likely
to succeed.
Overall this study identified mHTT levels as potential wet, easily assessable bio-
marker for HD progression. N-terminal HTT proteolysis is the likely cause for the
increase of mHTT over total HTT in peripheral immune cells.
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4.1 Background
Whilst primary pathology in HD is believed to arise from basal ganglia degener-
ation, HTT expression has been detected in all tissues studied (Li et al., 1993),
and expression in non-neuronal cells both within the brain and in the periph-
ery may contribute to HD pathology. Indeed, numerous studies of HD patients
and mouse models have described abnormalities in peripheral tissues, including
weight loss and muscle wasting despite high caloric intake, diabetes and changes
in the neuro-endocrine system (van der Burg et al., 2009).
HTT is also expressed in immune cells (Weiss et al., 2012), and both central and
peripheral immune system abnormalities have been shown in HD patients (Soulet
and Cicchetti, 2011). Microglia, the resident immune cells of the brain and pe-
ripheral myeloid cells share the same haematopoietic origin, although it remains
controversial as to whether circulating blood monocytes can replenish the mi-
croglial population within the brain during an individual’s lifetime (Ransohoff and
Perry, 2009). Whilst microglia seem to be sustained largely by self-renewal (Ajami
et al., 2007), disruption of the blood brain barrier by irradiation has shown that
blood monocytes are able to populate the brain and differentiate into microglia
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(Simard and Rivest, 2004). Microglial activation is observed in post-mortem HD
brain tissue (Sapp et al., 2001) and by PET imaging, showing that this activation
is already present in HD gene carriers before symptom onset (Tai et al., 2007).
Peripheral immune system dysfunction has previously been demonstrated in HD,
including changes in innate immune proteins such as complement components
and cytokines in HD patient plasma (Dalrymple et al., 2007). Moreover, elevated
plasma cytokine (Bjo¨rkqvist et al., 2008) and chemokine (Wild et al., 2011) levels
in HD patients correlate with disease progression and can be detected years be-
fore disease onset. It has been shown that primary human monocytes are hyper-
reactive in response to LPS, producing increased levels of IL-6. This phenotype
is replicated in murine mHTT expressing macrophages and microglia, demon-
strating that peripheral cells may be able to mirror pathology in the CNS in HD
(Bjo¨rkqvist et al., 2008).
Several recent studies have suggested that the peripheral immune system can
act as a modifier of HD neuropathology. Bone marrow transplantation (Kwan
et al., 2012a), administration of a KMO inhibitor (Zwilling et al., 2011) and reduc-
tion of the immune response by modulating of the CB2 pathway (Bouchard et al.,
2012) have proven to suppress or delay the HD phenotype in mice. These stud-
ies provide strong evidence that the immune system plays a disease-modifying
role in HD neuropathogenesis, but the mechanism by which mHTT expression in
immune cells causes this dysfunction has not yet been established.
Activation of immune cells by pathogens binding TLRs leads to the activation of
several signalling cascades including the NFκB and MAPK pathways. Intracellu-
lar signalling pathways leading to the activation of the transcription factor NFκB
are important regulators of cytokine production and play a key role in inflamma-
tion. Activation of TLRs leads to signal transduction via adapter proteins such
as MyD88 and IRAK1, leading to the phosphorylation and activation of IKK. This
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kinase phosphorylates IκB, which is then ubiquitinated and degraded by the pro-
teasome. This results in its dissociation from the NFκB transcription factor sub-
units (RelA, RelB, cRel, NFκB1, NFκB2), which are sequestered in an inactive
state in the cytoplasm when bound to IκB. The free NFκB molecules can then
translocate into the nucleus and activate gene transcription (Hayden and Ghosh,
2012). The NFκB pathway has previously been implicated in HD, with Khoshnan
et al. having shown in inducible PC12 cells and striatal extracts from R6/2 mice
that overexpression of mHTT exon 1 can activate the NFκB pathway by directly
interacting with IKKγ (Khoshnan et al., 2004). It remains to be shown that this
interaction also occurs in a human system with expression of full-length HTT at
normal allelic expression levels.
The aim for this part of my PhD project was to identify the mechanism of dysfunc-
tion in primary human HD ex vivo monocytes and macrophages. This involved,
characterising the immune cell dysfunction in HD and the study of upstream in-
tracellular signalling pathways, identifying NFκB pathway dysregulation as the
cause of HD immune dysfunction. Furthermore, overexpression and knock-down
techniques were used to investigate the role cell-intrinsic HTT plays in human
HD monocyte and macrophage function, while testing the feasibility of reversing
peripheral immune dysregulation by cell-targeted HTT-lowering.
4.2 Contributions
Dr Peter Klo¨hn helped with the fluorescent activated cell sorting, Gary Adam-
son helped with the DNA sequencing and Dr Holger Hummerich helped with the
bioinformatic analysis (all part of the MRC Prion Unit, UCL). All measurements
of HTT levels were done by Stephan Grueninger and Dr Andreas Weiss at No-
vartis, Basal. The initial cytokine profiling of adult onset HD monocytes was done
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by Anna Magnusson-Lind (Lund University, Sweden) and Dr. Nayana Lahiri (In-
stitue of Neurology, UCL). Glucan encapsulated siRNA particles were packaged
by Professor Gary Ostroff (University of Massachusetts, USA).
4.3 Methods
Cytokine production by primary human monocytes and macrophages isolated
from human HD and control samples (Section 2.5.4) and treated with IFNγ and
LPS (Section 2.6.1) was measured using multiplex ELISA assays (Section 2.7.2).
To further access the functionality of HD immune cells, uptake of latex beads
was measured using flow cytometry (Section 2.6.3). The human histiocytic lym-
phoma cell line (U937) was lentivirally transduced to overexpress wild-type or
mutant HTT (Section 2.5.2), before their cytokine production was analysed (Sec-
tion 2.6.1) to establish whether cell-intrinsic mHTT expression is sufficient to in-
duce immune dysfunction. Immunoprecipitation was used to detect interactions
between HTT and IKK (Section 2.8.3). Further investigating the NFκB pathway,
western blot analysis (Section 2.8.5) was used to assess IκB degradation and
imaging flow cytometry (Section 2.9.3) to assess nuclear translocation of NFκB
transcription factors. STAT signalling was assessed using intracellular flow cytom-
etry (Section 2.9.2). Transcription changes in HD monocytes were detected using
qPCR (Section 2.10) and visualised using bioinformatics (Section 2.10.4). Tran-
script lowering (Sections 2.5.5) was used to see whether HTT knock-down can
reverse the immune dysfunction in primary human monocytes and macrophages.
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4.4 Results
4.4.1 Establishing macrophages cultures from HD patients
Human blood monocytes are post-mitotic cells and were not cultured for longer
than 48 hours. Macrophages were differentiated from monocytes by adding GM-
CSF to the culture media. During differentiation, the cells flattened out and formed
projections. Macrophages from HD patients and controls showed no obvious dif-
ferences in cell morphology (Figure 4.1A). Counting the number of macrophages
post differentiation suggested no difference in proliferation and differentiation rate
between control and premanifest HD gene carriers, early- and moderate-stage
HD patients (Figure 4.1B). CD206 is a specific marker for macrophages and up-
regulated to the same extent during differentiation of either control or HD patient
cells (examples shown in Figure 4.1C).
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Figure 4.1: Characterisation of HD patient macrophages. Macrophages were differ-
entiated with 20 ng/ml GM-CSF for six days. (A) Light microscope images of macrophage
from control, premanifest HD gene carriers, early- and moderate-stage HD patients
showed no morphological differences. (B) Number of macrophages do not differ be-
tween control and premanifest HD gene carriers, early- and moderate-stage HD patients
(one-way ANOVA used as statistical test). Macrophages were counted on three or four
representative fields of view pre coverslip. n= biological repeats. (C+D) Example of
up-regulated CD206 expression on differentiated macrophages. CD206 was similarly
up-regulated on macrophages from (C) control and (D) HD patients.
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4.4.2 HD monocytes and macrophages are hyper-reactive
after LPS stimulation
HD patient monocytes are hyper-reactive, producing increased levels of IL-6 upon
stimulation with LPS in vitro (Bjo¨rkqvist et al., 2008). To extend these findings to
other cytokines, blood samples from a large cohort (n=53) of HD gene carriers
ranging from premanifest to moderate-stage disease and control subjects (n=27)
were collected (Table A.3). CD14+ monocytes were isolated and seeded in vitro,
before being primed with IFNγ and stimulated with LPS. In multiplex ELISA as-
says, stimulated monocytes from HD-mutation-positive subjects at each disease
stage, including those who were premanifest, were found to produce more of the
pro-inflammatory cytokines IL-6 and TNFα than control cells (Figure 4.2). Fur-
thermore, production of the pro-inflammatory IL-1β was significantly increased in
LPS-stimulated premanifest HD monocytes. Levels of the chemokine IL-8, anti-
inflammatory IL-10 and pro-inflammatory IL-12 did not differ between stimulated
HD and control cells (Figure 4.2).
Cytokine production by LPS-stimulated monocytes was normalised to the cy-
tokine production of non-stimulated cells from the same subject. Cytokine pro-
duction by non-stimulated monocytes was very low with 10 pg/ml for all cytokines
besides IL-8, for which levels were around 1 ng/ml in supernatants from non-
stimulated cells. Cytokine production by non-stimulated cells did not differ be-
tween control and HD-mutation-positive subjects at each disease stage.
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Figure 4.2: Pro-inflammatory cytokine production by monocytes is elevated in HD
patients. Monocytes were isolated from control and HD patient blood samples using
magnetic cell sorting. After stimulation with 10 ng/ml IFNγ and 2 µg/ml LPS for 24 h,
multiplex ELISA demonstrated that innate immune regulators IL-1β , IL-6 and TNFα are
elevated in culture media of HD patient blood monocytes. Data show mean concentra-
tions corrected to basal condition ± SEM, n= individual biological repeats, ANOVA with
post-hoc Tukey HSD test. *p<0.05; **p<0.01, ***p<0.001. Experiment performed by
Anna Magnusson-Lind and Dr Nayana Lahiri.
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Next, these findings were validated and expanded to juvenile HD patients carrying
on average 57 CAG repeats (14 more than the adult patient cohort in Figure
4.2). Due to the higher number of CAG repeats juvenile HD patients not only
suffer from an early disease onset but also a more progressive course of the
disease and atypical symptoms such as seizures (Squitieri et al., 2006). Immune
changes may therefore also be different in juvenile compared with adult onset
patients. The cytokine profile of monocytes, isolated from juvenile HD patients
and stimulated with IFNγ and LPS, showed a similar increase in the production
of pro-inflammatory cytokines as seen in cells isolated from adult onset patients
(Figure 4.3). However, due to the low sample size (n=4 for juvenile HD and n=6
for age matched control subjects) in this experiment, only IL-1β production was
found to be significantly increased.
Cytokine production was normalised to the protein content of the correspond-
ing well rather than non-stimulated samples for this experiment. Non-stimulated
monocytes isolated from juvenile HD patients did not differ from control cells,
producing less than 1 pg/µg IL-1β , IL-6 and TNFα and less than 10 pg/µg IL-8.
147
Results Myeloid cell function in HD patients
Figure 4.3: Cytokine profile of juvenile HD patient monocytes. Blood monocytes
isolated from juvenile HD patients were primed with 10 ng/ml IFNγ and stimulated with
2 µg/ml LPS. After 24 h cytokine concentrations in the supernatants were measured us-
ing multiplex ELISA, showing significantly increased IL-1β levels compared with control
samples. Graphs show mean concentrations corrected to protein content ± SEM, n=
individual biological repeats, unpaired two-tailed student two-tailed t tests. *p<0.05.
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When monocytes migrate into tissues, they differentiate into macrophages ca-
pable of eliciting effective immune responses to localised inflammatory signals
(Gordon and Taylor, 2005). To test whether HD macrophages are also abnormal,
blood monocytes were differentiated into macrophages using GM-CSF before be-
ing stimulated with IFNγ and LPS to assess their cytokine profile. Stimulated HD
macrophages from all disease stages produced significantly higher levels of IL-8
and TNFα compared with control cells (Figure 4.4).
Similar to the monocyte cytokine profile of juvenile HD patients, macrophage cy-
tokine production was normalised to protein content and non-stimulated cells
did not differ in cytokine production comparing control with HD. Non-stimulated
macrophages produced cytokine levels close to the lower detection range of the
MSD assay, producing less than 1 pg/µg IL-1β , IL-6 and TNFα and less than
20 pg/µg IL-8.
Taken together, these data show that immune cells isolated from HD patients are
hyper-reactive following stimulation.
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Figure 4.4: Pro-inflammatory cytokine production by macrophages is elevated in
HD patients. Macrophages, derived from blood monocytes using 20 ng/ml GM-CSF for
6 days, were primed with 10 ng/ml IFNγ and stimulated with 2 µg/ml LPS for 24 h before
cytokine concentrations in the supernatants were measured using MSD multiplex ELISA.
Compared with control cells, HD patient macrophages produced higher levels of IL-8 and
TNFα. Graphs show mean concentrations corrected to protein content ± SEM, one-way
ANOVA with post-hoc t-tests. *p<0.05; **p<0.01.
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4.4.3 The hyper-reactive immune phenotype is caused directly
by mHTT expression
Mutant HTT levels in immune cells have been shown to track measures of HD
progression, such as disease burden score and caudate atrophy (Chapter 3). To
test whether immune cell dysfunction is caused by cell-intrinsic mHTT expres-
sion, or instead by external disease-associated factors, the histiocytic lymphoma
U937 cell lines, a commonly used model of monocytes, was transduced with
lentiviral vectors expressing human HTT exon 1. The constructs contained either
wild-type HTT exon 1 with 29 CAG repeats or mutant HTT exon 1 with 71 or 129
CAG repeats, with all constructs also encoding for GFP. A vector expressing only
GFP and no HTT was used as control. Sorting the transduced cells using the
co-expressed GFP resulted in 99 % pure cultures (Figure 4.5).
Figure 4.5: Sorting efficiency of U937 cells transduced with HTT exon 1. U937 cells
were lentivirally transduced with HTT exon 1 carrying 29, 71 or 129 CAG repeats. All viral
vectors also encoded GFP, which was used to fluorescence-activated cell sort transduced
cells. FACS sorting was highly efficient, (A) showing cell population prior to sorting and
(B) showing 99 % pure HTT expressing U937 cells. FACS was assisted by Dr Klo¨hn.
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U937 cells represent an immature monocyte-like phenotype, but can be differ-
entiated using PMA and are known to produce pro-inflammatory cytokines fol-
lowing stimulation (Alciato et al., 2010). Testing two different concentrations of
PMA, U937 cells at both doses were found to up-regulate the macrophage marker
CD206 indicating differentiation (Figure 4.6). As 10 ng/ml PMA already induced
differentiation of U937 cells, this concentration was used in all future experiments.
Figure 4.6: U937 cells differentiate into macrophage-like cells. U937 cells were
treated with 10 or 100 ng/ml PMA for 3 days. During this time cells settled down to
form a monolayer and expressed the macrophage marker CD206 as measured by flow
cytometry.
HTT expression in the transduced cells was demonstrated using the TR-FRET
immunoassay. In contrast to control lines (non-transduced U937 cells and empty
vector transduced U937 cells), which showed no detectable HTT signal, CAG re-
peat length dependent expression of soluble mHTT is detectable in the two cell
lines expressing HTT exon 1 carrying 71 or 129Q (Figure 4.7A). Previous stud-
ies have shown that the 2B7-MW1 antibody combination used to detect soluble
mHTT can detect HTT with polyQ lengths starting at 17Q (Baldo et al., 2012),
explaining why a small signal was observed in cells transduced with the 29Q con-
struct. Interestingly, both of the mHTT expressing cell lines also contained ag-
gregated mHTT, measured using the MW8-MW8 antibody combination, with the
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cells expressing 129 CAG repeats containing 30 times more aggregates than the
cells expressing 71 CAG repeats (Figure 4.7B). Interestingly, while this model of
HD myeloid cells shows HTT aggregates, this has never been detected in primary
human HD immune cells using the same assay (Weiss, personal communication).
Figure 4.7: Transduced U937 cells express both soluble and aggregated HTT. U937
cells were lentivirally-transduced with (m)HTT exon 1 containing either 29, 71 or 129Q
repeats. Expression of both soluble and aggregated (m)HTT protein post-transduction
was confirmed using 2B7-2166 or MW8-MW8 TR-FRET, respectively, showing increased
levels of soluble HTT in all three cell lines expressing exogenous HTT and aggregated
mHTT in both mHTT expressing cell lines. TR-FRET measurements were performed in
collaboration with Dr Andreas Weiss.
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To assess whether intrinsic HTT expression causes the increase in cytokine pro-
duction found in HD patient cells, the HTT exon 1 expressing U937 cell lines
were differentiated with PMA for 3 days before stimulation with IFNγ and LPS and
analysis of their cytokine profile. Stimulated U937 cells expressing either 71 or
129Q mHTT produced significantly increased levels of IL-6 and TNFα compared
with those expressing the 29Q wild-type HTT construct (Figure 4.8). Cells ex-
pressing 129Q produced significantly higher IL-1β levels compared with control,
whereas IL-8 levels did not differ. Therefore, cell-intrinsic expression of mHTT
exon 1 seems to be sufficient to recapitulate the hyper-reactive immune pheno-
type observed in monocytes and macrophages from HD patients.
Figure 4.8: Expression of mHTT induces elevated cytokine production. U937 cells
were lentivirally transduced with either wild-type HTT exon 1 containing 29Q or mHTT
exon 1 containing 71 or 129Q repeats. Innate immune regulators were elevated in PMA-
differentiated mHTT expressing U937 cells stimulated for 24 h with 10 ng/ml IFNγ and
2 µg/ml LPS. Data shown as mean corrected for protein content ± SEM, n=4 technical
repeats for all conditions, two-way ANOVA with Bonferroni post-tests, *p<0.05; **p<0.01,
***p<0.001.
154
Results Myeloid cell function in HD patients
4.4.4 LPS stimulation of HD macrophages results in increased
phagocytosis
In addition to cytokine production, the ability to ingest pathogens by a cellular
process called phagocytosis is a key function of monocytes and macrophages.
Phagocytosis not only clears pathogens and debris at sites of inflammation, but
also forms the first step in the activation of the adaptive immune system (Walport
et al., 2008). Phagocytosis by monocyte-derived macrophages was assessed
by incubating cells with green fluorescent latex beads and measuring the per-
centage of cells having taken up beads via flow cytometry (gating shown in Fig-
ure 4.9A). Interestingly, basal phagocytosis (Figure 4.9B) was unchanged, but
LPS stimulation for 24 h revealed a significant difference between HD and con-
trol macrophages (Figure 4.9C). A significantly higher percentage of HD patient
macrophages phagocytosed beads compared with controls after LPS stimulation.
The percentage of HD macrophages taking up only one bead was significantly
increased, while the percentage of cells taking up two or three beads was not
statistically different.
Figure 4.9 (following page): Increased phagocytosis by HD patient macrophages.
Monocyte-derived macrophages were incubated with green fluorescent latex beads for
1 h at 37 ◦C before the percentage of cells taking up green fluorescent beads was anal-
ysed using flow cytometry. (A) Macrophage were gated in the FCS and SSC channels
according to their size before the FL-1 channel was used to determine what percentage
of cells phagocytosed which number of beads. (B) Basal phagocytosis levels of un-
stimulated HD patient macrophages were unchanged compared with control cells, whilst
(C) HD patient macrophages stimulated with 2 µg/ml LPS for 24 h showed a significant
increase in the percentage of phagocytosing cells. Grey points represent control, red
points represent HD macrophages. Unpaired two-tailed student t tests, *p<0.05. n= 5 for
control and HD, representing biological repeats.
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Doublet discrimination was used to prove that the increase in green fluorescence
intensity detected in the phagocytosis assay corresponded with an increase in
the number of beads taken up by a cell. Therefore, the green fluorescent latex
beads, used for the assay, were run on the FACS machine comparing the FL-1
height measure, used to measure fluorescence intensity, to FL-1 width, a mea-
sure of the time the beads need to pass the laser. Single beads will need a shorter
amount of time to pass the laser than doublets or triplets allowing a comparison
of the fluorescence emitted by singlet, doublet or triplet beads. Looking at the for-
ward scatter (FSC-correlating to particle size) and side scatter (SSC-correlating
to particle granularity) already showed different sized particles, which looking into
the FL-1 width channel were confirmed as singlet, doublet of triplet beads (Figure
4.10). Comparing the fluorescence intensity, FL1-H, between the different beads
revealed an increase similar to that seen in the phagocytosis assay between sin-
glet, doublet and triplet beads, thus validating the assay.
Figure 4.10: Doublet discrimination validates phagocytosis assay. Green fluores-
cent latex beads were run on the flow cytometer without adding cells. In the left graph
comparing particle size (FSC on the y-axis) and particle granularity (SSC on the x-axis),
three populations representing singlet, doublet and triplet beads are shown. In the right
graph, comparing the fluorescence intensity (y-axis) with the time it takes the particle to
cross the laser (x-axis) demonstrated an increase in fluorescence when detecting multi-
ple beads compared with singlets.
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4.4.5 Dissection of signalling pathways in HD monocytes
HD monocytes and macrophages resemble normal monocytes and macrophages
when unstimulated, but are hyper-reactive in response to LPS showing increased
cytokine production and abnormal phagocytosis. This suggests that mHTT af-
fects the signalling cascade induced by LPS. Testing whether expression changes
in the main LPS receptor, TLR4, were responsible for the HD phenotype, TLR4
transcript levels were analysed in native HD and control monocytes using qPCR.
TLR4 levels were unaltered in HD monocytes isolated from patients across all
disease stages (Figure 4.11), suggesting downstream effects.
Figure 4.11: TLR4 expression does not differ between HD and control cells. CD14+
monocytes from both HD patients and controls were isolated from whole blood using
magnetic cell sorting. RNA was extracted from these unstimulated cells and used for
gene expression analysis via qPCR, which showed no differences in TLR4 expression
levels. Data shown as relative gene expression ± SEM, normalised against expression
of B2M, GAPDH, BACTIN, one-way ANOVA.
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4.4.5.1 mHTT interacts with the NFκB pathway
The NFκB pathway, one of the main signalling cascades downstream of TLR4,
has previously been implicated in HD. Khoshnan et al. have shown that mHTT
exon 1 expression activates the NFκB pathway by directly interacting with the γ
subunit of the IKK trimer, both in inducible rat PC12 cells and striatal extracts from
R6/2 mice (Khoshnan et al., 2004). To test whether this interaction occurs in hu-
man primary HD immune cells, PBMCs from early-stage HD patients and control
subjects were isolated for co-immunoprecipitation experiments. Full-length HTT
was detectable in both the control and HD samples with two anti-HTT antibodies
(2B7 and 2166), whereas co-precipitation of IKKγ was observed only in the HD
sample (Figure 4.12). This demonstrates a direct interaction between mHTT and
IKKγ in primary human HD cells.
Figure 4.12: mHTT interacted directly with the NFκB pathway. HTT was co-
immunoprecipitated from PBMC whole cell lysates using either 2166 or 2B7 anti-HTT
antibodies, before immunoblotting for HTT and IKK. Shown is an example blot of sam-
ples from one control and one HD subject, with relevant bands marked. Experiment has
been repeated six times with same result and similar (or stronger) background levels.
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Activation of the IKK complex leads to the phosphorylation and degradation of
IκB, the endogenous inhibitor of NFκB (Hayden and Ghosh, 2012). To evaluate
whether the interaction of mHTT with IKKγ leads to increased IKK complex acti-
vation and subsequent changes in IκB degradation, HD and control monocytes
were stimulated with LPS over a time-course of 2 hours to analyse IκB levels by
western blot. Control monocytes demonstrated a drop in IκB levels over the first
15 minutes, followed by a recovery of IκB levels over the next two hours, repre-
senting a normal pattern of NFκB activation upon stimulation (Figure 4.13) (Gross
and Piwnica-Worms, 2005). Following stimulation of HD monocytes, a different
pattern was observed: IκB levels dropped within 5 minutes and did not recover to
baseline levels within the two hour time-course (Figure 4.13). This demonstrates
that IκB is degraded more rapidly and over a prolonged period of time in primary
human HD cells due to IKK activation.
Figure 4.13: IκB degradation is faster in HD patients. Control and HD monocytes,
isolated from whole blood using magnetic cell sorting, were stimulated with LPS over
a two hour time-course after which cells were lysed for western blot analysis. While
in control cells LPS-induced degradation of IκB occurred within 15 min of stimulation
and recovered within 2 hours, HD monocytes demonstrated a rapid loss of IκB and no
recovery of the protein. Shown are two example blot of samples from one control and
one HD subject each. Repeated twice with similar results.
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Under steady-state conditions, IκB binds NFκB and blocks its translocation to the
nucleus. Degradation of IκB allows the NFκB transcription factors (RelA, RelB,
cRel, NFκB1, NFκB2) to enter the nucleus and affect transcription (Beinke and
Ley, 2004). In order to test whether increased IκB degradation in HD monocytes
leads to more rapid nuclear translocation of NFκB, levels of RelA translocation
in HD and control monocytes were analysed using imaging flow cytometry. Cells
were stained with DAPI to mark the nucleus and with anti-RelA antibodies (Figure
4.14A). Analysis of the levels of RelA and DAPI co-localisation showed higher
levels of RelA translocation in HD cells at every time point over a 90 minute period
post-LPS stimulation, with significantly increased translocation at 5, 10 and 60
minutes (Figure 4.14B).
Thus, mHTT binds IKKγ and is likely to cause increased NFκB activity by in-
creased IκB degradation and subsequent NFκB translocation. This would be
expected to lead to increased transcription of NFκB target genes, as represented
by increased cytokine production by the cells.
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Figure 4.14: NFκB translocation into the nucleus is faster in HD monocytes.
Translocation of the NFκB transcription factor RelA to the nucleus in LPS stimulated
blood monocytes was measured using imaging flow cytometry; (A) example images are
shown here. In untranslocated cells the green RelA staining surrounded the nuclear
DAPI staining, whilst in cells demonstrating translocation of RelA the colours merge. (B)
Increased RelA translocation into the nucleus following LPS stimulation was observed in
HD monocytes (n=7) compared with controls (n=7). n= individual biological repeats.
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4.4.5.2 Transcriptional changes affect signalling pathways in HD myeloid
cells
Transcriptional dysregulation is a central pathogenic mechanism in HD (Hodges
et al., 2006). Therefore, it was tested whether basal differences in transcription
play a role in the mHTT induced immune hyper-reactivity by analysing differences
in the expression of genes related to the NFκB pathway. The mRNA expression
levels of 84 genes were tested in untreated human monocytes using the SABio-
science NFκB signalling pathway PCR array, identifying seven genes that were
significantly up-regulated (TLR2, LTBR, CD40, TMED4, AKT1, IL10, FR2) and
one gene that was significantly down-regulated (CHUK ) in HD compared with
control cells (Table 4.1 for top 20 hits, full list in Appendix Table A.5). Four of
the up-regulated genes showed a fold change (FC) equal or higher than 1.5:
CD40 (FC=1.5); AKT1 (FC=1.5); IL10 (FC=1.85) and F2R (FC=2.23). Further-
more, the adaptor molecules IRAK1, TICAM2, MYD88, and TRADD, were also
up-regulated (Table 4.1). Interestingly, CHUK, which encodes for IKK , was found
to be down-regulated, whilst all other parts of the IKK complex, IκB and the NFκB
transcription factors were unchanged. The array also screened intracellular sig-
nalling pathways closely linked to the NFκB pathway, such as the MAPK and
PI3K/AKT pathways. Increased AKT protein levels have been found in HD pa-
tient lymphoblasts (Colin et al., 2005) and AKT1 is one of the genes up-regulated
in HD monocytes (FC=1.5, p= 0.031). Moreover, the genes composing the tran-
scription factor AP-1, CJUN and FOS, are also up-regulated in HD monocytes
(Table 4.1). Therefore, both of these pathways may also contribute to the in-
creased immune response observed after stimulation of HD monocytes.
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Table 4.1: The top twenty gene changes within the NFκB pathway observed in HD
monocytes. Data presented as fold change calculated from ∆∆CT values, unpaired two-
tailed student t test was used as statistical method. n= 10 for HD and control.
Gene name Fold change p value
TLR2 1.48 0.01
LTBR 1.35 0.01
CHUK 0.77 0.02
CD40 1.51 0.02
TMED4 1.23 0.02
AKT1 1.54 0.03
IL10 1.85 0.04
F2R 2.23 0.04
IRAK1 2.00 0.05
CJUN 2.22 0.05
TICAM2 1.32 0.05
MYD88 1.26 0.05
FOS 1.87 0.06
TRADD 1.25 0.06
RAF1 1.12 0.07
SLC44A2 1.29 0.07
ATF1 1.16 0.07
IL6 2.49 0.08
To validate these findings, six candidate genes, chosen on the basis of array
FC (CD40, AKT1, IRAK1, CJUN, IL6 and IL10), were quantified by qPCR using
different primer sets and cells from a different patient cohort (10 control and 10
HD subjects). The relative changes in gene expression when comparing HD and
control human monocytes matched the previous findings for all six genes (Figure
4.15). Expression levels for CD40, IRAK1 and IL10 were significantly increased
in HD compared with control monocytes, whilst expression changes in AKT1,
CJUN and IL6 demonstrated an upwards trend, not reaching significance due
large inter-individual differences.
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Figure 4.15: Validation of gene expression changes identified using PCR signalling
arrays. After 3 days in culture, RNA was isolated from unstimulated monocytes and
used for gene expression analysis via qPCR. This showed the same up-regulation in HD
versus control cells as the original array. Data shown as relative gene expression ± SEM,
unpaired two-tailed student t tests, *p<0.05; **p<0.01.
Using Cytoscape software (Shannon et al., 2003), the gene expression changes
within the TLR4 signalling pathway were visualised (Figure 4.16) showing chan-
ges in several key molecules within the pathways activated by TLRs, includ-
ing AKT1, CJUN, FOS and a range of adapter molecules such as IRAK1 and
TICAM2. These changes may lead to increased signalling along the NFκB sig-
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nalling cascade upon stimulation. Known NFκB target genes such as IL6, IL8
and IL1B also exhibited trends towards differential expression, although they did
not reach statistical significance due to large inter-individual variability.
Figure 4.16: Expression of several key molecules within the NFκB pathway is al-
tered in HD. Monocytes under basal unstimulated conditions were analysed by qPCR
using pre-validated primers from SABioscience (n= 10 biological repeats, for control and
early-stage HD patients). Changes in mRNA expression levels were analysed using Cy-
toscape, allowing construction of a pathway map to visualise gene expression changes
within the TLR4/LPS signalling cascade. Nodes stand for the different genes, red and
green colour indicating up- or down-regulation in HD compared with control cells, respec-
tively. Connecting lines visualise connections between genes (red: experimental data;
green: array data; lilac: STRING data; blue: combined data). Network analysis was
performed in collaboration with Dr Holger Hummerich.
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Next, bioinformatic approaches were utilised in an attempt to identify transcription
factors involved in the transcriptional changes found in mHTT expressing mono-
cytes. Using Genomatix gene2promoter software, promoter regions featured in
the seven genes that were significantly up-regulated in HD monocytes were com-
pared with the promoter regions of the 70 genes that were unchanged. Genes
with near significance (IRAK1, JUN, TICAM2, MyD88, FOS, TRADD and IL6)
were excluded from this analysis, as the sample size of 10 human subjects per
group may be the reason for these changes not reaching statistical significance.
Interestingly, the promoter regions of the excluded genes were more similar to the
promoter regions found in genes with altered expression than in those that were
unchanged.
Analysing whether genes found to be up-regulated in unstimulated HD monocytes
are regulated by NFκB, the pathway identified to be hyper-activated in these cells
after LPS stimulation, indicated that this may not to be the case as genes found
up-regulated in baseline HD monocytes do not show higher abundance of NFκB
binding sites in their promoters (Table 4.2). Interestingly, the promoter site for
AP-1 is more than twice as prevalent in up-regulated genes compared with those
that were unchanged. Additionally, five out of the seven promoter regions found to
be more than two-fold more prevalent in up-regulated compared with unchanged
genes were binding sites for different zinc finger transcription factors.
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Table 4.2: Promoter analysis of genes found to be expressed differently in HD
monocytes. Using the Genomatix software gene2promoter abundance of transcription
factor binding sites was compared between genes found up-regulated and genes found
unchanged in HD monocytes.
Promoter
region
Transcription factor Fold
change
Abundance
in unchanged
genes
Abundance
in changed
genes
NFKB p65/50 0.8 72(51/70) 57(4/7)
ZF05 C2H2 zinc finger tran-
scription factor 5
3.3 13(9/70) 43(3/7)
CSEN Calsenilin, presenilin
binding protein, EF hand
transcription factor
2.7 16(36/70) 43(2/7)
RP58 PRP58 (ZFP238) zinc
finger protein
2.5 3(9/70) 29(2/7)
AP1F JUN/FOS-activating pro-
tein a
2.5 23(16/70) 47(4/7)
BTBF BTB/POZ (broad com-
plex, Trantrach, Bric
brac/pox viruses and
zinc fingers) transcrip-
tion factor
2 22(15/70) 43(3/7)
INSM zinc finger protein
insulinoma-associated 1
(IA-1)
1.9 51(36/70) 100(7/7)
SPZ1 Testis-specific bHLH-Zip
transcription factors
1.9 38(27/70) 71(5/7)
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4.4.5.3 JAK-STAT signalling is unchanged
In addition to signalling pathways downstream of TLR4, pathways activated by
cytokine receptors may also play a role in HD immune dysfunction. Plasma cy-
tokine levels are elevated in HD patients (Bjo¨rkqvist et al., 2008), which could lead
to chronic activation of the pathways downstream of cytokine receptors in HD
monocytes and macrophages. The STAT signalling pathway is activated mainly
via cytokine receptors and not TLRs, whilst also being involved in cytokine pro-
duction (Levy and Darnell, 2002). To assess the level of phosphorylated STAT
(pSTAT) molecules in HD cells, PBMCs were isolated from whole blood by den-
sity centrifugation and stained with the monocyte marker CD64+. Cells were then
either left unstimulated or treated with specific JAK/STAT activators such as IFNγ,
IL-6 and GM-CSF for STAT1, 3 and 5, respectively. After staining the cells with
intracellular antibodies for pSTAT1, 3 or 5, levels of the molecules were assessed
using flow cytometry. For analysis, monocytes were identified by CD64 staining
before pSTAT levels were quantified (gating shown in Figure 4.17).
Figure 4.17: Example for gating for STAT phosphoflow analysis. PBMCs were iso-
lated using density centrifugation, stimulated with for example IFNγ to initiated STAT1
phosphorylation. For flow cytometry analysis monocytes were identified by gating on
CD64 positive cells (left panel) before pSTAT1 levels were blotted as histogram. Overlay
of unstimulated and IFNγ-stimulated cells showed a shift in pSTAT1 expression levels in
monocytes upon stimulation. pSTAT1 levels were quantified as geometric mean. The
same gating was used for pSTAT3 and 5 stimulated by IL-6 or GM-CSF, respectively.
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Comparing pSTAT levels between control and HD patients showed no difference
in STAT phosphorylation in untreated monocytes, or after any of the treatments
(Figure 4.18).
Figure 4.18: STAT signalling appears normal in HD patient monocytes. PBMCs were
isolated using density centrifugation, stimulated with either IFNγ (causing STAT1 phos-
phorylation), IL-6 (causing STAT3 phosphorylation) or GM-CSF (causing STAT5 phos-
phorylation) and stained for CD64+ and pSTAT1, 3 and 5, respectively. Flow cytometry
was used to assess the amount of pSTAT molecules in untreated and treated cells. Data
shown as mean pSTAT levels normalised to control levels ± SEM. One-way ANOVA
showed no statical significance.
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In addition, the fold change of activation, calculated by dividing the level of pSTAT
after stimulation by pre-treatment levels, was also unchanged in HD compared
with control cells (Figure 4.19). This suggests that STAT signalling is not abnormal
in HD immune cells.
Figure 4.19: Fold change activation of STAT signalling appears normal in HD pa-
tient monocytes. PBMCs were isolated using density centrifugation, stimulated with
either IFNγ (causing STAT1 phosphorylation), IL-6 (causing STAT3 phosphorylation) or
GM-CSF (causing STAT5 phosphorylation) and stained for CD64+ and pSTAT1, 3 and 5,
respectively. Flow cytometry was used to assess the amount of pSTAT molecules before
calculating the fold-activation by dividing post-treatment pSTAT levels by pre-treatment
levels. Data shown as mean fold change ± SEM. One way ANOVA.
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4.4.6 Lowering HTT levels reverses the HD immune phenotype
Lowering HTT expression using siRNA is a promising therapeutic approach for
HD (Sah and Aronin, 2011). This PhD investigated whether lowering total HTT
levels can reverse the hyper-reactive phenotype in primary human HD mono-
cytes and macrophages. In a novel approach taking advantage of the cells ability
to phagocytose, anti-HTT siRNA was packaged into 1,3-D-glucan-encapsulated
siRNA particles (GeRPs) for delivery into primary human monocytes or macro-
phages (Aouadi et al., 2009). Cells seeded on coverslips and co-cultured with
the GeRPs readily took them up via phagocytosis as shown by fluorescence mi-
croscopy (Figure 4.20A). Testing different macrophage to GeRP ratios, up to 90 %
of macrophages took up green fluorescent GeRPs when they were added at a ten
fold particle to cell ratio, demonstrating high transfection efficiency at this concen-
tration (Figure 4.20B).
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Figure 4.20: Primary human phagocytic cell can efficiently take up GeRPs. (A)
Primary human control monocytes were seeded on poly-L-lysine coated coverslips and
treated with empty GeRPs for 12 h. Uptake via phagocytosis was visualised via micros-
copy (GeRPs = green; DAPI = blue). (B) Monocyte-derived macrophages were incubated
with empty GeRPs at different cell to particle ratio for 12 h. After fixing the cells with 3.7 %
PFA, uptake was quantified by flow cytometry. Data shown as mean ±SEM (n=2 for
controls and n=3 for HD). Experiment performed in collaboration with Prof Gary Ostroff,
who produced all GeRPs.
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Next, the efficacy of the anti-HTT siRNA GeRPs was tested three days after
siRNA delivery in macrophages, using both qPCR for HTT RNA levels and TR-
FRET for HTT protein levels. Macrophages treated with anti-HTT siRNA con-
taining GeRPs had 60-70 % less HTT mRNA and 50 % less HTT protein, com-
pared with macrophages treated with scrambled siRNA-containing GeRPs (Fig-
ure 4.21).
Figure 4.21: GeRPs effectively knock-down total HTT in primary human immune
cells. Monocyte-derived macrophages were treated with either scrambled or anti-HTT
siRNA containing GeRPs for 3 days, before cells were lysed for either RNA or protein ex-
traction. Total HTT RNA measured by qPCR and protein levels measured by TR-FRET
were reduced by 70 % and 50 %, respectively, in cells treated with anti-HTT siRNA com-
pared with cells treated with scrambled siRNA. Data shown as mean HTT levels ±SEM
(n=10 for controls and HD for qPCR; n=2 for controls and n=3 for HD for TR-FRET, each
combining 2 independent experiments, n stands for individual biological repeats). Paired
t test ***p<0.001. Experiment performed in collaboration with Prof Gary Ostroff, who
produced all GeRPs and Dr Andreas Weiss, who performed TR-FRET measurements.
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As expected, the decrease in HTT levels was the same in both control and HD
macrophages, and there was no preference of expression-lowering between the
mutant and wild-type HTT alleles (Table 4.3).
Table 4.3: anti-HTT siRNA efficiently lowers both wild-type and mutant HTT alleles.
Levels of total and mutant HTT were measured in monocyte-derived macrophages from
HD patients using TR-FRET with antibody combinations, 2B7-2166 and 2B7-MW1, re-
spectively. Experiment performed in collaboration with Prof Gary Ostroff, who produced
all GeRPs and Dr Andreas Weiss, who performed TR-FRET measurements.
Subject
knock-down of protein level
mHTT levels total HTT levels
control - 45.89 %
HD 46.60 % 47.20 %
HD 28.10 % 23.25 %
control - 48.90 %
HD 48.70 % 50.80 %
Next, the effect of lowering total HTT levels on cytokine production was analysed.
After treating primary human monocyte-derived macrophages with GeRPs con-
taining anti-HTT or scrambled siRNA for three days, IFNγ-primed cells were stim-
ulated with LPS and cytokine production was measured using multiplex ELISA
assays. In agreement with the previous findings, IL-8 and TNFα levels were
significantly higher in HD as compared with control cells, when both had been
treated with scrambled siRNA (Figure 4.22). However, lowering HTT levels in
HD macrophages using anti-HTT GeRPs reversed this increase, by significantly
reducing the production of IL-6, IL-8 and TNFα (Figure 4.22). IL-1β production
showed a similar trend, but the difference was not statistically significant. Inter-
estingly, lowering HTT levels in control cells also significantly reduced IL-6, IL-8
and TNFα levels, suggesting a role for wild-type HTT in cytokine production, in
addition to the derangement of the NFκB pathway caused by mHTT binding IKK.
It is possible that both a loss of wild-type function and a toxic gain of mutant func-
tion contribute to the phenotype. Thus, lowering HTT levels by 50 % can partially
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reverse the hyper-reactivity in HD patient macrophages using a novel method of
siRNA delivery. The use of GeRPs to achieve cell-targeted gene knockdown has
to date shown significant promise in mice, but this is the first report showing ef-
ficient siRNA delivery, pathogenic gene knock-down and rescue of a deleterious
phenotype using this method in primary human immune cells.
Figure 4.22: Anti-HTT siRNA containing GeRPs decreases elevated cytokine pro-
duction in HD patient cells. HD and control macrophages were treated with either anti-
HTT or scrambled siRNA for three days, before the cells were stimulated with 10 ng/ml
IFNγ and 2 µg/ml LPS for 24 h. Measuring cytokine production with multiplex ELISA
assays showed that lowering HTT levels reduces IL-6, IL-8 and TNFα levels following
stimulation. Data shown as mean concentrations normalised to protein content ±SEM
(n= 9 for controls and n=8 for HD, combined from 3 independent experiments, n stands
for individual biological repeats), two-way ANOVA with Bonferroni post-tests. *p<0.05;
**p<0.01, ***p<0.001. Experiment performed in collaboration with Prof Gary Ostroff,
who produced all GeRPs.
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Subsequently, siRNA was used to test whether HTT lowering can reverse the
transcriptional changes observed in baseline HD patient monocytes. IRAK1 (main
adapter molecule between TLR4 and NFκB), CD40 (immunomodulatory molecule
giving co-stimulatory signals to both innate and adaptive immune cells) and CJUN
(part of the AP-1 transcription factor) expression was increased in HD mono-
cytes (Table 4.1). Following three days of treatment with GeRPs containing either
scrambled or anti-HTT siRNA, expression of these candidate genes analysed by
qPCR. HTT levels were assessed to validate the levels of knock-down. Treatment
with anti-HTT siRNA resulted in a 50 % reduction in HTT mRNA levels in both
HD and control macrophages (Figure 4.23A/B). However, only the HD monocytes
demonstrated a significant 20-30 % reduction in the expression of IRAK1, CD40
and CJUN when treated with anti-HTT compared with scrambled siRNA (Figure
4.23A). Lowering HTT in control cells did not affect levels of IRAK1, CD40 and
CJUN transcript expression (Figure 4.23B), suggesting that the transcriptional
dysregulation of these genes in HD myeloid cells is caused specifically by a gain
of mHTT function, rather than loss of wild-type protein function.
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Figure 4.23: Lowering total HTT levels reverses transcriptional changes found in
HD monocytes. HD and control monocytes were incubated with either scrambled or
anti-HTT siRNA containing GeRPs for 3 days before RNA isolation. Using qPCR, efficient
HTT knock-down was demonstrated as well, as lowering of key NFκB pathway molecules
IRAK1, CD40 and JUN in (A) HD patient cells but not (B) controls. Data shown as relative
gene expression (n= 10 biological repeats for controls and HD) with standard error bars,
paired t test *p<0.05; **p<0.01. Experiment performed in collaboration with Prof Gary
Ostroff, who produced all GeRPs.
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4.5 Discussion
Plasma pro-inflammatory cytokine levels are elevated in HD patients, even in the
premanifest stages of the disease (Bjo¨rkqvist et al., 2008). Here, HD PBMCs
are demonstrated to be a source of the increased pro-inflammatory cytokines, as
both monocytes and macrophages isolated directly from HD patients and stimu-
lated with LPS, produced significantly more IL-6, IL-8 and TNFα compared with
controls. Supporting the finding that plasma cytokine levels are already elevated
in premanifest subjects with a mean of 16 years to clinical onset (Bjo¨rkqvist et al.,
2008), myeloid cells isolated from premanifest HD patients were hyper-reactive
to the same degree as cells isolated from late-stage disease patients. This sug-
gests an early deficit that is already present many years before disease onset.
This may offer an early marker as to when to intervene with potential modulatory
therapies.
Expression of mHTT exon 1 in a monocyte-like cell line demonstrated that the
hyper-reactive phenotype is due to a cell-intrinsic effect of mHTT expression and
not to non-cell autonomous secondary factors. However, caveats of this exper-
iment should be noted. Firstly, it was necessary to utilise a cell line, as trans-
ducing primary human myeloid cells is inefficient and technically challenging and
secondly, HTT exon 1 constructs were used, due to the size of the full-length
HTT gene. The cell model created therefore overexpressed a N-terminal HTT
fragment, which cannot recapitulate all functions of the full-length HTT protein
and carries a CAG repeat length significantly greater than adult-onset HD pa-
tients (who normally range between 40-50 CAGs (Myers, 2004)). In addition, the
mHTT expressing U937 lines formed HTT aggregates, which are not observed in
primary human immune cells. These may be caused either by the very long CAG
expansion or the fragment nature of the overexpressed mHTT. HTT fragments
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have been found in human PBMCs (Weiss et al., 2012), but these ranged in size
and were lower in concentration than the fragments in overexpressing U937 cells.
This may explain the lack of aggregate detection in primary human immune cells.
Interestingly, U937 cells expressing HTT exon 1 with 129Q show 30 times more
aggregates than U937 cell expressing 79Q while both cell lines express similar
levels in cytokines, suggesting that aggregated mHTT is not the driver behind
immune dysfunction.
Given the increased cytokine production and phagocytosis in LPS stimulated HD
macrophages, as well as the fact that expression levels of the LPS receptor TLR4
did not differ between HD patients and control subjects, mHTT may interfere with
signalling pathway(s) downstream of TLR4. One of the main pathways activated
by TLR4 is the NFκB pathway, which had been previously implicated in HD in
murine studies (Khoshnan et al., 2004; Steffan, 2010). Investigating the NFκB
pathway, mHTT was shown to bind the regulatory γ subunit of IKK. Furthermore,
enhanced activity of the NFκB pathway was identified in HD cells, with increased
IκB degradation and concurrent RelA translocation into the nucleus. IKKγ is the
regulatory subunit of the IKK trimer, consisting of one regulatory (γ) and two ki-
nase subunits (α and β ), and is a critical component without which cells are unre-
sponsive to all upstream stimuli of this pathway (Israe¨l, 2000). During signal trans-
duction, polyubiquitin chains form the scaffold on which TAK1/TAB2/3 and IKK
complexes are formed to induce TAK1-dependent activation of IKKγ (Miyamoto,
2011). In agreement with a model previously described (Khoshnan and Patter-
son, 2011), our data suggests that mHTT can function as an alternative scaffold
in the NFκB pathway, binding IKKγ to initiate IKK complex formation, increase
transduction down the signalling cascade and cause increased cytokine produc-
tion (Figure 4.24). Interestingly, a recent study showed that activating the immune
modulator CB2, which dampens NFκB signalling (Rajesh et al., 2007), reduces
increased serum IL-6 levels in HD mouse models (Bouchard et al., 2012).
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Figure 4.24: Proposed mechanism of immune dysfunction in HD. (A) In wild-type
HTT expressing myeloid cells, LPS binds TLR4 and activates the NFκB pathway trig-
gering production of pro-inflammatory cytokines such as IL-6 and TNFα. (B) mHTT
interferes with the NFκB pathway by two distinct mechanisms. The mutant protein binds
IKKγ directly causing increased IκB degradation and NFκB transcription factor transloca-
tion, allowing increased transcription of target genes such as IL-6 and TNFα. Moreover,
mHTT causes transcriptional changes leading to increased expression of key molecules
within the signalling cascade likely to increase signalling transduction rate.
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Khoshnan et al. have described the same interaction of mHTT and IKKγ in both
murine striatal neurons and rat PC12 cells (Khoshnan et al., 2004), with cells ex-
pressing exon 1- mHTT only and not the full-length mutant protein. This agrees
with our findings that a N-terminal human exon 1 mutant mHTT fragment is suf-
ficient to induce elevated cytokine production in a histiocytic cell line. This is also
in keeping with a recent report demonstrating increasing N-terminal fragmenta-
tion of mHTT in human myeloid cells as the disease progresses (Weiss et al.,
2012) (Chapter 3). Thus, the ability of mHTT to act as a scaffold for IKKγ must
be mediated by either its N17, polyQ or polyP domains, or by a specific confor-
mation of the mHTT N-terminus. It may be a combination of these factors, as the
N17 region folds back onto the polyP region to form a hinge-like structure. When
the polyQ region, linking the two protein domains expands, the N-terminal head-
piece and the polyP region are unable to interact, leaving the polyP region open
for other protein-protein interactions (Dlugosz and Trylska, 2011). Indeed, exon
1-encoded mHTT fragments lacking the polyP region do not bind IKK and intra-
bodies binding the polyP region inhibit NFκB activation (Khoshnan et al., 2004).
This indicates the polyP region as a possible binding site. However, deletion of a
protein domain will also change protein conformation so the possibility that mHTT
displays conformation-specific binding sites cannot be excluded.
The finding that mHTT alters the NFκB pathway in human HD monocytes may be
relevant to other cell types and tissues, including the CNS. The NFκB pathway is
present and active in both neurons and glial cells (O’Neill and Kaltschmidt, 1997).
Pharmacological inhibition of NFκB impairs memory and learning (Mattson and
Meffert, 2006), and NFκB pathway activation is critical for neuronal survival and
neurite outgrowth (Teng and Tang, 2010). Increased levels of NFκB activity have
been shown in both Alzheimer’s disease (Kaltschmidt et al., 1997) and Parkin-
son’s disease (Hunot et al., 1997). In HD, blocking NFκB function in rat PC-12
cells leads to reduced mHTT toxicity, implying that the NFκB pathway contributes
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to neurotoxicity in HD (Khoshnan et al., 2004). Glial cells have been shown to
promote neuronal death by producing high levels of inflammatory cytokines, re-
active oxygen species and excitotoxins, mediated by the NFκB pathway (Mattson
and Meffert, 2006). In HD, microglia have been found to be activated using PET
imaging (Tai et al., 2007) and were shown to be hyper-reactive as seen in ex vivo
murine cell culture (Bjo¨rkqvist et al., 2008), but the potential role of NFκB in these
phenotypes remains to be examined.
This work further identified gene expression changes in key molecules involved
in immune signalling in native HD patients’ monocytes. Several adapter proteins
downstream of TLR4, such as IRAK1, TICAM2 and MyD88 were found to be
slightly elevated in native HD patient’s monocytes. A cumulative baseline in-
crease in expression of several of these adapter proteins may lead to increased
signal transduction from TLR4 to NFκB, further increasing NFκB pathway dys-
regulation. Another gene found to be up-regulated in HD monocytes was CD40,
which is expressed in peripheral and central cells such as monocytes, microglia
and neurons. Interactions between CD40 and its ligand CD154, mainly expressed
on T cells, regulate the immune response on several levels. Monocytes are
activated leading to up-regulation of genes for cytokine production and antigen
presentation, and priming of the adaptive immune system (Grewal and Flavell,
1998). This points to further functional abnormalities in the immune system of
HD patients, suggesting a possible deficit in the communication between antigen
presenting cells and the adaptive immune system. Furthermore, CD40 mediates
cell adhesion needed for leukocyte trafficking (Alderson et al., 1993). Given re-
cent studies showing defective migration in HD due to defective actin remodeling
(Kwan et al., 2012b) (Chapter 5), the increase in CD40 expression could also be
a compensatory response for immune cells to counteract their decreased motility.
FOS and CJUN, subunits of the AP-1 transcription factor, were also up-regulated
in primary human myeloid HD cells. Interestingly, FOS and JUN levels have been
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found to be increased in AD patient brains (Anderson et al., 1994), and the MAP
kinase needed for JUN activation, JNK, is elevated and involved in neurotoxicity
in HD mouse (Fan et al., 2012) and rat models (Perrin et al., 2009). Thus, it can
not be excluded that dysregulation in these signalling pathways may contribute to
the HD immune phenotype.
Promoter regions of the altered genes in baseline monocytes did not contain
more NFκB binding sites than the unaltered genes. This indicates that NFκB,
while playing a role in the increased cytokine production after LPS stimulation,
may not be involved in transcriptional changes in baseline monocytes. Binding
sites for AP-1, however, were two-fold more prevalent in the promoter regions of
the genes found to be up-regulated in unstimulated HD monocytes. It is known
that the AP-1 subunits, FOS and CJUN, regulate their own expression in a feed-
back loop (Angel et al., 1988), and transcript levels of these two transcription
factors were found to be up-regulated in primary human myeloid HD cells. Thus,
the JNK/MAPK pathway may, in addition to the NFκB pathway, be either affected
by or play a role in the immune dysfunction observed in HD. Furthermore, mutant
HTT binding directly to DNA to influence gene expression cannot be excluded.
Benn et al. have proposed that mHTT might alter DNA conformation upon direct
binding, affecting transcription factors binding to their promoter regions (Benn
et al., 2008). Chromatin immunoprecipitation experiments are required to find
which transcription factors bind the up-regulated genes in unstimulated HD mono-
cytes.
Importantly, this study shows that lowering total HTT levels by only 50 % partially
rescued the hyper-reactive HD phenotype, with a reversal of both elevated cy-
tokine production and transcriptional changes observed in human HD myeloid
cells ex vivo. This is the first report showing that lowering HTT in cells freshly iso-
lated from HD patients can reverse cellular dysfunction caused by mHTT expres-
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sion - an important first demonstration of the reversibility of cellular dysfunction
after HTT lowering in human tissue. HTT lowering was achieved using a novel
phagocytosis-dependent approach, in which siRNAs are packaged into glucan
particles isolated from yeast (Aouadi et al., 2009). This study is the first to use
this technique in primary human macrophages and demonstrated that a 90 %
transfection rate can be achieved (Figure 4.20), much higher than the 10-20 %
transfection rate achieved by traditional methods such as lentiviral transduction.
These findings validate the potential of HTT lowering therapy as well as the pos-
sibility of using these peripheral cells to test siRNA efficiency and safety.
Interestingly, cytokine release was also decreased in control cells treated with
anti-HTT siRNA, indicating a second mechanism by which wild-type HTT influ-
ences cytokine production beyond the effect of mHTT on IKKγ. Wild-type HTT
has been shown to play a role in both to actin remodeling (Kwan et al., 2012b;
Munsie et al., 2011) and microtubule-mediated transport (Gauthier et al., 2004).
As both processes are needed for the trafficking of cytokines to the cell surface
membrane for release (Lacy and Stow, 2011), a reduction of wild-type HTT lev-
els might exert a loss of function by hindering normal actin and microtubule re-
modeling causing changes in cytokine release. A future study using allele specific
silencing of mutant but not wild-type HTT will help determine the exact contribu-
tions loss of wild-type HTT and gain of mHTT function has on the myeloid cell
dysfunction in HD.
This study demonstrates hyper-reactive immune cells in HD and represents the
first demonstration of phenotypic reversibility on HTT lowering in primary human
cells in HD. It also identifies the underlying intracellular mechanisms of immune
dysfunction in human cells in HD. This is important as the immune system has
clearly been shown to be a modifier of HD pathogenesis in various mouse mod-
els (Bouchard et al., 2012; Kwan et al., 2012a; Zwilling et al., 2011). There is
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currently a search for genetic and environmental modifiers of HD as the CAG re-
peat expansion only explains 50-70% of variance in age of onset, and its role in
modulating disease progression is variable (Andrew et al., 1993; Brinkman et al.,
1997). The remainder of the variance is likely due to environmental and other ge-
netic factors (Wexler et al., 2004). The immune system may be a powerful mod-
ifier of HD age of onset and progression, with an interaction of both genetic and
environmental factors. This has already been shown to the case in large genome
wide association studies in Alzheimer’s disease where several key genes involved
in the innate immune system were shown to increase susceptibility to developing
AD (Harold et al., 2009; Lambert et al., 2009).
Finally, the work presented here, also suggests a potential new therapeutic target
for HD through modulating NFκB activation and downstream targets. The mus-
cle wasting, weight loss and depression that occurs in HD (van der Burg et al.,
2009) may be related to increased peripheral cytokine levels. Therefore, modu-
lating the immune system may have beneficial effects in both the CNS and the
periphery. Indeed, an anti-inflammatory, anti-IL-6 antibody treatment in R6/2 HD
mice has already been show to improve both weight loss and disease progression
(Bouchard et al., 2012). This work therefore has implications for both understand-
ing the role of the innate immune system as a modifier of neurodegeneration and
modulation of the immune system as a possible therapeutic in HD.
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5 Mutant huntingtin impairs
migration of immune cells
5.1 Background
As shown in the previous chapters, mHTT levels in immune cells track with mark-
ers of disease progression such as disease burden score and brain atrophy
(Chapter 3). Furthermore, mHTT expression in primary human monocytes and
macrophages causes increased cytokine production by directly interfering with
the NFκB pathway (Chapter 4). These findings, in addition to recent studies
showing that the immune system can modify HD progression (Bouchard et al.,
2012; Kwan et al., 2012a; Zwilling et al., 2011), provide strong evidence that the
peripheral immune system is abnormal in HD and might contribute to neurode-
generation. Additionally, microglia, the resident immune cells in the brain, are
also abnormal in HD and may contribute to pathogenesis. Microglia activation
and reactive gliosis were found in the brains of HD patients (Sapp et al., 2001).
Furthermore, PET of HD patients also demonstrated increased microglial activa-
tion in the striatum and cortex, correlating with clinical severity of the disease (Tai
et al., 2007).
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The migration of immune cells to sites of infection or injury is an early and es-
sential step in the immune responses. Activated immune cells migrate into af-
fected tissues and communicate through chemokines, small molecules that es-
tablish a chemotactic gradient from their release point, which attracts cells carry-
ing the corresponding receptor. Monocytes, macrophages, and microglia express
chemokine receptors and adhesion molecules that control and direct migration in
response to inflammatory signals (Imhof and Aurrand-Lions, 2004; Moser et al.,
2004). MCP-1 is one of the key regulators of monocyte and macrophage mi-
gration during inflammation, and acts via CCR2 expressed on the cell surface
(Deshmane et al., 2009). For microglia, both ATP and C5a can effectively induce
migration, interestingly through different and additive molecular pathways (Miller
and Stella, 2009).
Efficient migration relies on the remodelling of the actin cytoskeleton, a key me-
diator of cell polarisation and chemotaxis (Jones, 2000). In the brain, microglia
quickly rearrange their actin networks, form membrane ruffles and leading edges
to extend their processes once activated by stimuli such as ATP (Inoue, 2002;
Koizumi et al., 2007). Even in the healthy brain, microglia continuously survey
their microenvironment by extending and retracting their processes, while their
cell bodies remain motionless (Nimmerjahn et al., 2005). In the periphery, mono-
cytes circulate the bloodstream before migrating into perivascular tissue and dif-
ferentiating into tissue macrophages or DCs. Upon activation by inflammatory
stimuli, peripheral immune cells migrate and accumulate at the site of infection,
contribute to the local resolution of the infection or migrate further into lymph
nodes (Imhof and Aurrand-Lions, 2004; Moser et al., 2004). Overall, migration
of immune cells is a critical step during the initial response to injury or inflam-
mation, and defects in cell migration prevent appropriate responses to infections
(Kurihara et al., 1997).
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Work by Kwan et al. studied the effect mHTT expression has on the migration
abilities of microglia and peripheral myeloid cells in HD mouse models (Kwan
et al., 2012b). Primary microglia from both the YAC128 and BACHD models dis-
play significantly decreased migration towards chemotactic stimuli such as ATP
and C5a compared with microglia isolated from WT litter-mates (Figure 5.1).
Figure 5.1: Microglia isolated from HD mice demonstrate impaired chemotactic re-
sponses to ATP and C5a. Primary microglia from (A) YAC128 and (B) BACHD mice
show significantly less migration towards both 100 µM ATP and 100 nM C5a compared
with WT litter-mates. Cells were allowed to migrate for 3 hours through the transwell sys-
tem. Data shown as mean ± SEM. n is 6 experimental replicates. * p<0.05; ** p<0.01,
*** p<0.001 (unpaired two-tailed student t test). Data by Dr Wanda Kwan, re-produced
from Kwan et al. 2012b.
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Microglia isolated from HD mice further demonstrate reduced extension and move-
ment of their processes in an ATP gradient (Kwan et al., 2012b). Validating this
in vitro data, Kwan et al. also showed impaired HD microglial function in vivo
using time-lapse in vivo two-photon microscopy. Under basal conditions, process
extension is less frequent in BACHD mice, and while WT microglia demonstrate
rapid extension of processes and engulfment of an injury site caused by focal
laser ablation, microglia from HD mice respond with a delay (Kwan et al., 2012b).
Furthermore, murine peripheral HD macrophages show a similar migration de-
fect, demonstrated by reduced macrophage recruitment into the peritoneum af-
ter thioglycollate challenge (Kwan et al., 2012b). Reduced membrane ruffling
in microglia isolated from both the YAC128 and the BACHD mice, and reduced
p-cofilin levels in microglia and peripheral immune cells indicate impaired actin
remodelling in HD immune cells as possible reason for the reduced migration
ability (Figure 5.2) (Kwan et al., 2012b).
The aim of this study was to test the hypothesis of impaired migration in HD
immune cells caused by defective actin remodelling in primary human monocytes
and macrophages, which will allow us to evaluate the importance of these findings
for the human disease.
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Figure 5.2: Murine HD microglia show decreases membrane ruffling and cofilin
levels. (A) Primary microglia from BACHD mice have less membrane ruffling upon stim-
ulation with 100 µM ATP and 100 ng/ml M-CSF compared with WT microglia. Cells were
stained with rhodamine-phalloidin, and the percentage of cells with membrane ruffling
was quantified within 10 min. Values are mean ± SEM of three independent experi-
ments. * p<0.05; ** p<0.01 (unpaired two-tailed student t test). (B) Reduced cofilin
and p-cofilin levels in HD versus WT microglia were revealed by western blot on primary
BACHD and WT microglia stimulated with 100 µM ATP over 20 min. Data by Dr Wanda
Kwan, re-produced from Kwan et al. 2012b.
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5.2 Contributions
Initial migration assays looking at monocyte migration towards MCP-1 and RAN-
TES were done in collaboration with Dr Ralph Andre (UCL, Institute of Neurol-
ogy). Part of the work presented in this chapter has been published in the Journal
of Clinical Investigation in Collaboration with Paul Muchowski’s lab and the data
described in the introduction.
Kwan, W., Tra¨ger, U., Davalos, D., Chou, A., Bouchard, J., Andre, R., Miller, A.,
Weiss, A., Giorgini, F., Cheah, C., Mo¨ller, T., Stella, N., Akassoglou, K., Tabrizi, S.
J. and Muchowski, P. J. (2012b), Mutant huntingtin impairs immune cell migration
in Huntington disease, J Clin Invest 122(12), 473747.
5.3 Methods
Primary human monocytes and macrophages were isolated and differentiated as
described in Section 2.5.4. Migration abilities were analysed using a transwell mi-
gration assay, in which cells were separated by a membrane from a well contain-
ing a chemoattractant (Section 2.6.2). Chemokine receptor levels in unstimulated
monocytes were measured on RNA and protein level using qPCR (Section 2.10)
and flow cytometry (Section 2.9.1), respectively. In order to assess the actin cy-
toskeleton response, macrophages were stimulated with a chemoattractant and
membrane ruffling was assessed using microscopy (Section 2.11.3). Phospho-
cofilin (p-cofilin) levels were assessed by western blot (Section 2.8.5) and MCP-1
production was measured by ELISA (Section 2.7.1).
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5.4 Results
5.4.1 Monocytes and macrophages from HD patients show
altered migration abilities
A transwell system was used to analyse the migration ability of monocytes iso-
lated from HD patients. Primary monocytes were seeded in the upper chamber
of the transwell, and the number of cells migrating into the lower, chemokine filled
well was counted. In the absence of a chemoattractant, only very few cells mi-
grated through the transwell and no difference was detected between HD and
control cells. MCP-1 and RANTES are important pro-inflammatory chemokines
mediating monocytes and macrophages migration in vivo (Moser et al., 2004). In
addition to these two stimuli, migration towards ATP and C5a was tested since pri-
mary microglia isolated from HD mice show defective migration towards those two
chemoattractants (Figure 5.1 from (Kwan et al., 2012b)). Upon stimulation, HD
patient monocytes demonstrated a significant defect in migration towards MCP-1
and ATP (Figure 5.3A/B), independent of the donors disease stage, with cells iso-
lated from premanifest HD gene carriers already demonstrating a striking defect.
Furthermore, premanifest HD gene carrier cells also demonstrated decreased
migration towards C5a (Figure 5.3C). Interestingly, migration towards RANTES
was unchanged in HD compared with control monocytes (Figure 5.3D).
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Figure 5.3: HD patient monocytes demonstrate a striking migration defect. Using a
5µm transwell system, blood monocytes isolated from HD patients showed a significant
defect in migrating towards (A) 50 ng/ml MCP-1, (B) 100 µM ATP and (C) 10 nM C5a
whilst migration towards (D) 100 ng/ml RANTES was normal compared with control cells.
Monocytes were left to migrate for 1.5 h at 37 ◦C . Cells migrated into the lower chamber
were counted using a Neubauer counting chamber. Data shown as mean ± SEM. n=
individual biological repeats. Two-way Anova with Bonferroni post tests. * p<0.05; **
p<0.01, *** p<0.001. Experiment performed in collaboration with Dr Ralph Andre.
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In addition to monocytes, tissue macrophages also migrate towards inflammatory
stimuli within a tissue as well as into lymph nodes, after the cells have been acti-
vated to elicit an adaptive immune response (Imhof and Aurrand-Lions, 2004).
To test the migration capability of HD patient macrophages, a similar set up
as the one used for monocytes was utilised. Monocyte-derived macrophages
were seeded in the upper chamber of the transwell and the number of cells
that migrated through the membrane towards the chemoattractant stimulus was
counted. While monocyte migration was assessed after 1.5 h by counting the
number of cells in the lower chamber, the bigger and adherent macrophages
were left to migrate for 16 h using transwells with larger pore-sizes. Macrophages
adhere to the transwell membrane and cells stuck to the lower side of the mem-
brane were counted.
HD patient macrophages showed the same defect in migration towards MCP-
1, ATP and C5a as seen in HD monocytes, when compared with control cells
(Figure 5.4A/B/C). However, HD macrophage migration towards RANTES also
demonstrated a trend for impairment compared with control macrophages (Figure
5.4D). Thus, both primary human monocytes and macrophages demonstrated
decreased migration to a wide range of different chemokines, similar to findings
in primary murine HD microglia (Figure 5.1 from (Kwan et al., 2012b)).
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Figure 5.4: HD patient macrophages show decreased migration towards different
stimuli. Using a 8µm transwell system, monocyte-derived macrophages from HD pa-
tients (premanifest and manifest subjects) showed a significant defect in migrating to-
wards (A) 50 ng/ml MCP-1, (B) 100 µM ATP and (C) 10 nM C5a. Migration towards (D)
100 ng/ml RANTES was also decreased compared with control. Cells were left to migrate
for 16 h after which the cells attached to the transwell membrane were stained with crys-
tal violet and counted via light microscopy. Data shown as mean ± SEM. n= individual
biological repeats. Two-way Anova with Bonferroni post tests.* p<0.05; ** p<0.01, ***
p<0.001.
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5.4.2 Chemokine receptor levels on HD monocytes
For chemoattractants to induce the necessary cellular change needed for cell
movement, they must bind their receptors on the surface of the target cells. A
decrease in chemokine receptors expression is, therefore, a possible explana-
tion for lower migration of HD immune cells. To investigate this possibility, the
levels of the MCP-1 receptor CCR2 and the two RANTES receptors CCR1 and
CCR5 were assessed on both RNA and protein levels. CCR2 transcript levels
(Figure 5.5A) and cell surface expression (Figure 5.5B), tested by qPCR and flow
cytometry respectively, were reduced on unstimulated HD monocytes. Similar to
the decrease in migration, CCR2 levels were significantly decreased throughout
all HD disease stage, even in premanifest HD gene carriers. Interestingly, RNA
levels for CCR1 and CCR5 were not changed in HD monocytes (Figure 5.5C/D).
These findings suggest that the migration defect in primary human HD mono-
cytes demonstrated in this study might at least partially be caused by reduced
chemokine receptor expression.
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Figure 5.5: Chemokine receptor expression levels in HD patient monocytes. (A)
qPCR analysis and (B) flow cytometry showed decreased CCR2 transcript and cell sur-
face expression levels in HD monocytes compared with control. (C) CCR1 and (D) CCR5
transcript levels were unchanged in HD patient compared with control monocytes. Data
shown as mean ±SEM, unpaired two-tailed student t test for (B) and one-way ANOVA
with Dunnett’s multiple comparison test for (A,C,D). * p<0.05; ** p<0.01, *** p<0.001.
n= individual biological repeats.
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5.4.3 HD macrophages produce increased levels of MCP-1
CCR2 expression can be regulated by different cytokines as well as directly by its
own ligand, MCP-1 (Tangirala et al., 1997). As it has previously been shown that
MCP-1 levels are elevated in HD plasma (Wild et al., 2011), MCP-1 production
was analysed by ELISA in IFNγ-primed and LPS stimulated HD macrophages.
Measuring MCP-1 levels in the culture supernatants 24 h post stimulation re-
vealed the HD macrophages produce significantly more MCP-1 compared with
control cells (Figure 5.6). This result suggests desensitisation of immune cells by
high MCP-1 plasma levels as a possible cause for decreased CCR2 levels on HD
monocytes.
Figure 5.6: Human HD macrophages produce significantly more MCP-1. Monocyte-
derived macrophages were stimulated with 10 ng/ml IFNγ and 2 µg/ml LPS for 24 h before
MCP-1 levels in the culture media were assayed by ELISA quantification, showing ele-
vated production of the chemokine by HD (all disease stages) compared with control
cells. Data shown as mean ±SEM, n= individual biological repeats, unpaired two-tailed
student t test. * p<0.05.
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5.4.4 Chemokine receptor levels on HD macrophages
Unlike the finding of lowered CCR2 levels in HD patient monocytes, CCR2 tran-
script levels (Figure 5.7A) and cell surface expression (Figure 5.7B) seems un-
changed in HD patient macrophages compared with control cells. Supported by
the fact that mRNA levels of P2Y12, the purinergic receptor that mediates mi-
gration in response to ATP (Haynes et al., 2006), and of the C5a receptor do
not significantly differ between primary microglia from HD mice and WT litter-
mates (Kwan et al., 2012b), these findings points towards a broader defect in
macrophage migration independent of chemokine receptor levels.
Figure 5.7: Chemokine receptor expression levels in HD patient macrophages. (A)
qPCR analysis and (B) flow cytometry showed no difference in CCR2 transcript and
cell surface expression in HD monocyte-derived macrophages (isolated from all disease
stages) compared with control. Data shown as mean ±SEM, n= individual biological
repeats, unpaired two-tailed student t test showed no significances.
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5.4.5 Impaired actin remodelling in HD myeloid cells
Given that migration of immune cells requires rapid remodelling of the actin cy-
toskeleton (Jones, 2000) and a report of defective actin turnover via cofilin in HD
during cellular stress response (Munsie et al., 2011), the actin cytoskeleton was
analysed in primary human monocytes and macrophages. During the cellular
response to a chemotactic stimuli, cells undergo a process called membrane ruf-
fling by which they form lamellipodia as well as microspikes extending beyond the
leading edge of the lamellipodia called filopodia (Mattila and Lappalainen, 2008).
To test the hypothesis that actin remodelling is changed in HD macrophages,
F-actin fibres were stained with phalloidin and the percentage of cells forming
filopodia was quantified (Figure 5.8A). Upon stimulation with 50 ng/ml MCP-1
or 100 µM ATP for 10 min, a significantly reduced number of HD macrophages
formed filopodia compared with control cells (Figure 5.8B). Five minute treatment
with ATP, also, showed a trend to decreased filopodia formation in HD compared
with control cells, while no difference was detected at baseline. These results are
consistent with findings in HD microglia showing decreased membrane ruffling in
BACHD compared with WT mice (Figure 5.2 from (Kwan et al., 2012b)).
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Figure 5.8: HD macrophages form less filopodia. Monocyte-derived macrophages,
differentiated on 13 mm coverslips, were stimulated with either 50 ng/ml MCP-1 or 100 µM
ATP for 5 or 10 min before F-actin was stained with Alexa Fluor 568 phalloidin. (A) Ex-
ample pictures showing typical field of view used to quantify percentage of cells forming
filopodia for both control and HD patients. Arrows indicated cells with filopodia. (B) Quan-
tification of macrophages, showing filopodia as percentage of total macrophages in field
of view, demonstrated a decreased number of cells with filopodia in response to 10 min
ATP and MCP-1 in HD (both premanifest and manifest) samples compared with controls.
Data shown as mean ±SEM, one-way ANOVA with Dunnett’s multiple comparison test *
p<0.05; ** p<0.01, *** p<0.001. n= individual biological repeats.
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The actin-binding protein cofilin is essential for the regulation of actin depolymeri-
sation, and is required for effective cell migration. Cofilin is regulated by reversible
phosphorylation, whereby phosphorylation inhibits cofilin’s function. Cofilin inac-
tivation leads to decreased actin severing, needed for fresh branching of actin
fibres in lamellipodia and in general for the dynamic remodelling of the actin net-
work (Dawe et al., 2003). Stimuli, such as ATP, can trigger changes in the actin cy-
toskeleton by activation of cofilin-phosphatase’s and dephosphorylation of cofilin
(Huang et al., 2006). Work in HD mouse models has shown decreased cofilin
and p-cofilin levels in microglia (Figure 5.2B) as well as peripheral macrophages
(Kwan et al., 2012b). Analysing p-cofilin levels using western blot showed signifi-
cantly decreased levels of the actin-binding protein in primary human HD mono-
cytes compared with controls (Figure 5.9). This finding supports the hypothesis
that (m)HTT influences cofilin levels and thereby affected the actin filament dy-
namics necessary for cellular movement.
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Figure 5.9: Decreased levels of p-cofilin in primary human HD monocytes. West-
ern blot analysis on baseline monocytes lysates using a p-cofilin antibody demonstrated
decreased p-cofilin levels in HD cells isolated from all disease stages compared with
controls. An anti-GAPDH antibody was used as loading control and densitometry was
performed to quantify band density. Data shown as mean ±SEM, unpaired two-tailed
student t test. * p<0.05. n= individual biological repeats.
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5.5 Discussion
Abnormal immune cell function has been shown in primary human HD monocytes
and macrophages (Chapter 4). Impaired migration of both peripheral (macro-
phages) and central (microglia) immune cells has been described in the BACHD
and YAC128 HD mouse models (Kwan et al., 2012b). Here, the migration ability
of HD patient cells was assessed ex vivo, demonstrating a striking defect in migra-
tion of both human HD monocytes and macrophages toward several chemokines.
In keeping with the previous finding that cytokines are elevated in HD patient
plasma years before symptom onset (Bjo¨rkqvist et al., 2008), migration defects
are already apparent in cells isolated from premanifest HD gene carriers. Fur-
thermore, murine HD microglia, which also demonstrate migration defects, are
isolated from early post-natal mice, long before significant neuronal loss occurs.
The cells, therefore, resemble premanifest HD while showing striking defects con-
sistent with early microglial dysfunction detected in HD patients using PET (Politis
et al., 2011; Tai et al., 2007). Thus, these findings confirm that peripheral immune
dysfunction is not a secondary phenomenon caused by degeneration of the basal
ganglia, but is independently occurring beforehand.
The molecular mechanism behind the migration defect in HD immune cells is
likely to be complex and remains to be fully explained. Decreased levels of the
MCP-1 receptor CCR2 on primary human HD monocytes might be one contribut-
ing factor. Increased MCP-1 levels found in HD plasma (Wild et al., 2011) and the
fact that HD macrophages produce more MCP-1 upon LPS stimulation suggest
autocrine desensitisation as an explanation for the decreased CCR2 expression
on HD monocytes. High concentrations of MCP-1 in the blood stream could,
thereby, cause monocytes to down-regulate the MCP-1 receptor in a feed back
loop (Tangirala et al., 1997). This would in turn result in HD monocytes migrating
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less towards MCP-1 compared with control cells in ex vivo assays as performed
in this study. HD patient macrophages derived from monocytes are in culture
for six days before the assay, which in monocytes takes place immediately af-
ter isolation. This prolonged time under culture conditions away from plasma
cytokines, decreases the possible effect of elevated plasma MCP-1 and may ex-
plain why normal CCR2 levels were found on HD macrophages while levels were
decreased on HD monocytes.
Nonetheless, macrophages display a migration defect towards MCP-1 despite
normal CCR2 levels suggesting a different, MCP-1/CCR2 independent mech-
anism causing the migration defect in macrophages and maybe also, at least
partially, in monocytes. Moreover, migration defects were found towards sev-
eral chemokines, which operate by different receptors and downstream signalling
pathways (Deshmane et al., 2009; Miller and Stella, 2009), suggesting that the
migration defect in HD immune cells is not likely due to a lack of chemokine recep-
tor expression, but an impairment to engage downstream signalling mechanisms
or machinery required for migration.
Increased filopodia formation and changed levels of the actin-binding protein
cofilin in the impaired immune cells indicated that mHTT affects proper regulation
of actin remodelling. These findings are supported by similar findings in HD mice
showing decreased lammellipodia formation and decreased cofilin and p-cofilin
levels in microglia upon stimulation (Kwan et al., 2012b). Interestingly, a recent
study has shown that full-length wild-type huntingtin colocalises with actin-cofilin
rods in the nucleus during stress response, while expression of mHTT leads to ini-
tial fewer, but more persistent nuclear rods (Munsie et al., 2011). Consistent with
this, the investigators also found cross-linked actin-cofilin rods in HD patient lym-
phoblasts correlating with disease stages. Strikingly, the mHTT phenotype was
also observed when lowering wild-type HTT levels. Further to this, Dictyostelium
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discoideum cells lacking endogenous huntingtin demonstrate disorganised actin
staining and defective chemotaxis while forming aggregates, suggesting an im-
portant role for wild-type HTT in actin remodelling and that migration defects may
at least partially be due to a loss of wild-type HTT (Myre et al., 2011).
Studies using transgenic mice lacking the CX3CR1 chemokine receptor gene
have shown that the impaired migration is accompanied by an increase in IL-
1β production upon LPS stimulation (Cardona et al., 2006). Indeed, elevated
plasma cytokine (Bjo¨rkqvist et al., 2008) and chemokine (Wild et al., 2011) lev-
els have been shown in HD patients, suggesting that elevated levels of pro-
inflammatory marker might be a compensatory mechanism to induce immune
cell migration. Additionally, actin remodelling defects could affect cytokine pro-
duction as cytokine secretion relies on a functional cytoskeleton (Lacy and Stow,
2011). Transgenic mice lacking chemokine receptor genes have impaired wound
healing (Ishida et al., 2008), are unable to clear infections and mount an inef-
fective immune response (Boring et al., 1997; Kurihara et al., 1997). While the
incidence of infections or defects in wound healing have not been systematically
studied in HD patients, a study identifying conditions associated with reduced sur-
vival in HD patients showed increased likelihood for chronic skin ulcers (Lanska
et al., 1988), which may be related to the migration defect described here. Animal
studies analysing healing of scratch wounds are ongoing in HD animal models.
Cell motility is not just impaired in peripheral immune cells, microglia isolated
from HD mice also demonstrate defective migration in in vitro assays (Kwan et al.,
2012b). Furthermore, in vivo murine HD microglia show less process extensions
under basal conditions and respond delayed to brain injury modelled using laser
ablation. This suggests a weaker immune response to injury and infection within
the HD brain as well as impaired microglial function in the healthy brain, where
resting microglia constantly survey their environment to check the integrity and
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function of the brain (Nimmerjahn et al., 2005). Microglia provide trophic support
for neurons and physically interact with synapses (Wake et al., 2009). Interest-
ingly, a loss of synapses has been described in R6/2 and BACHD mice (Kwan
et al., 2012a) suggesting that mHTT expressing microglia may not be efficient in
synapse surveillance, possibly contributing to synapse and network dysfunction
in HD.
Actin remodelling is not only crucial for immune cell migration towards injury but
also for neuronal cell development, where filopodia guide the neuronal growth
cone (Mattila and Lappalainen, 2008), and synapse function (Dillon and Goda,
2005). Interestingly actin polymerisation in dendritic spines of striatal neurons
is greatly reduced in HD mice (Lynch et al., 2007), maybe explaining abnormal
spine morphology found in striatal and cortical neurons of HD mice (Spires et al.,
2004) and patients (Graveland et al., 1985)
In summary, these findings provide evidence that primary human HD immune
cells do not migrate normally, which may be linked or contribute to early immune
dysfunction and chronic cytokine elevation in HD. Migration defects are know to
cause recurrent infections and immune dysregulation (Blundell et al., 2010). Fur-
ther studies will be needed to determine the consequence of this defect on HD
patients. In light of several recent publications supporting a role of the periph-
eral immune system as modifier of HD progression (Bouchard et al., 2012; Kwan
et al., 2012a; Zwilling et al., 2011), this study underlines the critical link between
blood cells and neurodegeneration in HD.
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HD mouse models
6.1 Background
Animal models are a vital tool in the research of genetic diseases, as they allow
the characterisation of the biology of the disease, genetic modifications of the
system, and testing of possible treatments. Before using any model, however,
the model needs to be evaluated as to whether it resembles the part of human
disease pathology you want to study.
In the HD field, a large variety of animal models have been established: from in-
vertebrate models such as Drosophila melanogaster (Kazemi-Esfarjani and Ben-
zer, 2000) and Caenorhabditis elegans (Parker et al., 2001) to mammalian mod-
els, including rodent models such as mice (Sathasivam et al., 1999) and larger
primate models (Yang et al., 2008). While invertebrate models have great poten-
tial for discovery studies, such as therapeutic screens (Voisine et al., 2007) due
to their cost efficiency and short life-span, their lack of homology to the human
genome (C. elegans genome is only 40 % homologous to the human one) often
requires findings to be validated in more similar mammalian models. Further-
more, looking at immune dysfunction in HD, invertebrate’s immune responses are
very different to those in humans with the adaptive immune system not present
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and innate immune cells showing distinct differences (Beck and Habicht, 1996).
Comparing mammalian models of HD, mouse models are the most commonly
used due to their quick reproduction and the availability of hundreds of trans-
genic mouse strains allowing genetic manipulation within the HD models simply
by breeding. The most widely used and best characterised mouse model of HD
is the R6/2 mouse. This model ubiquitiously express the 5’ end of the human
HTT gene carrying only exon 1 with 150 CAG repeats (Mangiarini et al., 1996).
R6/2 mice demonstrate a fast and progressive phenotype with a very early symp-
tomatic onset at 6-8 weeks. They demonstrate motor symptoms such as chorea-
like movements, brain volume loss and peripheral changes such as weight loss
and diabetes (Bjo¨rkqvist et al., 2005; Li et al., 2005; Mangiarini et al., 1996). The
major disadvantage of this model is the fact that it only expresses a N-terminal
fragment of the HTT gene, not the full-length gene. Therefore, R6/2 mice may not
model the full impact the expression of endogenous mHTT has. However, several
full-length HTT models have been developed. For example, bacterial and yeast
artificial chromosomes were used to create the BACHD (Gray et al., 2008) and
YAC128 mouse models (Slow et al., 2003), respectively. YAC128 mice, which
express the full-length human HTT gene carrying 128 CAG repeats, develop
a progressive motor deficits from the age of six months. At nine months, the
mice show cortical and striatal atrophy with corresponding behavioural changes
(Van Raamsdonk et al., 2005b). Other groups have taken a knock-in approach
to expand the CAG repeat in the endogenous murine Htt gene rather than in-
ducing overexpression of a human HTT sequence. In this study, Hdh150Q/150Q
mice, expressing 150 CAG repeats (Lin et al., 2001) were used. With disease
onset from 15 months, Hdh150Q/150Q mice demonstrate a phenotype similar to 12
week old R6/2 mice at 22 months of age, including features such as widespread
mHTT aggregates throughout the brain, transcriptional dysregulation in the stria-
tum and cerebellum, 20 % weight loss and motor deficits include gait abnormali-
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ties and reduced performance at motor tasks (Woodman et al., 2007). All these
mouse models have advantages and disadvantages; for examples, YAC128 mice
are heavier than WT mice at all ages (Slow et al., 2003), while weight loss is
a major feature of HD (Aziz et al., 2008) and is observed in both the R6/2 and
Hdh150Q/150Q mouse models (Woodman et al., 2007). On the other hand, the
YAC128 mice are the only model in which motor deficits and neuronal loss highly
correlate (Slow et al., 2003). The TRACK-HD study showed a similar correla-
tion in HD patients demonstrating significant difference in brain volume between
premanifest HD gene carrier and early stage patients (Tabrizi et al., 2009, 2012,
2011). It is therefore important to validate the different HD mouse models in order
to find out which best represents different aspects of HD pathology.
Here, different HD mouse models were evaluated in regard to the immunological
changes found in peripheral immune cells from HD patients. HD patient plasma
contains more pro-inflammatory cytokines compared with controls (Bjo¨rkqvist
et al., 2008; Wild et al., 2011). Furthermore, as shown in Chapter 4, primary
human monocytes and macrophages are hyper-reactive upon LPS stimulation
in vitro, demonstrating increased cytokine production and phagocytosis. Previ-
ous investigations have already shown elevated levels of pro-inflammatory cy-
tokines such as IL-6 and IL-1β in the plasma of the fragment R6/2, the full-length
Hdh150Q/150Q and YAC128 HD mouse models (Bjo¨rkqvist et al., 2008). Moreover,
peripheral immune cells were found to migrate abnormally in both the R6/2 and
BACHD mice (Kwan et al., 2012b), clearly demonstrating abnormal immune func-
tion in HD mouse models.
During this PhD, cytokine production and other key immune cell functions were
analysed using ex vivo murine cells. Assessing several commonly used sources
for murine monocytes and macrophages, such as blood, spleen and bone mar-
row, allowed not only the comparison of different mouse models, but also of dif-
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ferent isolation protocols and immune cell subsets, while trying to replicate and
further investigate the HD immune dysfunction in mice.
6.2 Contributions
Cytokine production (from spleen and bone marrow cells) and functional analysis
(adhesion and migration assays) of R6/2 was done in collaboration with Dr Ralph
Andre, UCL London and Anna Magnusson-Lind, Lund University, Sweden. Ex-
periments were carried our both in London (mice provided by Prof Gillian Bates at
King’s College London) and Lund (mice provided by Dr Maria Bjo¨rkqvist at Brain
Disease Biomarker Unit, Lund University). Cytokine profiling of Hdh150Q/150Q mice
was done in collaboration with Dr Ralph Andre, UCL London in London (mice pro-
vided by Prof Gillian Bates at King’s College London). Analysis of YAC128 mice
was done by C. Connolly in Dr Blair Leavitt’s lab in Vancouver. All FR-FRET
assays were done by Dr Andreas Weiss at Novartis, Basel.
6.3 Methods
The cytokine production by murine CD11b+ cells, isolated from blood, peritoneum,
spleen and bone marrow (Section 2.5.6) and stimulated with IFNγ and LPS for
24 h were analysed using multiplex ELISA (Section 2.7.2). HTT levels were mea-
sured by TR-FRET (Section 2.8.6) and the percentage of immune cell subsets in
R6/2 spleens were analysed by flow cytometry (Section 2.9.1). For further func-
tional analysis cells underwent phagocytosis (Section 2.6.3), adhesion (Section
2.6.4) and migration assays (Section 2.6.2).
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6.4 Results
6.4.1 Cytokine profiling of myeloid cells in the R6/2 mouse
model
In order to determine whether murine blood monocytes are similarly hyper-re-
active as HD patient cells, IFNγ-primed murine monocytes isolated using anti-
CD11b magnetic beads, were stimulated with LPS. After 24 h, supernatants were
analysed using the MSD multiplex ELISA platform. To ensure sufficient cell num-
bers for the experiment (100 000 cells per well in 96-well plates), blood monocytes
from WT and R6/2 mice were pooled from multiple individual animals according
to genotype. Analysing multiple wells of each genotype showed an increase in IL-
6 and TNFα but not in IL-1β production in R6/2 compared with WT cells (Figure
6.1A).
To further analyse innate immune function in R6/2 mice, the cytokine profiles of
other R6/2 monocyte populations were characterised. Splenic and bone marrow
monocytes were isolated using anti-CD11b magnetic beads, and cultures (es-
tablished from individual mice seeding 500 000 cells per well in 24-well plates)
were primed with IFNγ and stimulated with LPS for 24 h. Analysing cytokine pro-
duction by splenic monocytes isolated from R6/2 mice demonstrated an increase
in IL-1β , whilst IL-6 and TNFα levels were unchanged compared with WT mice
(Figure 6.1B). Interestingly, R6/2 bone marrow monocytes showed no difference
in cytokine production when compared with WT cells (Figure 6.1C).
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Figure 6.1: Altered cytokine production by monocytes from R6/2 mice. (A) CD11b+
monocytes were isolated from pooled blood samples obtained from R6/2 and WT mice.
Cell cultures primed with 10 ng/ml IFNγ and stimulated with 2 µg/ml LPS for 24 h showed
significant differences in IL-6 and TNFα production. (B) R6/2 splenic monocytes and
(C) R6/2 bone marrow monocytes were isolated using anti-CD11b magnetic beads, and
individual cultures from each mouse were stimulated with 10 ng/ml IFNγ and 2 µg/ml
LPS for 24 h. Measuring cytokine production in supernatants using the MSD multiplex
ELISA platform, R6/2 spleen monocytes demonstrated changes in IL-1β levels, whilst
bone marrow monocytes from R6/2 mice showed the same cytokine levels as WT cells.
Graphs show mean concentrations corrected to protein content ± SEM. Unpaired two-
tailed student t tests. (A) n=technical repeats of pooled samples from different mice,
(B+C) n=biological repeats representing individual mice. Spleen and bone marrow cell
profiling was done in collaboration with Dr Ralph Andre and Anna Magnusson-Lind.
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In addition to monocyte subsets, IL-6 production from different tissue specific
macrophages primed with IFNγ and stimulated with LPS was measured via ELISA.
Surprisingly, IL-6 production by bone marrow-derived (Figure 6.2A) and peri-
toneal (Figure 6.2B) macrophages did not show any differences when comparing
R6/2 and WT mice. In conclusion, increased cytokine production, as seen in HD
patients monocytes and macrophages, could only partially be repeated in R6/2
monocytes and macrophage subsets.
Figure 6.2: Cytokine production by macrophages from R6/2 mice. (A) Bone mar-
row monocytes were isolated using anti-CD11b magnetic beads and differentiated into
macrophages using 20 ng/ml M-CSF for 6 days. Measuring cytokine production using
IL-6 ELISAs after priming the cells with 10 ng/ml IFNγ and stimulation with 2 µg/ml LPS
for 24 h showed no difference in IL-6 production comparing R6/2 and WT bone marrow-
derived macrophages. (B) Similarly, peritoneal macrophages from R6/2 mice stimulated
in the same way showed no difference in IL-6 production compared with WT cells. Graphs
show mean concentrations corrected to protein content ± SEM. n=biological repeats rep-
resenting individual mice. Unpaired two-tailed student t tests. Experiment was done in
collaboration with Dr Ralph Andre and Anna Magnusson-Lind.
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6.4.2 Cytokine profiling of myeloid cells in full-length HD
mouse models
In addition to the R6/2 fragment model, which expresses only exon 1 of the human
HTT gene, the Hdh150Q/150Q knock-in mouse model, expressing 150 CAG repeats
in the endogenous mouse Htt gene (Lin et al., 2001), was analysed in regard to
cytokine production. IFNγ-primed Hdh150Q/150Q blood monocytes stimulated with
LPS demonstrated a significant increase in IL-1β and TNFα production when
compared with WT mice. IL-6 levels were also elevated in Hdh150Q/150Q cells com-
pared with WT cells (Figure 6.3A). Analysing splenic monocytes, Hdh150Q/150Q cell
demonstrated significantly elevated IL-6 and TNFα production, and a slight in-
crease in IL-1β levels compared with WT cells (Figure 6.3B). Interestingly, CD11b+
bone marrow monocytes isolated from Hdh150Q/150Q mice did not show any chan-
ges in cytokine production compared with WT mice (Figure 6.3C). This result, to-
gether with the lack of elevated cytokine production by R6/2 bone marrow mono-
cytes and macrophages, indicates that bone marrow cells behave differently to
mature peripheral myeloid cells.
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Figure 6.3: Altered cytokine production by monocytes from Hdh150Q/150Q mice. (A)
Blood monocytes, (B) splenic monocytes and (C) bone marrow monocytes were iso-
lated using anti-CD11b magnetic beads and individual mouse cultures were stimulated
with 10 ng/ml IFNγ and 2 µg/ml LPS for 24 h. Cytokine production was analysed using
the MSD multiplex ELISA platform. Whilst bone marrow cells produced similar levels
of cytokine compared with WT, both blood and splenic monocytes produced significantly
higher levels of pro-inflammatory cytokines. Graphs show mean concentrations corrected
to protein content ± SEM. Unpaired two-tailed student t tests. n=biological repeats rep-
resenting individual mice. Experiment was done in collaboration with Dr Ralph Andre and
Anna Magnusson-Lind.
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A third HD mouse model shown to have increased levels of plasma cytokine is
the YAC128 model (Bjo¨rkqvist et al., 2008), which expresses the entire human
HD gene (Slow et al., 2003). When stimulating IFNγ-primed bone marrow-derived
macrophages with control standard endotoxin (CSE), no difference in IL-6 produc-
tion was detected comparing YAC128 and WT cells (Figure 6.4A), strengthening
the hypothesis that bone marrow cells are not a good model for peripheral im-
mune changes in HD. Stimulating peritoneal macrophages with CSE showed that
IL-6 production by YAC128 cells was significantly increased compared with WT
mice (Figure 6.4B), replicating the hyper-reactive macrophage phenotype seen
in HD patients.
Figure 6.4: Altered cytokine production by macrophages from YAC128 mice.
(A) Macrophages were differentiated from bone marrow monocytes and cultured with
20 ng/ml M-CSF for 6 days. Cultures were then stimulated for 24 h with 100 µg/l
CSE. Measuring IL-6 levels using ELISA showed no difference in cytokine production
from YAC128 bone marrow-derived cells compared with WT controls. (B) Peritoneal
macrophages obtained via peritoneal lavage were stimulated with 100 µg/l CSE for 24 h
before IL-6 levels were measured using ELISA. A significant increase in cytokine pro-
duction by YAC128 peritoneal macrophages was seen when compared with WT. Graphs
show mean concentrations corrected to protein content ± SEM. Unpaired two-tailed stu-
dent t-tests. *p<0.05. Experiment done by C. Connolly.
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6.4.3 HTT levels in bone marrow and spleen of R6/2 mice
Work presented in Chapter 3 linked mHTT levels measured in primary human
immune cells with markers of disease progression such as disease stage, dis-
ease burden score and caudate atrophy. The fact that myeloid cells isolated from
R6/2 bone marrow appear normal in comparison to myeloid cells found in pe-
ripheral organs isolated from the same mouse may therefore be explained by
differences in mHTT expression levels. Assessing mHTT levels in whole bone
marrow lysates, CD11b+ sorted bone marrow cells and spleen lysates, using the
TR-FRET immunoassay, showed that in two out of three R6/2 mice mHTT levels
are nearly ten times lower in bone marrow cells compared with spleen (Figure
6.5). No mHTT signal was detectable in any organ isolated from control mice
(data not shown). These results may explain the observation that bone marrow
cells produce cytokine levels similar to WT cells.
Figure 6.5: HTT levels in R6/2 spleen and bone marrow. R6/2 bone marrow cells,
CD11b+ cells isolated from bone marrow using magnetic cell sorting and spleen cells
were lysed and used to assess mHTT levels. TR-FRET measures demonstrated that in
two out of three mice spleen had ten times more mHTT than bone marrow cells. Data
shown as percentage of the signal intensities over lysis buffer background signal after
normalisation to total protein levels. was done in collaboration with Dr Andreas Weiss.
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6.4.4 R6/2 mouse spleens demonstrate normal proportions of
immune cells
In order to dissect immune dysfunction further, the proportions of immune cell
subsets within the spleen of R6/2 mice were analysed. The main function of
the spleen is the production and recycling of red blood cells. However, large
populations of immune cells can be found in the white pulp of the spleen (Mebius
and Kraal, 2005). Single cell suspensions prepared from digested spleens were
stained with anti-CD3, anti-CD19 and anti-CD11b antibodies as markers for T
cells, B cells and myeloid cells, respectively. Figure 6.6A shows the gating used
in flow cytometry analysis to determine the percentage of the different cell types
in the R6/2 spleen. No changes in the B cell, T cell and myeloid cell populations
were found comparing R6/2 and WT mice (Figure 6.6B).
Figure 6.6: Splenic B cell, T cell and myeloid cell populations are unchanged in
R6/2 mice. Spleens were digested, homogenised and, after red blood cell lysis, stained
with 2 µg/ml anti-CD3 APC, 5 µg/ml anti-CD19 FITC and 2 µg/ml anti-CD11b PE antibod-
ies. (A) Percentage of each cell population was determined via flow cytometry analysis
using the gating as shown. (B) No differences in the percentage of B cells, T cells and
myeloid cells were detected comparing R6/2 and WT mice spleens using unpaired two-
tailed student t tests.
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Next, spleen cells were stained with anti-CD3, anti-CD4 and anti-CD8 antibodies
to investigated the abundance of CD4+ Th cells and CD8+ cytotoxic T cells in the
spleens of R6/2 compared with WT mice. No difference in T cell subsets was
detected in R6/2 mice (Figure 6.7).
Figure 6.7: T cell subtypes are unchanged in R6/2 spleen of mice. Spleens were
digested, homogenised and, after red blood cell lysis, stained with 2 µg/ml anti-CD3 PE,
5 µg/ml anti-CD8 FITC and 2 µg/ml anti-CD4 APC antibodies. (A) Percentage of each
cell population was determined via flow cytometry analysis using the gating shown here.
(B) No changes in the percentage of total, helper and cytotoxic T cells in spleen were
detected comparing R6/2 and WT mice using unpaired two-tailed student t tests.
Looking at myeloid cell subsets in detail, spleen cell suspensions were stained
with anti-F4/80 antibody as a macrophage marker and a combination of anti-
CD11c, anti-B220 and anti-CD11b antibodies to distinguish between CD11c+,
B220+ plasmacytoid DCs; CD11c+, B220−, CD11b− lymphoid-derived DCs; and
CD11c+, B220−, CD11b+ myeloid-derived DCs. Comparing R6/2 and WT mice,
no difference in the percentage of macrophage and DC subsets was detectable
(Figure 6.8).
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Figure 6.8: Myeloid cell subsets are unchanged in spleens of R6/2 mice. Spleens
were digested, homogenised and, after red blood cell lysis, stained with 2 µg/ml anti-
CD11b PE, 2 µg/ml anti-CD11c FITC, 2 µg/ml anti-F4/80 APC Cy7 and 2 µg/ml anti-
B220 APC antibodies. (A) Percentages of each cell population were determined via
flow cytometry analysis using the gating as shown. (B) No changes in the percentage of
macrophages, plasmacytoid, myeloid-derived and lymphoid-derived DCs were found in
the spleens of R6/2 and WT mice using unpaired two-tailed student t tests.
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Looking specifically at CD11b+ spleen cells, MHC class II expression was used
to categorise myeloid cells in a resting or activated state. Comparing the percent-
age of resting (CD11b+, MHCIIlow) and activated (CD11b+, MHCIIhigh) myeloid
cells in spleens from 8 week old animals did not show a difference between R6/2
and WT mice (Figure 6.9A). However, 12 week old R6/2 mice demonstrated a
significant decrease of activated myeloid cells in their spleens whilst the percent-
age of resting monocytes was significantly increased (Figure 6.9B). This change
in myeloid cell activation is likely to be a side-effect of the progressing disease in
end-stage 12 week old R6/2 mice, as the effect was not seen in mice at 8 weeks
old.
Figure 6.9: Ratio of resting versus activated myeloid cells is altered in end-stage
R6/2 mice. Spleens were digested, homogenised and, after red blood cell lysis, stained
with 2 µg/ml anti-CD11b PE, 2 µg/ml anti-CD11c FITC, 2 µg/ml anti-MHCII APC antibod-
ies. (A) At 8 weeks of age, no differences in resting (CD11b+, MHCIIlow) and activated
(CD11b+, MHCIIhigh) myeloid cells were detected between R6/2 and WT mice. (B) At 12
weeks, R6/2 mice demonstrated a significant increase in CD11b+/ MHCIIlow resting cells
while CD11b+/ MHCIIhigh activated myeloid cells are significantly decreased. Unpaired
two-tailed student t test.
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6.4.5 Peritoneal macrophages from R6/2 mice show increased
phagocytosis
Phagocytosis is a key function of macrophages and in Section 4.4.4 a significant
elevation in phagocytosis was observed in LPS-stimulated blood-derived HD pa-
tient macrophages compared with control cells. To see whether R6/2 mice dem-
onstrate a similar phenotype, bone marrow-derived and peritoneal macrophages
were incubated with green fluorescent latex beads and the percentage of cells
phagocytosing beads was analysed via flow cytometry. LPS-stimulated bone
marrow-derived macrophages from R6/2 mice did not demonstrate a difference
in phagocytosis levels compared with WT mice (Figure 6.10A). Peritoneal macro-
phages isolated from R6/2 mice, however, showed a small elevation in the per-
centage of phagocytosing cells upon LPS stimulation, similar to the results in HD
patients (Figure 6.10B).
Figure 6.10: Phagocytosis levels in macrophages isolated from R6/2 mice.
Macrophages were incubated with green fluorescent latex beads for 1 h before the num-
ber of cells taking up beads was analysed using flow cytometry. (A) Levels of phago-
cytosis in LPS (2 µg/ml) stimulated bone marrow-derived macrophages were similar in
WT and R6/2 mice, whilst (B) peritoneal macrophages from R6/2 mice stimulated with
2 µg/ml LPS for 24 h showed a significant increase in phagocytosis levels. Data are rep-
resentative of two independent experiments. n= biological repeats representing individual
mice. Unpaired two-tailed student t test.
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6.4.6 Other myeloid cell functions are unchanged in R6/2 mice
Analysing the differentiation of macrophages from blood monocytes showed no
difference in cell morphology or differentiation rate in HD patients (Section 4.4.1).
Counting the number of differentiated, adhered bone marrow-derived macropha-
ges four days after seeding also showed no difference in R6/2 compared with WT
cells (Figure 6.11A). In addition, adhesion of peritoneal macrophages appeared
to be normal in R6/2 mice, as the same number of R6/2 and WT macrophages
adhered to the tissue culture plastic 2 h after seeding (Figure 6.11B).
HD patients demonstrate a striking defect in monocyte and macrophage migration
towards the chemoattractant MCP-1 (Section 5.4.1). To test this phenotype in
R6/2 mice peritoneal macrophages were seeded on to transwells and the number
of cells migrating towards MCP-1 located in the lower chamber of the transwell
system was counted. Interestingly, peritoneal macrophages from R6/2 and WT
mice showed similar levels of migration, both under basal conditions and towards
MCP-1 (Figure 6.11C).
225
Results Immune dysfunction in different HD mouse models
Figure 6.11: Monocytes from R6/2 mice demonstrate no functional changes in cell
adhesion, migration and differentiation. (A) Bone marrow monocytes were isolated
using anti-CD11b magnetic beads and were differentiated using 20 ng/ml M-CSF. Four
days post seeding, adhered differentiated macrophages were detached and counted.
(B) Peritoneal macrophages obtained via peritoneal lavage were seeded on to tissue
culture plates. After 2 h the number of adhered cells was counted and no difference
in adherence was observed when comparing WT and R6/2 cells. (C) Using an 8µm
transwell system peritoneal macrophages from R6/2 mice did not show a difference in
basal or MCP-1 (50 ng/ml) induced migration. Data shown as mean ± SEM. n= biological
repeats representing individual mice. Unpaired two-tailed student t tests. Experiments
were done in collaboration with Dr Ralph Andre and Anna Magnusson-Lind.
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6.5 Discussion
It has been shown previously that different HD mouse models recapitulate the
human HD phenotype in regard to increased plasma cytokine levels. Cytokine
levels have been found to be increased the plasma from R6/2, Hdh150Q/150Q and
YAC128 mice (Bjo¨rkqvist et al., 2008). In this study blood monocytes isolated
from R6/2 and Hdh150Q/150Q were shown to be hyper-reactive upon LPS stimula-
tion in vitro, producing high levels of IL-6 and TNFα and replicating the human
phenotype described in Chapter 4.
Bone marrow-derived cells, both CD11b+ monocytes and monocyte-derived mac-
rophages, do not exhibit increased pro-inflammatory cytokine production in any
of the HD mouse models analysed. Interestingly, mHTT expression in bone mar-
row cells was found to be ten times less compared with spleen tissue in two out
of three R6/2 mice analysed. As bone marrow consists of different types of stem
cells and we are especially interested in myeloid cells, CD11b+ cells were iso-
lated and their mHTT expression levels were compared with whole bone marrow
mHTT levels, showing no difference. So whilst this result needs to be replicated,
it indicates that low mHTT levels in bone marrow cells may be the cause for the
different phenotype seem in bone marrow compared with peripheral cells. These
results are particularly interesting in light of a recent paper describing how bone
marrow transplants, when given from HD donor to HD recipient mice, can im-
prove certain aspects of HD pathology such as behavioural changes (Kwan et al.,
2012a). Bone marrow transplantation from both WT and BACHD mice into irra-
diated BACHD mice decreased the time the animal took to cross a beam in the
balance beam task at 6 months of age. Furthermore, while BACHD mice that did
not receive a bone marrow transplant develop deficits in total open-field activity
at 12 months of age, WT and BACHD mice receiving WT or BACHD bone mar-
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row transplants show no difference. Bone marrow transplants, both from WT and
BACHD donors do not improve all behavioural deficits and it is apparent that WT
bone marrow transplant have greater benefit for the recipient. While it remains
to be shown how the transplants confer their benefits, the lower mHTT load in
bone marrow cells may play a role, especially when replacing microglia, which
are thought to be self-renewing (Ransohoff and Perry, 2009) and therefore may
accumulate mHTT over their life time.
Looking at cytokine production by CD11b+ myeloid cells isolated from the spleen,
Hdh150Q/150Q mice demonstrated elevated IL-6, IL-1β and TNFα levels similar
to the changes seen from Hdh150Q/150Q blood monocytes. The same cells from
R6/2 mice, however, only showed an increase in IL-1β , whilst IL-6 and TNFα
levels were unchanged. In contrast to blood, CD11b+ cells from spleen comprise
a cell suspension that includes macrophages and DCs as well as the desired
monocytes. Testing whether a shift in the percentage of these different cell type
within the spleen accounts for the rise in IL-1β levels in R6/2 compared with
control cells, no difference in the macrophage, DC and monocyte populations
was detected. However, when looking at activation levels in splenic monocytes
using MHCII expression levels as a marker, significantly more resting and fewer
activated monocytes were found in R6/2 mice at 12 weeks of age. It might be,
therefore, that this difference in the isolated population from spleen, and not a
cell-intrinsic hyperreactivity of the cells accounts for the difference in IL-1β levels
detected in R6/2 spleen. This means splenic cells from R6/2 mice may not be a
good model for the peripheral myeloid cell function in HD.
While R6/2 monocytes isolated from blood recapitulate the human immune phe-
notype, cytokine production by peritoneal macrophages isolated from R6/2 mice
was unchanged compared with WT cells. Interestingly, peritoneal macrophages
isolated from YAC128 mice produced increased levels of IL-6 upon CSE stim-
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ulation compared with WT. It is unclear why macrophages from R6/2 mice do
not exhibit the same hyper-reactive phenotype as YAC128 mice. The difference
could be due to the fact that R6/2 mice only express a N-terminal fragment of
the mutant protein (Mangiarini et al., 1996), while YAC128 mice express the full-
length protein (Slow et al., 2003). Alternatively, the R6/2 colony used in this
study was on a CBA×C57Bl/6 background whilst the YAC128 mice were on a
FVB background and this difference in background genetics could explain the dif-
ferences in the phenotype. The influence of different genetic backgrounds has
been shown in YAC128 mice when comparing the mice on three different back-
grounds (C57BL/6, FVB/N and 129 strains) (Van Raamsdonk et al., 2007). Strain
influenced motor dysfunction, cognitive deficits, brain pathology and peripheral
changes such as weight by modulating the nuclear localisation of mHTT as op-
posed to altered mHTT expression levels. Interestingly, mice on the FVB back-
ground showed a stronger HD phenotype compared with C57BL. For obvious
reasons it is not possible to compare strain effects between different mouse mod-
els. It is important however, to keep this difference in mind as it might influence
some of the differences seen in this study.
Looking at other cellular functions, phagocytosis in peritoneal macrophages from
R6/2 mice was increased upon LPS stimulation, resembling the human pheno-
type. However, R6/2 peritoneal macrophages did not demonstrate any migration
defect in our hands. In a different study, R6/2 mice demonstrate decreased num-
bers of infiltrating peritoneal macrophages after inducing a peritonitis with thiogly-
colate, when compared with WT mice (Kwan et al., 2012b). Although our ex vivo
experiments did not show the same trend, it is important to note that the two ex-
periments are not looking at the same aspect of migration. In our in vitro migration
assay, the ability of peritoneal macrophages to migrate through a membrane to-
wards one chemokine was tested, while an induced peritonitis is not only looking
at macrophage migration but also monocyte infiltration from the blood stream into
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the peritoneum. This process requires migration though epithelium and cell-cell
interactions (Imhof and Aurrand-Lions, 2004), which might be affected in HD and
are not modelled in the in vitro assay used here. Furthermore, the in vivo peritoni-
tis experiment showed that R6/2 mice have decreased infiltration of monocytes
and macrophages into the peritoneum, but infiltration did still occur (Kwan et al.,
2012b). It might be that as an unintentional consequence of isolating peritoneal
macrophages, more functional cells were selected, which despite a possible de-
fect managed to migrate into the peritoneum in the first place.
Both the fragment R6/2 and full-length HD models, YAC128 and Hdh150Q/150Q
recapitulate aspects of the human disease and all three models should be con-
sidered for future studies investigating the immune dysfunction in HD and/or tar-
geting it for therapeutics. The use of mouse models is especially interesting as it
allows us to not only study the peripheral immune system, but also the immune
cells within the CNS, and this will yield answers as to whether peripheral myeloid
cells can provide insights into the function of, in humans inaccessible, microglia.
Deciding which tissue is the best for isolation of HD myeloid cells, is difficult. Both
R6/2 and Hdh150Q/150Q blood monocytes mimic the human phenotype well and
are a good model for the human disease, as these are the exact same cells
the human disease has been studied in. Unfortunately, especially when iso-
lated from 12 week old end-stage R6/2 mice, only around 100,000 to 300,000
monocytes can be recovered from one mouse. Large animal number are there-
fore required for any experiments. The use of alternative sources for monocytes
and macrophages such as bone marrow and spleen also demonstrated caveats.
Bone marrow monocytes and bone marrow monocyte-derived macrophages did
not show differences in cytokine production and phagocytosis, leading to the
conclusion that immature bone marrow cells are not a good model to assess
monocyte cell function in HD. Splenic monocytes from the R6/2 and Hdh150Q/150Q
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mouse models, on the other hand, respond in a hyper-reactive manner to LPS,
but due to their diverse composition (CD11b+ cells isolated from spleen can be
monocytes, macrophages or DCs), this does not resemble studies on human
blood cells that are 100 % monocytes. As flow cytometry showed that the abun-
dance of the different cell types does not differ between WT and R6/2, splenic
cells may still be used to compare the genotypes, although conclusions as to
which cell type is responsable for changes in phenotype would be difficult to draw.
Even if ex vivo immune cell studies are not easy to perform due to cell numbers,
after proving dysfunction of the immune system in HD mouse models in form of
increased plasma cytokine level (Bjo¨rkqvist et al., 2008) and cytokine production
by murine blood monocytes in vitro, the mouse models can now be used to tar-
get different molecules in the pathway identified in human cells (Chapter 4) and
thereby help to understand the role the peripheral immune system plays in HD
progression.
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In neurodegenerative diseases such as HD, disability is primarily caused by death
and dysfunction of neurons. However, non-neuronal cells have been shown to
contribute to the progressive neuronal loss. Transgenic expression of N-terminal
mHTT solely in astrocytes causes an age-dependent neurological phenotype
similar to HD (Bradford et al., 2009), providing evidence that non-neuronal cells
might be crucial for disease progression. Understanding dysfunction in non-
neuronal cells may therefore provide insights into HD pathology, biomarkers and
therapeutic targets.
7.1 Innate immune cell function in HD
The work presented in this thesis demonstrates dysfunction in several key func-
tions of innate immune cells. The hyper-reactive phenotype of HD monocytes
and macrophages, characterised by increased cytokine production and phago-
cytosis upon LPS stimulation was shown to be caused by dysregulation of the
NFκB pathway. Functioning as a scaffolding protein for IKKγ, mHTT binds the
protein, allowing quicker activation of the kinase and the downstream pathway
upon stimulation via LPS. Contrasting this hyper-reactive phenotype, data pre-
sented in Chapter 5 showed decreased migration of human HD myeloid cells.
Decreased levels of MCP-1’s receptor CCR2, found on HD monocytes, may pro-
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vide a link between the hyper-reactive phenotype and the migration defect in the
HD cells, as increased production of MCP-1 may lead to decreased levels of its
receptor via autocrine desensitisation. However, normal levels of CCR-2 found on
HD macrophages indicated a different mechanism and indeed, mHTT-dependent
changes in actin remodeling were found in this thesis and several other studies
(Munsie et al., 2011; Myre et al., 2011). It is therefore likely that the migration de-
fect and the hyper-reactive phenotype in HD myeloid cells are not directly linked,
but caused by effects of mHTT expression on different cellular pathways.
This thesis further demonstrated that by lowering total HTT levels in primary
human HD monocytes and macrophages HD-specific phenotypes such as in-
creased cytokine production and transcriptional dysregulation can be, at least
partially, reversed. This is the first report showing that lowering HTT levels in ex
vivo human cells can reverse cellular dysfunction in HD. This finding validate the
potential of HTT lowering therapy and opens the possibility of using ex vivo cells
to test siRNA efficiency and safety in addition to mouse models.
Tracking total and mHTT levels in immune cells revealed that mean mHTT lev-
els in monocytes, T cells and B cells differ significantly between HD patients and
controls, as well as between premanifest and manifest patients. mHTT levels as-
sociated significantly with measures of disease progression in monocyte and T
cells from HD patients. Interestingly, looking at epithelial cells no such correla-
tion was observed, emphasising the potential pathogenic role of immune cells in
HD. The fact that mHTT levels measured in T cells tracked with disease burden
and caudate atrophy indicates a pathogenic accumulation of mHTT in adaptive
immune cells similar to that demonstrated in the innate immune system. Future
work should therefore address whether the increase in mHTT levels in B and T
cells leads to functional changes in the adaptive immune system. Different T and
B cell subsets found in the blood could be compared between control and HD
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samples, analysing their overall abundance. Furthermore, T cell functions such
as cytokine production, cell proliferation, cytotoxicity and T helper function should
be investigated.
7.2 Modeling human immune dysfunction in mice
Analysing immune cell function in different HD mouse models, this thesis showed
similar hyper-activation of blood monocytes in the Hdh150Q/150Q and R6/2 mouse
models of HD, while bone marrow cells showed no differences compared with
controls. The use of transgenic animals as models of HD has caveats. Most
models carry a CAG repeat length significantly greater than adult-onset HD pa-
tients, who normally range between 40-50 CAGs. Additionally, R6/2 mice over-
express a N-terminal HTT fragment, which cannot recapitulate all functions of
the full-length HTT protein and causes a fast progression more similar to juvenile
HD (Mangiarini et al., 1996). However, while these limitations should be kept in
mind, rodent models are crucial in understanding disease pathology and testing
potential therapies.
Several recent studies in HD mice have demonstrated that, using bone marrow
transplants (Kwan et al., 2012a) and by modulating the immune response via
CB2 signalling (Bouchard et al., 2012), the immune system is a modifier of HD
progression. To objectively test the effect a bacterial or viral challenge, in a con-
trolled environment, will have on HD progression, mice should be injected with
viral components or LPS peripherally. A questionnaire based study in AD has
linked systemic inflammatory incidents in AD patients with increased serum lev-
els of pro-inflammatory cytokines and an increased rate of cognitive decline over
a 6-month period (Holmes et al., 2009). While the reports on the inflammatory
incidents are subjective, a similar study in HD may be of use. In addition to this,
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a conditional gene knock-out of HTT in myeloid cells, using the myeloid cell spe-
cific LysM promoter (Clausen et al., 1999), will provide the answer to the question
which role myeloid cells play in HD pathology.
7.3 Need for biomarkers in HD
Biomarkers are indicators of a certain biological state. In case of disease, biomark-
ers should be significantly elevated or decreased in comparisons to controls and
ideally also change with disease progression. While this thesis described signif-
icant changes in cytokine production by HD myeloid cells, no differences were
seen between the different disease stages. The lack of correlation with disease
progression, overlap in measures between control and HD patient cells, and the
lengthy protocol make LPS-induced cytokine production an unlikely biomarker. In
addition, caution needs to be taken when using immune markers as biomarkers.
Cytokines are known to vary diurnally and that this pattern changes with dis-
ease progression, which makes standardised sample collection challenging. Fur-
thermore, cytokine levels can be altered by infections, immunomodulatory sub-
stances such as cortisol, body mass index, smoking, diet and exercise adding
to the challenge of reliably using cytokine levels as specific disease markers.
In addition, neurodegenerative diseases are slowly progressive and changes in
immune markers are subtle (Bjo¨rkqvist et al., 2009). More likely perhaps, im-
mune molecule levels should be used in a large panel, or in conjunction with
other biomarkers such as CSF immune markers and neuroimaging. The use of
large panels has already been suggested for AD, where eighteen plasma pro-
teins, including TNFα, IL-11, IL1-β and CCL5, have been used to classify blinded
samples from AD and control subjects with 90 % accuracy, and identify patients
that will progress from mild cognitive impairments to AD in the following 2-6 years
(Ray et al., 2007).
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In the case of HD, which can be diagnosed before symptom onset due to its
monogenetic nature, biomarkers will be crucial for clinical trials and potential
treatments for the premanifest gene carriers as classical end points such as func-
tional score do not exist for this group. The significant differences in mHTT levels
between controls, premanifest and manifest subjects, described in this thesis,
may therefore provide a valuable biomarker able to track disease progression for
clinical trials. However given overlap in the measurements between groups, more
data will be needed to assess how robust mHTT level track disease progression.
Additionally, multiple-end point data will always provide a better picture of disease
progression and effectiveness of treatment than relying on a single measure.
7.4 Therapy targeting immune dysfunction
Given the results in this thesis, the involvement of NFκB pathway dysregulation
in HD should be further investigated, especially as NFκB signalling is not only
crucial in innate immune activation but also in neuronal survival (Teng and Tang,
2010). Targeting the NFκB pathway to lower its activation using drugs, first in cel-
lular HD models then in vivo in HD mice will inform us whether the NFκB pathway
is a possible target for therapy. A study in rat PC12 cells has already shown, that
blocking NFκB function leads to reduced mHTT toxicity (Khoshnan et al., 2004).
Drugs targeting the pathway for HD should, therefore, be designed to target im-
mune cells as well as neurons and for in vivo studies should be able to cross the
BBB. Additionally, crossing HD mice onto conditional NFκB knock-out mice will
further our understanding of the role immune activation plays in HD. Targeting the
pathway further downstream is also a possibility and indeed, an peripherally ad-
ministered neutralising anti-IL-6 antibody treatment has been shown to improve
both weight loss and disease progression in R6/2 mice (Bouchard et al., 2012).
However, while limiting unwanted immune responses during neurodegenerative
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diseases may be neuroprotective, it is important to understand which immune
activation is helpful, by for example clearing dead cells or protein aggregates
and which immune response is toxic to the surrounding tissue. In the case of
AD, targeted stimulation of macrophages to increase the phagocytosis of Aβ has
beneficial effects on disease outcome (Frenkel et al., 2005), the same could be
true for early microglial activation in HD.
Lowering HTT levels is one major strategy for HD therapy. The novel method of
siRNA delivery used in this thesis has potential therapeutic relevance to HD and
other diseases where immune dysregulation is a feature. Glucan particles are
a versatile phagocytic cell targeted delivery system and have been administered
by oral, subcutaneous, intraperitoneal and intravenous routes in mice and rats
(Aouadi et al., 2009). In future studies, administration of GeRPs loaded with anti-
HTT siRNA to reverse the inflammatory phenotype will test the therapeutic poten-
tial of lowering HTT levels in immune cells. GeRPs could be administered either
intrathecally to directly target phagocytic microglial cells and infiltrating mono-
cyte/macrophages, or intravenously to target circulating monocytes, a precursor
pool for inflammatory cells trafficking into inflamed brain sites.
Overall, work presented in this thesis has helped understanding the cellular mech-
anisms causing of immune cell dysfunction in HD, has implications for the role of
the innate immune system in neurodegeneration and has provided new possi-
ble targets for therapeutics both in form of the NFκB pathway and in targeting
immune cells via HTT lowering using GeRPs.
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A.1 Appendix I - RPMI1640 media formulation
Table A.1: Components of RPMI 1640 media. Formulation of RPMI1640 media bought
from Invitrogen #31870074.
Components Molecular
Weight
Concentra-
tion (mg/L)
mM
Glycine 75 10 0.133
L-Arginine 174 200 1.15
L-Asparagine 132 50 0.379
L-Aspartic acid 133 20 0.15
L-Cystine 240 50 0.208
L-Glutamic Acid 147 20 0.136
L-Histidine 155 15 0.0968
L-Hydroxyproline 131 20 0.153
L-Isoleucine 131 50 0.382
L-Leucine 131 50 0.382
L-Lysine hydrochloride 146 40 0.274
L-Methionine 149 15 0.101
L-Phenylalanine 165 15 0.0909
L-Proline 115 20 0.174
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L-Serine 105 30 0.286
L-Threonine 119 20 0.168
L-Tryptophan 204 5 0.0245
L-Tyrosine 181 20 0.11
L-Valine 117 20 0.171
Biotin 244 0.2 0.00082
Choline chloride 140 3 0.0214
D-Calcium pantothenate 477 0.25 0.000524
Folic Acid 441 1 0.00227
Niacinamide 122 1 0.0082
Para-Aminobenzoic Acid 137 1 0.0073
Pyridoxine hydrochloride 206 1 0.00485
Riboflavin 376 0.2 0.000532
Thiamine hydrochloride 337 1 0.00297
Vitamin B12 1355 0.005 3.7E-06
i-Inositol 180 35 0.194
Calcium nitrate (Ca(NO3)2 4H2O) 236 100 0.424
Magnesium Sulfate (MgSO4-7H2O) 246 100 0.407
Potassium Chloride (KCl) 75 400 5.33
Sodium Bicarbonate (NaHCO3) 84 2000 23.81
Sodium Chloride (NaCl) 58 6000 103.45
Sodium Phosphate dibasic
(Na2HPO4)
142 800 5.63
D-Glucose (Dextrose) 180 2000 11.11
Glutathione (reduced) 307 1 0.00326
Phenol Red 376.4 5 0.0133
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A.2 Appendix II - Vector maps
Figure A.1: Vector map for A2UCOE without HTT exon 1. Vector map of
p’HRsincpptUCOEeGFP+linker+WPRE showing sites of the GFP insert and the ampi-
cillin resistance.
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Figure A.2: Vector map for A2UCOE with HTT exon 1. Vector map of
p’HRsincpptUCOE+htt exon1 IRES eGFP 129CAG as example for all three HTT exon
1 carrying vectors, showing sites of the exon 1 insertion, GFP site and the ampicillin
resistance gene.
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A.3 Appendix III - Sequencing
29Q2           --NNNNNNNNNNGNNNNNNNNNTCTNCTACAGCGCCAGGACGAGTCCGGTTCGTGTTCGT 58 
reference      -GCTGCCGGGACGGGTCCAAGATGGACGGCCGCTC------AGGTTCTGCTTTTACCTGC 53 
                                     *   *  * ** *        ** * * *  *    *  
 
29Q2           CCGCGGAGATCTCTCTCATCTCGCTCGGCTGCGGGAAATCGGGCTGAAGCGACTGGTACC 118 
reference      GGCCCAGAGCCCCATTCAT--TGCCCCGGTGCTGAGCGGCGCCGCGAGTCGGCCCGAGGC 111 
                  *      * *  ****   ** * * *** *     **    **  ** *  *   * 
 
29Q2           CGGGTCTAGAATCGATAAGCTTGAGCTCGATATCGTCGAGTAGATACCATGGCGACCCTG 178 
reference      C---TCCGGGGACTGCCGTGCCGGGCGGGAGACCG-----------CCATGGCGACCCTG 157 
               *   **  *   *         * **  ** * **           ************** 
 
29Q2           GAAAAGCTGATGAAGGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAGCAG 238 
reference      GAAAAGCTGATGAAGGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAGCAG 217 
               ************************************************************ 
 
29Q2           CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAACAGCAGCAGCAGCAG 298 
reference      CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAA--------------- 262 
               *********************************************                
 
29Q2           CAGCAGCAGCAACAGCCGCCACCGCCGCCGCCGCCGCCGCCGCCTCCTCAGCTTCCTCAG 358 
reference      ------------CAGCCGCCACCGCCGCCGCCGCCGCCGCCGCCTCCTCAGCTTCCTCAG 310 
                           ************************************************ 
 
29Q2           CCGCCGCCGCAGGCACAGCCGCTGCTGCCTCAGCCGCAGCCGCCCCCGCCGCCGCCCCCG 418 
reference      CCGCCGCCGCAGGCACAGCCGCTGCTGCCTCAGCCGCAGCCGCCCCCGCCGCCGCCCCCG 370 
               ************************************************************ 
 
29Q2           CCGCCACCCGGCCCGGCTGTGGCTGANGAGCCGCTGCACCGACCGTGAGTTTGGGCCCGC 478 
reference      CCGCCACCCGGCCCGGCTGTGGCTGAGGAGCCGCTGCACCGACCA-AAGAAAGAACTTTC 429 
               ************************** *****************   **   *  *   * 
 
29Q2           TGCAGTCGACGGT-ACCGCG-GGCCCGGGATCCGCCCCTCTCCCTCCCCCCCCCCCTAAC 536 
reference      AGCTACCAAGAAAGACCGTGTGAATCATTGTCTGACAATATGTGAAAACATAGTGGCACA 489 
                **   * *     **** * *   *    ** * *  * *       *        *   
Figure A.3: Alignment of the A2UCOE 29Q vector with the reference HTT sequence.
Plasmid DNA was sequenced and aligned to a reference HTT sequence using CLUSTAL
2.0.12. Sequencing matched between the starting codon and the first nucleotides of the
vector backbone (in red). A2UCOE demonstrated small expansion of the CAG repeat
from 29 to 31 repeats.
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71Q             --NNNNNNNNNNNNNNNNNNNNAGTTCTNCTACAGCGCCAGGACGAGTCCGGTTCGTGTT 58 
reference       ----------GCTGCCGGGACGGGTCCAAGATGGACGGCCGCTCAGGTTCTGCTTTTACC 50 
                                                   ** * *  *  ** * * *  *    
 
71Q             CGTCCGCGGAGATCTCTCTCATCTCGCTCGGCTGCGGGAAATCGGGCTGAAGCGACTGGT 118 
reference       TGCGGCCCAGAGCCCCATTCAT--TGCCCCGGTGCTGAGCGGCGCCGCGAGTCGGCCCGA 108 
                 *    *      * *  * **   ** * * *** *     **    **  ** *  *  
 
71Q             ACCCGGGTCTAGAATCGATAAGCTTGAGCTCGATATCGTCGAGTAGATACCATGGCGACC 178 
reference       GGCC---TCCGGGGACTGCCGTGCCGGGCGGGAGACCG-----------CCATGGCGACC 154 
                  **   **  *   *         * **  ** * **           *********** 
 
71Q             CTGGAAAAGCTGATGAAGGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAG 238 
reference       CTGGAAAAGCTGATGAAGGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAG 214 
                ************************************************************ 
 
71Q             CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 298 
reference       CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAACAG--------- 265 
                ***************************************************  
 
71Q             CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 358  
reference       ------------------------------------------------------------  
 
 
71Q             CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 418 
reference       ------------------------------------------------------------ 
 
 
71Q             CAGCAGCAGCAGCAGCAACAGCCGCCACCGCCGCCGCCGCCGCCGCCGCCTCCTNANCTT 478  
reference       ---------------CAACAGCCGCCACCGCCGCCGCCGCCGCCGCCGCCTCCTCAGCTT 306 
                               *************************************** * *** 
 
71Q             CCTCAGCCGCCGCCGCAGGCACAGCCGCTGCTGCCTCAGCCGCAGCCGCCCCCGCCGCCG 366 
reference       CCTCAGCCGCCGCCGCAGGCACAGCCGCTGCTGCCTCAGCCGCAGCCGCCCCCGCCGCCG 538 
                ************************************************************   
 
71Q             CCCCCGCCGCCACCCGGCCNGGCTGTGGCTGAGGAGCCGNTGCACCGNNCGTGAGGNTNG 426                               
reference       CCCCCGCCGCCACCCGGCCCGGCTGTGGCTGAGGAGCCGCTGCACCGACCA-AAGAAAGA 598      
                ******************* ******************* *******  *    *   
Figure A.4: Alignment of the A2UCOE 71Q vector with the reference HTT sequence.
Plasmid DNA was sequenced and aligned to a reference HTT sequence using CLUSTAL
2.0.12. Sequencing matched between the starting codon and the first nucleotides of the
vector backbone (in red) and verified 71 CAG repeats in this construct.
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129Q            -----NNNNNNNNNNNAGTTCTNCTACAGCGCCAGGACGAGTCCGGTTCGTGTTCGTCCG 55 
reference       ----GCTGCCGGGACGGGTCCAAGATGGACGGCCGCTCAGGTTCTGCTTTTACCTGCGGC 56 
                                 ** *        ** * *  *   ** * * *  *    *     
 
129Q            CGGAGATCTCTCTCATCTCGCTCGGCTGCGGGAAATCGGGCTGAAGCGACTGGTACCCGG 115 
reference       CCAGAGCCCCATTCAT--TGCCCCGGTGCTGAGCGGCGCCGCGAGTCGGCCCGAGGCC-- 112 
                *      * *  ****   ** * * *** *     **    **  ** *  *   **   
 
129Q            GTCTAGAATCGATAAGCTTGAGCTCGATATCGTCGAGTAGATACCATGGCGACCCTGGAA 175 
reference       -TCCGGGGACTGCCGTGCCGGGCGGGAGACCG-----------CCATGGCGACCCTGGAA 160 
                 **  *   *         * **  ** * **           ***************** 
 
  
129Q            AAGCTGATGAAGGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAGCAGCAG 235 
reference       AAGCTGATGAAGGCCTTCGAGTCCCTCAAGTCCTTCCAGCAGCAGCAGCAGCAGCAGCAG 220 
                ************************************************************ 
 
129Q            CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 295 
reference       CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAACAG--------------- 265 
                ***************************************** **** **  * ** ** * 
 
129Q            CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 255 
reference       ------------------------------------------------------------ 265 
 
129Q            CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 215 
reference       ------------------------------------------------------------ 265 
 
129Q            CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 275 
reference       ------------------------------------------------------------ 265 
 
129Q            CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 335 
reference       ------------------------------------------------------------ 265 
 
129Q            CAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCCGCCACCGCCGCCG  395 
reference       ---------------------------------------------CCGCCGCCGCCGCCT 265 
         ***** ******** 
Figure A.5: Alignment of the A2UCOE 129Q vector with the reference HTT se-
quence. Plasmid DNA was sequenced and aligned to a reference HTT sequence using
CLUSTAL 2.0.12. Sequencing failed to go past the CAG repeat due to the large number
of repeats, but the number of repeats could be validated as 129.
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A.4 Appendix IV - Patient details
Table A.2: HTT CAG repeat length for HD patients participating in the study re-
ported in Chapter 3. The CAG repeat length for patients in the cohort was 40-47 CAG
repeats, with the exception of one early stage patient with a larger repeat size of 59.
Experiment Disease stage n number CAG
(mean±SD)
Monocytes
Premanifest 8 43.00 ± 1.92
Early 10 45.20 ± 5.45
Moderate 7 43.29 ± 2.75
T cells
Premanifest 7 42.57 ± 1.62
Early 10 45.20 ± 5.45
Moderate 7 43.29 ± 2.75
B cells
Premanifest 7 42.57 ± 1.62
Early 10 45.20 ± 5.45
Moderate 7 43.29 ± 2.75
Monocytes
Premanifest 15 43.53 ± 1.77
Early 31 43.45 ± 3.52
Moderate 5 44.60 ± 1.95
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Table A.3: HTT CAG repeat length and age for all subjects participating in the study
presented in Chapter 4. Cohorts listed separately for each experiment.
Experiment Subject group n num-
ber
Age
(mean±SD)
CAG
(mean±SD)
Monocyte cytokine
profiling I
Control 27 45.4 ± 11.7 -
Premanifest HD 17 42.2 ± 9.9 42.8 ± 2.1
Early HD 22 49.1 ± 11.7 43.5 ± 2.8
Moderate HD 14 59.4 ± 7.3 43 ± 1.3
Monocyte cytokine
profiling II
Control 6 25.0 ±1.1 -
Young onset HD 4 27.2 ±4.0 56.8 ± 5.4
Macrophage
cytokine profiling
Control 9 45.2 ± 11.9 -
Premanifest HD 6 47.9 ± 6.6 42.7 ± 1.0
Early HD 10 46.7 ± 7.3 44.2 ± 2.8
Moderate HD 5 59.4 ± 7.3 44.8 ± 3.8
Phagocytosis
Control 5 48.7 ± 15.5 -
HD 5 49.0 ± 10.8 42.6 ± 2.1
TLR4 qPCR
Control 7 45.0 ± 12.2 -
Premanifest HD 6 43.5 ± 9.0 42.5 ± 2.0
Early HD 6 48.3 ± 10.1 44.2 ± 3.1
Moderate HD 7 54.5 ± 16.0 43.2 ± 2.8
Imaging flow
cytometry
Control 7 47.4 ± 17.9 -
HD 7 50.2 ± 13.4 44.6 ± 4.3
STAT flow analysis
Control 18 45.1 ± 14.5 -
Premanifest HD 11 49.7 ± 8.3 41.1 ± 2.5
Early HD 11 46.0 ± 13.0 45.8 ± 5.7
Moderate HD 8 57.1 ± 10.1 44.7 ± 3.4
PCR arrays
Control 10 45.8 ± 9.3 -
Early HD 10 48.7 ± 8.5 43.9 ± 2.8
Validation+
knock-down cell PCR
Control 10 48.2 ± 13.7 -
HD 10 52.3 ± 11.1 43.1 ± 2.2
HTT knock-down test
Control 10 42.5± 13.1 -
HD 10 51.5±7.4 42.8 ± 0.8
Cytokine profile of
knock-down cells
Control 9 48.0 ± 9.9 -
HD 8 51.3 ± 10.6 43.4 ± 1.6
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Table A.4: HTT CAG repeat length and age for all subjects participating in the study
presented in Chapter 5. Cohorts listed separately for each experiment.
Experiment Subject group n num-
ber
Age
(mean±SD)
CAG
(mean±SD)
Monocyte migration
towards ATP/C5a
Control 10 47.2 ± 16.3 -
Premanifest HD 4 38.6 ± 6.9 43.0 ± 9.4
Early HD 5 43.3 ± 16.4 48.4 ± 6.7
Moderate HD 8 54.4 ± 16.6 45.6 ± 5.3
Monocyte migration
towards MCP-1
Control 8 45.1 ± 13.9 -
Premanifest HD 9 43.0 ± 9.4 42.3 ± 2.8
Early HD 9 45.3 ± 15.0 46.4 ± 7.7
Moderate HD 11 61.1 ± 9.7 42.7 ± 2.1
Monocyte migration
towards RANTES
Control 6 38.6 ± 13.1 -
Premanifest HD 4 49.0 ± 11.3 41.57 ± 1.3
Early HD 5 52.7 ± 11.1 43.2 ± 1.5
Moderate HD 5 56.3 ± 9.3 42.0 ± 1.6
Macrophage
migration towards
ATP/C5a
Control 8 47.6 ± 15.3 -
HD 8 50.1 ± 14.5 44.6 ± 55.5
Macrophage
migration towards
MCP-1
Control 10 50.5± 15.9 -
HD 15 59.9± 11.8 42.9 ± 2.3
Macrophage
migration towards
RANTES
Control 8 50.2 ± 17.8 -
HD 13 48.9 ± 11.3 42.77 ± 2.1
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A.5 Appendix V - PCR signaling array results
Table A.5: Expression changes within the NFκB pathway observed in HD mono-
cytes. Data presented as fold change calculated from ∆∆CT values, unpaired two-tailed
student t tests used as for statistical analysis.
Gene name Fold change p-value
AGT 2.20 0.31
AKT1 1.54 0.03
ATF1 1.16 0.07
BCL10 0.90 0.43
BIRC2 0.95 0.53
CASP1 1.12 0.19
CASP8 0.79 0.23
CCL2 1.57 0.16
CD27 2.02 0.22
CD40 1.51 0.02
CFB 1.01 0.92
CFLAR 0.91 0.48
CHUK 0.77 0.02
CSF2 1.06 0.90
CSF3 0.86 0.69
EDARRADD 1.69 0.32
ELK1 1.17 0.14
ERG1 1.65 0.32
F2R 2.23 0.04
FADD 1.08 0.61
FASLG 1.08 0.61
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FOS 1.87 0.06
GJA1 0.61 0.08
HMOX1 1.20 0.82
HTR2B 0.80 0.30
ICAM1 1.41 0.011
IFNB1 1.09 0.75
IFNG 2.60 0.25
IKBKB 1.03 0.78
IKBKE 1.04 0.67
IKBKG 1.21 0.20
IL10 1.85 0.04
IL1A 1.26 0.27
IL1B 1.95 0.19
IL1R1 0.88 0.60
IL6 2.49 0.08
IL8 1.52 0.19
IRAK1 2.00 0.05
IRAK2 1.31 0.12
c-JUN 2.22 0.05
LPAR1 0.95 0.79
LTA 1.14 0.66
LTBR 1.35 0.01
MALT1 1.35 0.56
MAP3K1 1.04 0.77
MYD88 1.26 0.05
NFKB1 1.10 0.37
NFKB2 0.99 0.96
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NFKBIA 1.16 0.56
NLRP12 1.26 0.11
NOD1 1.11 0.30
PPM1A 0.96 0.76
RAF1 1.12 0.07
REL 0.97 0.81
RELA 1.15 0.22
RELB 1.21 0.39
RHOA 1.02 0.75
RIPK1 1.10 0.46
SCL3 1.25 0.21
SLC20A1 1.05 0.21
SLC44A2 1.29 0.07
STAT1 1.27 0.30
TBK1 1.03 0.68
TICAM1 1.06 0.64
TICAM2 1.32 0.05
TLR1 0.86 0.46
TLR2 1.48 0.01
TLR3 1.37 0.22
TLR4 1.07 0.59
TLR6 1.09 0.45
TLR7 0.98 0.95
TLR8 0.98 0.92
TLR9 0.79 0.26
TMED4 1.23 0.02
TNF 1.11 0.72
250
Appendix V - PCR signaling array results Appendices
TNFAIP3 1.15 0.41
TNFSRF10A 1.20 0.21
TNFSRF10B 1.04 0.74
TNFRAF14 1.19 0.17
TNFSF10 1.14 0.41
TNFSF14 1.04 0.83
TRADD 1.25 0.06
TRIM12 1.10 0.44
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